{"100-1.\n\u96a8\u8457\u814e\u529f\u80fd\u60e1\u5316\uff0c\u8f03\u56b4\u91cd\u7684CKD\uff08chronic kidney disease\uff09\u75c5\u4eba\u6703\u767c\u751f\u9178\u9e7c\u5e73\u8861\u7684\u7570\u5e38\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\nA. \u5927\u90e8\u5206\u7684\u75c5\u4eba\u6703\u7522\u751f\u6bd4\u6b63\u5e38\u4eba\u66f4\u591a\u91cf\u7684ammonia\u4ee5\u6392\u9664\u591a\u9918\u7684H\uff0b(\u6c2b\u96e2\u5b50)\nB. \u82e5\u6709\u9ad8\u8840\u9240\uff0c\u6703\u4f7fammonia\u88fd\u9020\u66f4\u589e\u52a0\uff0c\u4ee5\u5229\u6392\u9178.\nC. \u9ad8\u8840\u9240 (hyperkalemia)\u53cahyperchloremic metabolic acidosis \u53c8\u7a31type III RTA, \u5e38\u898b\u65bc\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a(DM nephropathy), \u6216\u814e\u5c0f\u7ba1\u9593\u8cea\u6027\u75be\u75c5 (tubulo-interstitial disease).\nD. \u7576\u8840\u4e2dbicarbonate\u4f4e\u65bc 20-23mmol/L\u5c31\u53ef\u8003\u616e\u88dc\u5145alkali.\nE. \u7576\u814e\u529f\u80fd\u6108\u4f86\u6108\u60e1\u5316, \u5e38\u5e38\u7531anion-gap metabolic acidosis\u8b8a\u6210non-anion-gap metabolic acidosis.\n": "(D)", "100-2.\n\u6709\u4e00\u4f4d70\u6b72\u5973\u6027, \u8173\u816b\u5df2\u5169\u9031, \u4eba\u53ef\u4ee5\u6d3b\u52d5. \u6bcf\u5929\u5c3f\u86cb\u767d\u6392\u6cc4\u7d046 gm , \u8840\u4e2d\u767d\u86cb\u767d(albumin)\u70ba2.8 g/dL,\u4e0b\u5217\u4f55\u7a2e\u63cf\u8ff0\u4e0d\u6b63\u78ba\uff1f\nA. \u9019\u985e\u75c5\u4eba\u6bcf\u4f4d\u90fd\u61c9\u5118\u65e9\u7d66\u4ee5\u6297\u51dd\u5291\uff08warfarin\uff09.\nB. \u5c3f\u6db2\u6aa2\u67e5\u53ef\u80fd\u4f34\u6709\u986f\u5fae\u8840\u5c3f\uff08microscopic hematuria\uff09.\nC. \u6709\u4e9b\u75c5\u4eba\u53ef\u80fd\u75c5\u60c5\u6703\u81ea\u52d5\u6539\u5584\uff08remission\uff09\nD. \u5982\u679c\u70ba\u539f\u767c\u6027\u814e\u708e\uff0c\u6700\u5e38\u898b\u7684\u53ef\u80fd\u6027\u70bamembranous nephropathy\u6240\u9020\u6210.\nE. \u80ba\u764c\u53ef\u80fd\u6703\u9020\u6210\u6b64\u7a2e\u4f75\u767c\u75c7.\n": "(A)", "100-3.\n\u6709\u4e00\u4f4d65\u6b72\u7537\u6027, \u61f7\u7591\u814e\u7d50\u77f3, \u63a5\u53d7IVU ( intravenous urography) \u6aa2\u67e5, \u7b2c\u4e09\u5929\u767c\u73feBUN\u753133 mg/dL\u5347\u81f360 mg/dL, \u8840\u4e2dcreatinine\u75312.1 mg/dL\u5347\u81f34.6 mg/dL,\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u986f\u5f71\u5291\u4e43\u7531\u8840\u7ba1\u64f4\u5f35\u4e4b\u6a5f\u8f49\u5c0e\u81f4\u814e\u640d\u50b7.\nB. \u5fc3\u81df\u8870\u7aed\uff08congestive heart failure\uff09\u75c5\u4eba\u8f03\u5bb9\u6613\u767c\u751f\u6b64\u4f75\u767c\u75c7,\nC. \u986f\u5f71\u5291\u4e4b\u5291\u91cf\u8207\u814e\u640d\u50b7\u4e4b\u7a0b\u5ea6\u901a\u5e38\u7121\u95dc.\nD. \u986f\u5f71\u5291\u53ef\u7d93\u904ereactive oxygen species\u4e4b\u6a5f\u8f49, \u4e3b\u8981\u50b7\u5bb3\u814e\u5c0f\u7403\uff08glomerular cells).\nE. \u901a\u5e38\u70ba\u53ef\u9006\u6027, \u5dd4\u5cf0\u671f(peak)\u70ba10-12\u5929, \u5927\u7d042 \u661f\u671f\u5167\u6062\u5fa9.\n": "(B)", "100-4.\n\u6709\u4e00\u500b\u5916\u570b\u4eba\u5230\u53f0\u7063\u65c5\u904a, \u56e0\u5c3f\u5f88\u591a\u4f86\u505a\u6aa2\u67e5, \u767c\u73fe\u5c3f\u6db2\u4e2dWBC 20-25/HPF, RBC 15-20/HPF, protein\uff0b, \u8840\u4e2dBUN 45 mg/dL, creatinine 3.8 mg/dL, \u5169\u5e74\u524d\u6aa2\u67e5\u8840\u4e2dcreatinine\u70ba2.5mg/dL, \u4ed6\u8aaa\u5e38\u5e38\u5403\u6b62\u75db\u8907\u65b9\uff08aspirin\uff0bphenacetin\uff0bacetaminophen\uff09\u5df2\u670915\u5e74\u4ee5\u4e0a\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\nA. \u75c5\u4eba\u7684\u814e\u75c5\u548c\u6b62\u75db\u85e5\u53ef\u80fd\u6709\u95dc.\nB. \u4ed6\u82e5\u7167IVU\uff08intravenous urography\uff09\u53ef\u80fd\u51fa\u73fe \u301dring sign\u301e.\nC. \u5c07\u4f86\u53ef\u80fd\u767c\u751f\u7684\u4f75\u767c\u75c7\u70barenal cell carcinoma.\nD. \u6b64\u7a2e\u75c5\u8b8a\u4e4b\u7279\u9ede\u70bapapillary necrosis\u53catubulo-interstitial inflammation.\nE. \u767c\u751f\u8ca7\u8840\u7684\u7a0b\u5ea6\u5f80\u5f80\u8207\u814e\u529f\u80fd\u8870\u7aed\u4e4b\u7a0b\u5ea6\u4e0d\u6210\u6bd4\u4f8b.\n": "(C)", "100-5.\n\u6709\u4e00\u4f4d62\u6b72\u5973\u6027, \u63a5\u53d7\u5316\u7642\uff08chemotherapy\uff09\u5f8c, \u767c\u73feBUN\u70ba42 mg/dL, creatinine 3.8 mg/dL, hemoglobin\u70ba9.0 g/dL, platelet 31 k/\u03bcl \uff08\u534a\u5e74\u524d4\u9805\u90fd\u6b63\u5e38\uff09, \u8840\u6db2\u62b9\u7247\u51fa\u73fefragmented RBC. \u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6b64\u75c5\u4e4b\u6b7b\u4ea1\u7387\u6975\u4f4e,\u5927\u591a\u6578\u53ef\u4ee5\u6cbb\u7652.\nB. \u6700\u5e38\u5f15\u8d77\u6b64\u73fe\u8c61\u7684\u5316\u7642\u85e5\u7269\u70bacyclophosphamide.\nC. \u767c\u751f\u904e\u7a0b\u5341\u5206\u7de9\u6162, \u4e0d\u6703\u7a81\u7136\u767c\u751f.\nD. \u7528\u985e\u56fa\u9187, \u8840\u6f3f\u4ea4\u63db\uff08plasma exchange\uff09\u53ca\u514d\u75ab\u6291\u5236\u5291\u53ef\u6210\u529f\u6cbb\u7652\u5927\u591a\u6578\u75c5\u60a3.\nE. \u75c5\u7406\u7d44\u7e54\u4e0a\u5448\u73fethrombotic microangiopathy.\n": "(E)", "100-6.\n\u4e00\u4f4d45\u6b72\u5973\u6027,\u75c5\u4eba\u610f\u8b58\u7a0d\u5fae\u4e0d\u6e05\u695a, \u5728\u6025\u8a3a\u8655\u88ab\u767c\u73fe\u8840\u9209\u70ba118mmol/L, \u4e0b\u5217\u90a3\u4e9b\u301d\u5168\u90e8\u6b63\u78ba\u301e\uff1f\r1.\u5927\u90e8\u5206\u4f4e\u8840\u9209\u7684\u6210\u56e0\u5e38\u4f34\u96a8\u4f4e\u8840\u6f3f\u6ef2\u900f\u58d3 (hypo-osmolality) .\r2.\u6240\u8b02SIADH\u4e43\u9ad8\u9ad4\u6db2\uff08hypervolemic\uff09hyponatremia \u4e2d\u6700\u5e38\u898b\u7684\u4e00\u7a2e\u539f\u56e0.\r3.\u4f4e\u8840\u9209\u53ef\u80fd\u56e0\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\uff08hyperthyroidism\uff09\u5f15\u8d77.\r4.\u75c5\u4eba\u610f\u8b58\u4e0d\u6b63\u5e38, \u5176\u6a5f\u8f49\u70ba\u8166\u6c34\u816b\uff08cerebral edema\uff09\r5.\u8840\u9209\u7a81\u7136\u964d\u4f4e\u81f3120 mmol/L\u4ee5\u4e0b, \u75c5\u4eba\u53ef\u80fd\u767c\u751f\u660f\u8ff7(coma)\u6216\u62bd\u6410\uff08seizure\uff09\r6.\u814e\u4e0a\u817a\u6a5f\u80fd\u4ea2\u9032\u4e5f\u53ef\u4ee5\u5f15\u767c\u6b64\u60c5\u6cc1\r7.\u559d\u4e0b\u5927\u91cf\u5564\u9152\u800c\u98df\u7269\u5403\u5f88\u5c11\u53ef\u80fd\u5f15\u767c\u6b64\u60c5\u6cc1, \u7a31\u70babeer potomania\nA. 1+2+3\nB. 2+6+7\nC. 1+2+6\nD. 3+6+7\nE. 4+5+7\n": "(E)", "100-7.\n\u4e00\u4f4d62\u6b72\u5a66\u4eba, \u8840\u9223\u70ba2.8 mmol/L, \u4eba\u6c92\u6709\u660e\u986f\u75c7\u72c0,\u4e0b\u5217\u90a3\u4e9b\u63cf\u8ff0\u301d\u5168\u90e8\u6b63\u78ba\u301e\uff1a\r1.\u5979\u7684\u8840\u4e2d\u526f\u7532\u72c0\u817a\u8377\u723e\u8499\uff08PTH\uff09\u4e0d\u4e00\u5b9a\u5347\u9ad8.\r2.\u6709\u5f88\u591a\u816b\u7624\u6703\u5206\u6cccPTH\u9020\u6210\u9ad8\u8840\u9223\r3.sarcoidosis\u9020\u6210\u9ad8\u9223\u662f\u56e0\u70ba\u5206\u6cccPTH\u4e4b\u6545\r4.\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\uff08hypothyroidism\uff09\u4fc3\u4f7f\u9aa8\u9abc\u4e4b\u9223\u79fb\u51fa\u800c\u9020\u6210\u9ad8\u9223\u8840\u75c7\r5.\u56b4\u91cd\u9ad8\u9223\u8840\u75c7\u53ef\u4ee5\u5f15\u8d77\u5fc3\u8df3\u6162\uff08bradycardia\uff09, \u5fc3\u623f\u5fc3\u5ba4\u50b3\u5c0e\u963b\u65b7\uff08AV block\uff09\r6.\u8a55\u4f30\u8840\u9223\u7570\u5e38\u7b2c\u4e00\u6b65\u9700\u5148\u77e5\u9053\u8840\u4e2d\u767d\u86cb\u767d\uff08Albumin\uff09\u7684\u6fc3\u5ea6.\r7.\u9ad8\u8840\u9223\u540c\u6642\u4f75\u6709\u4f4e\u8840PTH\u6fc3\u5ea6(hypercalcemia with suppessed PTH level)\u6700\u5e38\u898b\u7684\u539f\u56e0\u70ba\u60e1\u6027\u816b\u7624\uff08malignancy\uff09.\nA. 1+2+3\nB. 2+4+5\nC. 3+4+6\nD. 1+5+6\nE. 4+6+7\n": "(D)", "100-8.\n\u90a3\u4e00\u7a2e\u60c5\u5f62\u5bb9\u6613\u767c\u751f\u9ad8\u8840\u9240\uff08hyperkalemia\uff09\uff1f\nA. \u9ad4\u6eab\u904e\u4f4e\uff08Hypothermia\uff09\nB. Thyrotoxic periodic paralysis\nC. \u9382 (Magnesium) \u7f3a\u4e4f\nD. \u4f7f\u7528COX-2\u6291\u5236\u5291\nE. Total parenteral nutrition\n": "(D)", "100-9.\n\u4e00\u4f4d65\u6b72\u7537\u6027, \u6709\u5341\u4e8c\u6307\u8178\u6f70\u760d\u75c5\u53f2, \u7a81\u7136\u5410\u51fa\u5927\u91cf\u9bae\u8840, \u88ab\u9001\u5230\u6025\u8a3a\u8655\u6642\u8840\u58d3\u91cf\u523060/20mmHg, \u64da\u5bb6\u5c6c\u63cf\u8ff0, \u75c5\u4eba\u4f4f\u5728\u504f\u9060\u5730\u5340, \u82b1\u6578\u5c0f\u6642\u624d\u9001\u5230\u91ab\u9662, \u7d93\u6e2c\u91cf\u8840\u4e2d\u4e73\u9178(lactic acid) \u504f\u9ad8, \u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u4e73\u9178\u4e2d\u6bd2\uff08lactic acidosis\uff09\u70ba\u4e00\u7a2e\u6b63\u5e38anion gap\u4e4b\u9178\u4e2d\u6bd2 (acidosis).\nB. \u5206\u70batype A,B,C\u4e09\u7a2e.\nC. \u7d66\u4e88\u8840\u7ba1\u6536\u7e2e\u5291\uff08vasoconstrictor\uff09\u6709\u76ca\u7121\u5bb3.\nD. \u61c9\u6ce8\u5c04\uff08NaHCO3\uff09\u4f7f\u8840\u6db2PH\u5118\u5feb\u6062\u5fa9\u81f3\u6b63\u5e38.\nE. \u7528NaHCO3\u6cbb\u7642\u6709\u6642\u6703\u5f15\u8d77\u9ad8\u8840\u58d3\u53ca\u9ad4\u6db2\u904e\u591a\uff08fluid overload\uff09\n": "(E)", "100-10.\n\u4e0b\u5217\u90a3\u4e00\u9805\u4e0d\u662fhypercholemic metabolic acidosis \u7684\u6210\u56e0\uff1f\nA. \u8179\u7009 (diarrhea)\nB. \u6162\u6027mild to moderate\u814e\u75c5\uff08CKD\uff09\u3010\u7576\u814e\u5c0f\u7403\u904e\u6ffe\u7387\uff08GFR\uff09\u7d04\u4ecb\u65bc20-50ml/min\u6642\u3011\nC. \u7b2c\u4e8c\u578b\uff08type II\uff09\u814e\u5c0f\u7ba1\u9178\u5316\u75c7 (proximal RTA)\nD. \u4f4e\u814e\u7d20\u4f4e\u76ae\u8cea\u919b\u916e\u75c7\uff08hyporeninemic hypoaldosteronism\uff09\nE. \u916e\u9178\u4e2d\u6bd2\uff08ketoacidosis\uff09\n": "(E)", "100-11.\n44\u6b72\u7537\u6027\uff0c\u56e0\u70ba\u6025\u6027\u51a0\u5fc3\u75c7(acute coronary syndrome)\u4f4f\u9662\u3002\u4f4f\u9662\u8840\u58d3 162/100 mm Hg, \u4e0b\u80a2\u6c34\u816b(2+), \u5be6\u9a57\u5ba4\u6aa2\u67e5: [Albumin] 2.6 g/dL, t-Chol 320 mg/dL, LDL 178 mg/dL, \u86cb\u767d\u5c3f(4+). \u5982\u679c\u9032\u4e00\u6b65\u6aa2\u67e5\uff0c\u4f55\u7a2e\u6307\u6a19\u7684\u6578\u503c\u6700\u53ef\u80fd\u6703\u6bd4\u6b63\u5e38\u4eba\u504f\u4f4e?\nA. anti-thrombin III\nB. fibrinogen antigen and activity\nC. factor VII\nD. alpha-2 macroglobulin\nE. protein C and protein S levels\n": "(A)", "100-12.\n48\u6b72\u5973\u6027\u6700\u8fd1\u534a\u5e74\u56e0\u70ba\u7cd6\u5c3f\u75c5\u3001\u8840\u58d3\u504f\u9ad8\uff0c\u958b\u59cb\u63a5\u53d7\u4e0b\u5217\u85e5\u7269\u6cbb\u7642\uff0c\u8fd1\u4e09\u9031\u4ee5\u4f86\u81ea\u6211\u767c\u89ba\u6709\u96d9\u4e0b\u80a2\u8db3\u8e1d\u6309\u58d3\u5f0f\u6c34\u816b\u3002\u75c5\u4eba\u672c\u8eab\u9ad4\u91cd\u7121\u986f\u8457\u589e\u52a0\uff0c\u6c92\u6709exertional dyspnea, \u4e5f\u7121\u809d\u75be\u60a3\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5: \u86cb\u767d\u5c3f(-)\uff0c\u8840\u6e05albumin 4.1 g/dL, \u808c\u9178\u91501.1 mg/dL, AST 20 IU/L, ALT 18 IU/L, C3 \u8207 ANA \u7686\u6b63\u5e38\u3002\u6709\u95dc\u6b64\u75c5\u4eba\u7684\u8655\u7f6e\u5efa\u8b70\uff0c\u9664\u4e86\u63a7\u5236\u9e7d\u5206\u651d\u53d6\u4e4b\u5916\uff0c\u4f55\u8005\u61c9\u8a72\u7121\u95dc\uff1f\nA. \u66ab\u505c minoxidil\nB. \u66ab\u505c nifedipine (calcium channel blocker)\nC. \u66ab\u505c metformin\nD. \u66ab\u505c\u6216\u6e1b\u5c11\u4f7f\u7528 NSAID (nonsteroidal anti-inflammatory drugs)\nE. \u66ab\u505c thiazolidinediones\n": "(C)", "100-13.\n31\u6b72\u5973\u6027\u56e0\u767c\u71d2\u3001\u5026\u6020\u3001\u6c34\u816b\u3001\u9ad4\u91cd\u77ed\u671f\u5167\u66b4\u589e5\u516c\u65a4\u4f4f\u9662\u3002\u7406\u5b78\u6aa2\u67e5: \u9ad4\u6eab37.8\u00b0C\uff0c\u8840\u58d3153/110 mmHg\uff0c\u4e0b\u80a2\u6c34\u816b(3+)\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5: \u86cb\u767d\u5c3f(4+)\uff0c\u8840\u6e05C3 34 mg/dL\uff0canti-dsDNA \u5448\u73fe\u9ad8\u50f9\u6578; \u5c3f\u7d20\u6c2e 40 mg/dL\uff0c\u808c\u9178\u91502.5 mg/dL\u3002\u814e\u81df\u5207\u7247\u5728\u5f97\u5230\u768411\u500b\u814e\u7d72\u7403\u67097\u500b\u985e\u4f3c\u7684(\u5982\u5716)\u75c5\u7406\u8b8a\u5316 \u3002\u6709\u95dc\u6b64\u75c5\u4eba\u7684\u8a3a\u65b7\u53ca\u6cbb\u7642:\r1.\u75c5\u7406\u7d50\u679c\u986f\u793a\u70ba\u6162\u6027\u7684\u7b2c\u4e94\u7d1a\uff08class V\uff09lupus nephritis\u3002\r2.\u901a\u5e38\u9019\u6a23\u7684\u75c5\u7406\u8b8a\u5316\u9700\u8981\u8108\u885d\u7642\u6cd5\uff08pulse therapy)\uff0c\u5982: \u985e\u56fa\u9187\u8108\u885d\u7642\u6cd5\u3002\r3.\u4e5f\u53ef\u4f7f\u7528cyclophosphamide\u8108\u885d\u7642\u6cd5\uff0c\u5efa\u8b70\u5728\u524d6\u500b\u6708\u61c9\u6bcf\u6708\u7d66\u4e88\u975c\u8108\u6ce8\u5c040.5-1 g/m2\u3002\r4.\u61c9\u8a72\u5148\u5f9e\u53e3\u670d\u4f4e\u5291\u91cf\u985e\u56fa\u9187(prednisolone 0.5 mg/kg/day)\u958b\u59cb\u6cbb\u7642\u3002\r5.\u6b64\u985e\u75c5\u4eba\u6709\u6108\u986f\u8457\u7684interstitial fibrosis\uff0c\u9577\u671f\u9810\u5f8c\u6bd4\u8f03\u5dee\u3002\r6.\u5fc5\u8981\u6642\uff0c\u53ef\u4ee5\u642d\u914d\u5229\u5c3f\u5291\u6216aspirin\u3002\r\u4e0b\u5217\u4f55\u7a2e\u7d44\u5408\u662f\u6b63\u78ba\u7684\uff1f\nA. 1+2+3\nB. 1+3+4\nC. 2+3+6\nD. 1+4+6\nE. 4+5\n": "(C)", "100-14.\n\u4e00\u4f4d38\u6b72\u8077\u696d\u5a66\u5973\uff0c\u904e\u53bb\u8840\u58d3\u7d04138/84 mm Hg\uff0c\u5728\u61f7\u5b55\u7d0426\u9031\u7522\u524d\u6aa2\u67e5\u6642\u767c\u73fe: \u8840\u58d3 150/94 mm Hg\uff0c\u6709\u86cb\u767d\u5c3f (3+)\uff0c\u548c\u8f15\u5ea6\u8db3\u80cc\u6c34\u816b\u3002\u6709\u95dc\u8840\u58d3\u6cbb\u7642\uff0c\u4f55\u8005\u85e5\u7269\u8f03\u9069\u7576?\r1.hydralazine\r2.labetalol\r3.clonidine\r4.methyldopa\r5.captopril\r6.losartan\r7.aliskiren\nA. 1+4+5\nB. 1+2+4\nC. 2+5+7\nD. 3+4+6\nE. 1+3+6\n": "(B)", "100-15.\n\u4e00\u4f4d46\u6b72\u672b\u671f\u814e\u81df\u75c5\u7537\u6027\uff0c\u56e0\u70baHb 8.4 g/dL\u6545\u91ab\u5e2b\u958b\u7acberythropoietin (EPO, 2000 unit biweekly)\u6ce8\u5c04\u77ef\u6b63\u814e\u6027\u8ca7\u8840\u3002\u96a8\u5f8c\u7684\u516b\u500b\u6708\u671f\u9593\uff0c\u96d6\u7136\u589e\u52a0EPO\u5291\u91cf\u81f3 5000 unit biweekly\uff0c\u75c5\u4eba\u7684Hb\u537b\u9010\u6b65\u964d\u4f4e\u81f36.4 g/dL\u3002\u671f\u9593: \u814e\u529f\u80fd\u7121\u986f\u8457\u60e1\u5316\uff0c\u98f2\u98df\u6b63\u5e38\uff0c\u4e5f\u7121\u7f3a\u9435\u6027\u8ca7\u8840\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5: Reticulocyte count\u504f\u4f4e\uff0c\u800c\u9aa8\u96a8\u6aa2\u67e5\u70ba: Normal cellularity except diminished RBC precursors\u3002\u6709\u95dc\u75c5\u4eba\u7684\u8a3a\u65b7\u4e88\u8655\u7f6e\u5efa\u8b70\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u518d\u589e\u52a0EPO\u81f35000 units three times per week\nB. \u8003\u616e\u7d66\u4e88immunosuppressive agents\nC. \u5982\u679c\u63a5\u53d7\u814e\u81df\u79fb\u690d\uff0c\u8ca7\u8840\u61c9\u8a72\u6703\u6539\u5584\nD. \u6aa2\u67e5\u662f\u5426\u6709anti-erythropoietin antibody\nE. \u9593\u6b47\u6027\u8f38\u8840RBC\u88dc\u5145\uff0c\u77ef\u6b63\u8ca7\u8840\n": "(A)", "100-16.\n\u4e00\u4f4d58\u6b72\u5973\u6027\u56e0\u8179\u75db\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u75c5\u4eba\u6709\u7cd6\u5c3f\u75c5\u9577\u671f\u63a5\u53d7\u4e0b\u5217\u85e5\u7269\u6cbb\u7642\uff0c\u4e00\u5e74\u534a\u524d\u5be6\u9a57\u5ba4\u6aa2\u67e5: creatinine 1.4 mg/dL\uff0c\u4e94\u500b\u6708\u524d\u5347\u81f3 3.5 mg/dL\u3002\u5728\u6025\u8a3a\u7684\u91cd\u8981\u6578\u64da:\u5982\u4e0b: BP 162/88 mm Hg, HR 120 beats/min, respiratory rate 26 breaths/min, BT 35.2\u00b0C, PaO2 96% (room air)\u3002\u8179\u90e8\u89f8\u8a3a\u7121\u7279\u6b8a\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5\u6709 metabolic acidosis: pH 7.01; HCO3- 2.3  mmol/L; [Na] 145 mEq/L, [K] 5.2 mEq/L, [Cl] 99 mEq/L; glucose 78 mg/dL  \u60a8\u8a8d\u70ba: \u6700\u53ef\u80fd\u8ddf\u76ee\u524d\u6240\u4f7f\u7528\u7684\u4f55\u7a2e\u85e5\u7269\u6709\u95dc?\nA. furosemide\nB. metformin\nC. atenolol\nD. losartan\nE. amlodipine\n": "(B)", "100-17.\n\u4e00\u4f4d54 \u6b72\u5973\u6027\uff0c\u6c92\u6709\u7cd6\u5c3f\u75c5\u6216\u6709\u9ad8\u8840\u58d3\uff0c\u4f46\u662f\u6709 proteinuria (2.4 g/24 hr), microscopic hematuria, \u53capolymyalgia\u3002\u5176\u4ed6\u5be6\u9a57\u5ba4\u6aa2\u67e5: , Hb 8.6, MCV 90 (fL), MCHC 32 g/dL. serum creatinine 2.2 mg/dL, hypercalcemia ([Ca] 11.8 mg/dL), \u53ca urinary monoclonal protein\u3002\u814e\u81df\u751f\u6aa2(renal biopsy\uff0c\u7d50\u679c\u5982\u9644\u5716)\u3002\u75c5\u4eba\u7684\u8a3a\u65b7\u6700\u53ef\u80fd\u662f:\nA. Wegener's granulomatosis\nB. multiple myeloma\nC. Hemolytic Uremic Syndrome\nD. systemic lupus erythematosus (SLE)\nE. Henoch-Schonlein Purpura\n": "(B)", "100-18.\n\u4e00\u4f4d\u7d0440\u6b72\u7537\u6027\uff0c\u904e\u53bb\u5065\u5eb7\u60c5\u5f62\u826f\u597d\uff0c\u7121\u7cd6\u5c3f\u75c5\u3002\u672c\u6b21\u56e0\u5026\u6020\u3001\u8179\u75db\u3001\u8170\u9178\u5230\u6025\u8a3a\u3002\u7406\u5b78\u8207\u5be6\u9a57\u5ba4\u6aa2\u67e5: BP 132/82 mm Hg, edema (-), creatinine 3.0 mg/dL\u3002\u5c3f\u6db2\u6aa2\u67e5\u6709: proteinuria (+/-), O.B. (+), WBC 30-50/HPF \uff0c\u534a\u5e74\u524d\u5065\u5eb7\u6aa2\u67e5\u7684creatinine\u503c\u662f 1.0 mg/dL\u3002\u8acb\u554f: \u4e0b\u4e00\u6b65\u61c9\u8a72\u5148\u9032\u884c\u54ea\u7a2e\u6aa2\u67e5\u8a3a\u65b7\u6b65\u9a5f?\nA. \u6aa2\u6e2c \u6297\u6838\u6297\u9ad4 (ANA , anti-nuclear antibody)\nB. \u6aa2\u6e2c anti-GBM (glomerular basement membrane) antibody\nC. \u5b89\u6392\u505a renal sonography\nD. \u4f30\u7b97 eGFR \u8207\u62bd\u8840\u6aa2\u6e2c [Na], [K], [Ca]\nE. \u5b89\u6392\u505a renal biopsy\n": "(C)", "100-19.\n\u4e00\u4f4d\u7d0480\u6b72\u5c45\u4f4f\u5728\u990a\u8b77\u4e2d\u5fc3\u7684\u8001\u4eba\uff0c\u56e0\u70ba\u865b\u5f31\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u6aa2\u67e5\u767c\u73fe: BP 88/64 mm Hg, HR 100/min, BT 37.6\u00b0C, [Albumin] 3.0 g/dL, BUN 32 mg/dL, creatinine 0.8 mg/dL, [Na] 134 mEq/L, [K] 2.7 mEq/L, [Cl] 107 mEq/L\u3002ABG\u70ba pH 7.30, PaO2 90 mm Hg, PaCO2 23 mm Hg, HCO3- 11 mEq/L. \u6025\u8a3a\u91ab\u5e2b\u7684\u8a3a\u65b7\u70ba:\r1.metabolic acidosis\r2.respiratory acidosis\r3.anion-gap (+)\r4.non-anion-gap\r5.\u7b26\u5408hypoaldosteronism\r6.\u53ef\u80fd\u6709\u6f5b\u5728\u611f\u67d3\u75c7\r7.\u53ef\u80fd\u6709severe diarrhea \u6216\u4f7f\u7528diuretics\r\u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba?\nA. 1+3+6\nB. 2+3+5+7\nC. 1+4+5+7\nD. 1+3+7\nE. 1+4+6+7\n": "(A)", "100-20.\n\u6162\u6027\u814e\u81df\u75c5(CKD)\u662f\u570b\u4eba\u91cd\u8981\u7684\u91ab\u7642\u7d93\u6fdf\u8207\u5065\u5eb7\u8b70\u984c\u3002\u6839\u64daCKD\u7167\u8b77\u65b9\u6848\u8207\u570b\u5167\u6d41\u884c\u75c5\u5b78\u5c08\u5bb6\u7684\u591a\u9805\u7814\u7a76\uff0c\u4ee5\u53ca2010\u5e74\u6240\u51fa\u7248\u7684\u9ad8\u8840\u58d3\u6cbb\u7642\u6307\u5f15\u986f\u793a: \u63a7\u5236\u4ee5\u4e0b\u5371\u96aa\u56e0\u5b50\u8207\u6cbb\u7642\u5efa\u8b70\uff0c\u53ef\u4ee5\u5ef6\u7de9\u6216\u6e1b\u5c11 CKD\u9032\u5c55\u81f3\u672b\u671f\u814e\u81df\u75c5(ESRD)\u6216\u6d17\u814e(dialysis)\uff0c\u4f55\u8005\u9664\u5916?\nA. DM-CKD\u75c5\u4eba\uff0c\u5b9a\u671f\u6aa2\u6e2c\u86cb\u767d\u5c3f\nB. DM-CKD\u75c5\u4eba\uff0c\u5982\u679c\u6709\u86cb\u767d\u5c3f(> 1.0 g/day)\uff0c\u8840\u58d3\u63a7\u5236\u4ee5140/90 mm Hg\u70ba\u76ee\u6a19\nC. DM-CKD\u75c5\u4eba\uff0c\u5b9a\u671f\u6aa2\u6e2cHbA1C\uff0c\u63a7\u5236\u57287.0 %\u6216\u4ee5\u4e0b\nD. \u8840\u8102\u7570\u5e38(dyslipidemia)\u4e5f\u662f\u4e00\u500b\u5371\u96aa\u56e0\u5b50\uff0c\u5982: high LDL-cholesterol level\nE. \u5efa\u8b70\u4f4e\u9e7d(low salt)\u98f2\u98df\u7fd2\u6163\n": "(B)", "100-21.\n\u4e00\u4f4d70\u6b72\u5973\u6027\uff0c\u672c\u8eab\u6709\u9ad8\u8840\u58d3\uff0c\u4f7f\u7528atenolol \u548c furosemide\uff0c\u56e0\u70ba\u8fd1\u4e00\u9031\u4f86\u6709\u982d\u6688\u3001\u865b\u5f31\u60c5\u5f62\uff0c\u6240\u4ee5\u5df2\u7d93\u66ab\u505c\u8840\u58d3\u7528\u85e5\u3002\u5230\u6025\u8a3a\u6642: \u8840\u58d3 114/68 mm Hg, HR 100/min, BT 36.5\u00b0C, edema (-). \u5be6\u9a57\u5ba4\u6aa2\u67e5: Hb 10.5 g/dL, Hct 29%, albumin 3.8 g/dL, creatinine 1.1 mg/dL, [Na] 119 mEq/L, [K] 3.6 mEq/L, [Cl] 84 mEq/L, ABG\u70ba: pH 7.47, PaO2 98 mm Hg, PaCO2 44 mm Hg, HCO3- 27 mEq/L. \u6aa2\u6e2c\u5c3f\u4e2d\u96fb\u89e3\u8cea: [Na]urine 6 mEq/L, [K]urine 14 mEq/L. \u8acb\u554f: \u4ee5\u4e0b\u8a3a\u65b7\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. \u98f2\u98df\u4e2d\u9e7d\u5206(salt)\u651d\u53d6\u53ef\u80fd\u4e0d\u8db3\nB. \u7b26\u5408SIADH (syndrome of inappropriate antidiuretic hormone hypersecretion)\nC. ABG\u986f\u793a\u75c5\u4eba\u6709metabolic alkalosis\nD. \u53ef\u80fd\u8207\u4e4b\u524d\u4f7f\u7528diuretics (furosemide)\u6709\u95dc\nE. \u61c9\u8a72\u6aa2\u6e2cserum \u548c urine osmolality\uff0c\u6709\u52a9\u65bc\u9451\u5225\u8a3a\u65b7\n": "(B)", "100-22.\n\u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD, hemodialysis)\uff0c\u6709\u95dc\u8179\u819c\u900f\u6790(PD, peritoneal dialysis)\u7684\u6558\u8ff0\u8207\u9577\u671f\u5408\u4f75\u75c7\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. PD\u75c5\u4eba\u4f7f\u7528\u9ad8\u7cd6\u900f\u6790\u6db2\u662f\u70ba\u4e86\u8981\u9054\u5230\u900f\u6790\u6e05\u9664\u5c3f\u6bd2\u7d20(uremic toxin)\u7684\u6548\u679c\nB. PD\u75c5\u4eba\u5bb9\u6613\u51fa\u73fehypertriglyceridemia\uff0c\u662f\u56e0\u70ba\u4f7f\u7528\u9ad8\u7cd6\u900f\u6790\u6db2\nC. \u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD)\uff0c\u8179\u819c\u900f\u6790(PD)\u75c5\u4eba\u8f03\u5bb9\u6613\u767c\u751f\u8179\u819c\u708e(peritonitis)\nD. \u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD)\uff0c\u8179\u819c\u900f\u6790(PD)\u75c5\u4eba\u6bcf\u65e5\u86cb\u767d\u8cea\u6d41\u5931\u91cf\u8f03\u9ad8\nE. \u76f8\u8f03\u65bc\u8179\u819c\u900f\u6790(PD)\uff0c\u8840\u6db2\u900f\u6790(HD)\u75c5\u4eba\u8f03\u51fa\u73fe\u900f\u6790\u4e2d\u4f4e\u8840\u58d3\n": "(A)", "101-1.\n\u4e00\u4f4d65\u6b72\u7cd6\u5c3f\u75c5\u4eba\uff0c\u6709\u9ad8\u8840\u58d3\uff0c\u6e96\u5099\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u3002\u7406\u5b78\u6aa2\u67e5:BP 118/74, edema (-), serum [creatinine] 1.5 mg/dL\u3002\u76ee\u524d\u7528\u85e5\u70ba: metformin 500 mg bid, irbesartan 75 mg qd, trichlormethiazide 1 mg qd. \u70ba\u4e86\u964d\u4f4e\u767c\u751fcontrast nephropathy\u7684\u5371\u96aa\uff0c\u4ee5\u4e0b\u54ea\u9805\u63aa\u65bd\u6700\u4e0d\u5efa\u8b70\u3002\nA. \u505c\u7528metformin, \u66f4\u63db\u6210\u5176\u4ed6\u964d\u8840\u7cd6\u85e5\nB. volume expansion with saline, \u53ef\u4ee5\u52a0\u4e0a bicarbonate\nC. \u505c\u7528irbesartan, \u66f4\u63db\u6210fenoldopam\u964d\u8840\u58d3\u85e5\u6bd4\u8f03\u5b89\u5168\nD. \u7d66\u4e88 N-acetylcysteine\nE. \u6253radiocontrast agent\u524d\uff0c\u7d66\u4e88aminophylline\n": "(C)", "101-2.\n\u4e00\u4f4d24\u6b72\u5973\u6027\uff0c\u904e\u53bb\u7121\u75c5\u53f2\u3002\u7d042\u500b\u6708\u524d\u958b\u59cb\u6ce8\u610f\u51fa\u73fe\u6c34\u816b\uff0c\u9ad4\u91cd\u57282\u500b\u6708\u5167\u589e\u52a08\u516c\u65a4\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5: Albumin 2.8 g/dL, creatinine 0.8 mg/dL, t-Chol 280 mg/dL, LDL 163 mg/dL, urine protein-creatinine (P/C) ratio \u7d049 mg/mg, urinalysis O.B. (-), serum [K] 4 mEq/L, [Ca] 9.2 mg/dL, Hb 12 g/dL\u3002\u672c\u75c5\u4eba\u7684\u8a3a\u65b7\uff0c\u6700\u53ef\u80fd\u70ba?\nA. IgA nephropathy\nB. minimal change disease\nC. multiple myeloma with nephropathy\nD. systemic lupus erythromatous (SLE) with nephropathy\nE. membranoproliferative glomerulonephritis (MPGN)\n": "(B)", "101-3.\n\u6709\u95dchyperuricemia\u7684\u6cbb\u7642\uff0c\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u6558\u8ff0\u7684\u7d44\u5408\u662f\u6b63\u78ba\u7684?\r(1) asymptomatic hyperuricemia\u75c5\u4eba\u4f7f\u7528allopurinol\u53ef\u4ee5\u9810\u9632\u814e\u529f\u80fd\u60e1\u5316\r(2) asymptomatic hyperuricemia\u75c5\u4eba\u4f7f\u7528\u9810\u9632\u6027allopurinol\u53ef\u4ee5\u9810\u9632acute uric acid nephropathy\u767c\u751f\r(3) \u5df2\u7d93\u6709gouty arthritis\u7684\u75c5\u4eba\uff0c\u5efa\u8b70\u7d66\u4e88allopurinol\u9810\u9632uric acid stone\u6216calcium oxalate stone\u767c\u751f\r(4)\u5c0d\u65bc\u53cd\u8986\u767c\u751furic acid stone\u7684\u75c5\u4eba\uff0c\u4e5f\u53ef\u4ee5\u4f7f\u7528potassium-citrate\u6cbb\u7642\r(5) \u5df2\u4f7f\u7528allopurinol\u7684\u75c5\u4eba\u5982\u679c\u53c8\u767c\u751facute gouty arthritis, \u61c9\u8a72\u505c\u7528allopurinol, \u6539\u7528 colchicine\u4f86\u53d6\u4ee3\nA. (3)+(4)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (1)+(3)+(5)\n": "(A)", "101-4.\n\u4e00\u4f4dscleroderma (systemic sclerosis)\u7684\u75c5\u4eba\uff0c\u904e\u53bb\u8840\u58d3\u63a7\u5236\u826f\u597d\uff0c\u6709\u8f15\u5ea6\u86cb\u767d\u5c3f(+)\uff0ccreatinine\u7d041.8 mg/dL. \u6700\u8fd1\u4e00\u9031\u8840\u58d3\u5347\u9ad8(BP 158/92 mmHg), creatinine\u4e0a\u5347\u52303.0 mg/dL, \u5c3f\u6db2\u6aa2\u67e5protein (+++), O.B. (2+). \u91ab\u5e2b\u8a3a\u65b7\u75c5\u4eba\u53ef\u80fd\u4f75\u767c scleroderma renal crisis (SRC), \u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\nA. Scleroderma\u7684\u75c5\u4eba\u5927\u591a\u6709 Anti-nuclear Antibody (ANA) \u967d\u6027\nB. anti-Scl-70 antibody\u662fSRC\u7684risk predictor\nC. \u6709anti-RNA polymerase III (anti-RNA POL3) antibody\u7684\u4eba\u6bd4\u8f03\u4e0d\u6703\u767c\u751fSRC\nD. \u8840\u58d3\u63a7\u5236\u6700\u91cd\u8981\uff0c\u4f46\u61c9\u76e1\u91cf\u907f\u514d\u4f7f\u7528ACEI (angiotensin converting enzyme inhibitor)\uff0c\u52a0\u91cd\u814e\u81df\u60e1\u5316\nE. Scleroderma\u7684\u75c5\u4eba\u82e5\u4f7f\u7528prophylaxis glucocorticoid, \u53ef\u80fd\u6703\u6e1b\u5c11\u4f75\u767cSRC\n": "(A)", "101-5.\n\u4e00\u4f4dCKD(chronic kidney disease) Stage 4\u75c5\u4eba\uff0ccreatinine 3.8 mg/dL, Hb 8.6 g/dL. \u82e5\u8981\u4f7f\u7528erythropoiesis-stimulating agent, \u5982: erythropoietin (EPO). \u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u61c9\u6ce8\u610f\u662f\u5426\u6709\u9435\u8cea\u7f3a\u4e4f\uff0c\u4e00\u822c\u5efa\u8b70ferritin > 200 ng/mL, transferrin saturation (TS) > 20%\nB. Hb \u76ee\u6a19\u70ba>13 g/dL, \u4ee5\u6e1b\u5c11\u5fc3\u8840\u7ba1\u5408\u4f75\u75c7\uff0c\u4e26\u4fdd\u8b77\u814e\u529f\u80fd\nC. \u63a7\u5236\u6216\u6539\u5584secondary hyperparathyroidism, \u6709\u52a9\u65bcEPO\u6548\u679c\nD. \u5c11\u6578\u4eba\u82e5\u51fa\u73feanti-EPO antibody, \u6703\u6709pure RBC aplasia\nE. \u4f75\u7528ACEI (angiotensin converting enzyme inhibitor)\u53ef\u80fd\u6703\u5e72\u64fe\u6216\u964d\u4f4eEPO\u6548\u679c\uff1b\u800c\u4f7f\u7528statin\u985e\u964d\u4f4echronic inflammation\u53ef\u80fd\u6709\u52a9\u65bcEPO\u6548\u679c\n": "(B)", "101-6.\n\u6709\u95dc\u8179\u819c\u900f\u6790(peritoneal dialysis, \u7c21\u7a31PD)\u75c5\u4eba\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u767c\u751f\u8179\u819c\u708e(peritonitis)\u6700\u5e38\u898b\u7684\u83cc\u7a2e\u662f Gram negative \u83cc\u7a2e\nB. Pseudomonas\u6216fungal peritonitis, \u901a\u5e38\u4e0d\u6613\u6cbb\u7642,\u6709\u6642\u9700\u8981\u62d4\u9664PD \u5c0e\u7ba1 (remove PD catheter)\nC. \u5c0dPD\u75c5\u4eba, \u4f7f\u7528mupirocin\u5c0d\u65bc\u6709Staphylococcus aureus nasal carriage\u8005\uff0c\u53ef\u4ee5\u6709\u6548\u964d\u4f4eexit site infection\nD. \u8179\u819c\u708e\u7684\u8a3a\u65b7\u6a19\u6e96\u4e4b\u4e00\u662fcloudy peritoneal fluid, \u4e14\u5176\u4e2dWBC > 100 cells/mm3,\u4e00\u822c\u4ee5neutrophil\u70ba\u4e3b\nE. \u7531\u65bc\u900f\u6790\u65b9\u5f0f\u7684\u7279\u6027, PD\u75c5\u4eba\u6bd4\u8840\u6db2\u900f\u6790\u75c5\u4eba\u8f03\u5e38\u6709hypertriglyceridemia\u53cahypoproteinemia\n": "(A)", "101-7.\n35\u6b72\u5973\u6027\uff0c\u672c\u8eab\u6709CKD (chronic kidney disease) stage 5, \u56e0\u5de5\u4f5c\u4e2d\u8dcc\u5012\u767c\u751ftibia\u9aa8\u6298, \u5be6\u9a57\u5ba4\u6aa2\u67e5: creatinine 4.8 mg/dL, Hb 10.0 g/dL, [Ca] 8.2 mg/dL, [P] 5.9 mg/dL, iPTH 680 pg/mL (\u6b63\u5e38\u503c 10-65 pg/mL), \u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u9019\u662fCKD\u4f75\u767cadynamic bone disease\nB. \u53ef\u4ee5\u7d66\u4e88\u9069\u7576 active Vitamin D3 \u6cbb\u7642\nC. \u98f2\u98df\u885b\u6559\uff0c\u6307\u5c0ediet phosphate restriction (800-1000 mg/day)\nD. \u9019\u4f4d\u75c5\u4eba\u5982\u679c\u6aa2\u67e5alkaline phsphatase (ALP), \u6578\u503c\u61c9\u8a72\u6703\u6bd4\u6b63\u5e38\u503c\u504f\u9ad8\nE. \u5982\u679c\u505a\u9aa8\u75c5\u7406\u6aa2\u67e5\uff0c\u578b\u614b\u6bd4\u8f03\u50cfosteitis fibrosa, \u800c\u4e0d\u662favascular necrosis\n": "(A)", "101-8.\n\u4e00\u4f4d30\u6b72\u61f7\u5b55\u5973\u6027\uff0c\u56e0\u70ba\u8840\u58d3\u504f\u9ad8(BP 154/102 mm Hg), \u86cb\u767d\u5c3f(2+), \u4e0b\u80a2\u6c34\u816b\u4f86\u8a3a\u3002\u91dd\u5c0d\u8840\u58d3\u63a7\u5236\uff0c\u4ee5\u4e0b\u54ea\u4e00\u500b\u85e5\u7269\u6bd4\u8f03\u4e0d\u5408\u9069?\nA. labetalol\nB. hydralazine\nC. ramipril\nD. methyldopa\nE. \u5982\u679c\u51fa\u73fepre-eclampsia\u53capulmonary edema, \u53ef\u4ee5\u4f7f\u7528Intravenous nitroglycerin\n": "(C)", "101-9.\n\u4e00\u4f4d32\u6b72\u5973\u6027\u904e\u53bb\u7121\u9ad8\u8840\u58d3\u75c5\u53f2\u3002\u67d0\u65e5\u4e0a\u5348\u9192\u4f86\u767c\u73fe\u56db\u80a2\u7121\u529b\uff0c\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u7406\u5b78\u8207\u5be6\u9a57\u5ba4\u6aa2\u67e5: BP 128/68 mmHg, edema (-), [creatinine] 1.0 mg/dL, [Na] 138 mEq/L, [K] 2.8 mEq/L, [Mg]  1.0 mg/dL, ABG\u70ba pH 7.48, [HCO3-] 28 mEq/L, thyroid hormone (T3, T4, TSH)\u90fd\u6b63\u5e38. \u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\nA. \u53ef\u80fd\u662ftype I renal tubular acidosis (RTA), \u61c9\u8a72\u6aa2\u67e5urine anion-gap\nB. \u53ef\u80fd\u662ftype 2 renal tubular acidosis (RTA), \u61c9\u8a72\u6aa2\u67e5urine osmolality gap\nC. \u53ef\u80fd\u662fBartter's syndrome, \u53ef\u4ee5\u4f7f\u7528spironolactone \u6cbb\u7642hypokalemia\nD. \u53ef\u80fd\u662fGitelman's syndrome, \u53ef\u4ee5\u4f7f\u7528NSAIDs \u6cbb\u7642 polyuria \u548c salt wasting\nE. \u53ef\u80fd\u662frenin-secreting tumor,  \u61c9\u8a72\u5b89\u6392\u505a\u814e\u4e0a\u817a(adrenal gland)\u5f71\u50cf\u6aa2\u67e5\n": "(C)", "101-10.\n\u4e00\u4f4d54\u6b72\u5973\u6027\uff0c\u56e0\u5026\u6020\u3001\u86cb\u767d\u5c3f\u3001\u4e0b\u80a2\u6c34\u816b\u4f86\u8a3a\u3002\u7d93\u814e\u81df\u751f\u6aa2(renal biopsy)\u986f\u793a\u6709immune-complex\u53caC3 \u6c89\u7a4d\uff0c\u8a3a\u65b7\u70bamembranoproliferative glomerulonephritis (MPGN)\u3002\u6709\u95dcMPGN\u7684\u81e8\u5e8a\u8868\u73fe\u8207\u6cbb\u7642\uff0c\u4f55\u8005\u6558\u8ff0\u7d44\u5408\u662f\u6b63\u78ba\u7684?\r(1) \u8840\u6e05\u6aa2\u67e5\uff0c\u75c5\u4eba\u7684\u8840\u6e05C3\u503c\u901a\u5e38\u6703\u964d\u4f4e\r(2) \u8981\u7be9\u6aa2\u6709\u6c92\u6709infectious disease, \u5982: C\u578b\u809d\u708e\r(3) monoclonal gammopathy\u7b49chronic inflammation\u4e5f\u6703\u5408\u4f75MPGN\r(4) \u6cbb\u7642\u4ee5glucocorticoid \u6216cytotoxic agent\u70ba\u4e3b, \u4e14\u56e0\u70ba\u814e\u529f\u80fd\u9810\u5f8c\u4e0d\u597d\uff0c\u6545\u4e0d\u4f7f\u7528ACEI (angiotensin-converting enzyme inhibitor) \u6216angiotensin II-receptor blocker (ARB)\r(5) MPGN\u672b\u671f\u814e\u75c5\u8b8a\u75c5\u4eba\uff0c\u5982\u63a5\u53d7\u505a\u814e\u81df\u79fb\u690d\u4e4b\u5f8c\uff0c\u5f88\u5c11\u518d\u5fa9\u767c\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (2)+(3)+(5)\nD. (2)+(3)+(4)+(5)\nE. (1)+(4)+(5)\n": "(A)", "101-11.\n\u4e00\u4f4d70\u6b72\u7537\u6027\u56e0lymphoma\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u5f8c\uff0c\u51fa\u73fe\u6578\u65e5\u5641\u5fc3\u3001\u5614\u5410\u3002\u4e09\u5929\u5f8c\u88ab\u9001\u81f3\u6025\u8a3a\u767c\u73feWBC 11,000/mm3, Hb 8.0 g/dL, \u6709\u812b\u6c34\u75c7\u72c0\uff0c\u521d\u6b65\u8a3a\u65b7\u70batumor lysis syndrome\u53caacute kidney injury. \u4ee5\u4e0b\u54ea\u4e00\u7a2e\u72c0\u6cc1\uff0c\u6700\u4e0d\u5e38\u51fa\u73fe?\nA. hyperuricemia\nB. hypercalcemia\nC. hyperkalemia\nD. hyperphosphatemia\nE. serum creatinine level \u4e0a\u5347\n": "(B)", "101-12.\n\u6709\u4e0051\u6b72\u7537\u6027\uff0c\u4f4f\u9662\u4e2d\u767c\u73fe\u8840\u9209\uff08Na\uff09138 mmol/L\uff0c\u8840\u6c2f\uff08CL\u203e\uff09103 mmol/L\uff0c\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\uff1apH 7.3\uff0cPCO2 30mmHg\uff0cPO2 92 mmHg\uff0cHCO3\u203e 14 mEq/L\u3002\u4e0b\u5217\u90a3\u4e00\u7a2e\u70ba\u53ef\u80fd\u4e4b\u539f\u56e0\uff1f\nA. \u4f7f\u7528amphotericin B\nB. \u4f7f\u7528 magnesium sulfate\nC. \u98e2\u9913\uff08starvation\uff09\nD. \u4f7f\u7528cholestyramine\nE. \u814e\u529f\u80fd\u4e0d\u5168\uff08renal insufficiency\uff09\u4e4b\u75c5\u4eba\u4f7f\u7528\u975e\u985e\u56fa\u9187\u6297\u767c\u708e\u85e5\u7269\uff08NSAID\uff09\n": "(C)", "101-13.\n\u6709\u4e0072\u6b72\u7684\u8001\u5148\u751f\uff0c\u56e0\u5c3f\u9053\u611f\u67d3\u800c\u4f4f\u9662\uff0c3\u5e74\u524d\u5df2\u77e5\u8840\u4e2d\u808c\u9178\u9150\u7d042~3mg/dl\uff0c\u4f4f\u9662\u7528\u85e5\u7269\u6cbb\u7642\u6578\u5929\u5f8c\uff0c\u8840\u808c\u9178\u9150\u5347\u81f35.0mg/dl\uff0cBUN\u9ad8\u523098mg/dl\u3002\u4e26\u7121\u767c\u73fe\u660e\u986f\u814e\u8870\u7aed\u4e4b\u539f\u56e0\uff0c\u75c5\u4eba\u7121\u767c\u71d2\u3001\u76ae\u75b9(rash)\uff0c\u8840\u58d3130/80mmHg\uff0c\u5fc3\u8df378/min\uff0c\u5c3f\u91cf1100 cc/day\u3002\u4e0b\u5217\u4f55\u8005\u63cf\u8ff0\u4e0d\u5c0d?\nA. \u61c9\u61f7\u7591\u6025\u6027\u9593\u8cea\u6027\u814e\u708e(acute interstitial nephritis, AIN)\u4e4b\u53ef\u80fd\u6027\nB. AIN\u4ee5\u904e\u654f\u6027\u9593\u8cea\u6027\u814e\u708e( allergic interstitial nephritis) \u6700\u5e38\u898b\nC. \u975e\u985e\u56fa\u9187\u6297\u767c\u708e\u85e5\u7269(NSAID)\u5f15\u8d77\u4e4bAIN\u5e38\u7121\u767c\u71d2\uff0c\u76ae\u75b9\uff0c\u4f46\u5e38\u898b\u6025\u6027\u814e\u8870\u7aed\u4f75\u6709\u56b4\u91cd\u86cb\u767d\u5c3f\nD. \u5c3f\u4e2d\u55dc\u4f0a\u7d05\u767d\u8840\u7403(eosinophil) \u662f\u5426\u589e\u52a0\u5c0d\u8a3a\u65b7AIN\u5927\u6709\u5e6b\u52a9\uff0c\u5176\u654f\u611f\u5ea6\u53ca\u7279\u7570\u6027\u7686\u4f73\uff0c\u61c9\u8a72\u90fd\u8981\u4f5c\u6b64\u6aa2\u67e5\nE. AIN\u4e0d\u4e00\u5b9a\u8981\u9760\u814e\u7a7f\u524c\u8a3a\u65b7\n": "(D)", "101-14.\n\u6709\u4e0049\u6b72\u7537\u6027, \u56e0\u814e\u75c5\u75c7\u5019\u7fa4(nephrotic syndrome)\u4f4f\u9662\uff0c\u5ffd\u7136\u767c\u751f\u53f3\u8170\u75bc\u75db\uff0c\u9a57\u5c3f\u767c\u73fe\u8840\u5c3f\uff0c\u86cb\u767d\u5c3f\u3001\u814e\u529f\u80fd\u4e0b\u964d\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u61c9\u61f7\u7591\u814e\u975c\u8108\u6813\u585e(renal vein thrombosis)\nB. \u6b64\u7a2e\u75c5\u4eba\u56e0\u51dd\u8840\u7570\u5e38\u9020\u6210\u6613\u51dd\u8840\u72c0\u614b\uff08hypercoagulable state\uff09\u800c\u5bb9\u6613\u767c\u751f\u6b64\u75c7.\nC. \u75c5\u7406\u8b8a\u5316\u70ba\u819c\u6027\u814e\u75c5\u8b8a(membranous nephropathy)\u8005\u6700\u6613\u767c\u751f\u6b64\u4f75\u767c\u75c7.\nD. \u6700\u654f\u611f\uff08\u5e7e\u4e4e100%\uff09\u4e4b\u6aa2\u67e5\u65b9\u6cd5\u70ba\u675c\u535c\u52d2\u8d85\u97f3\u6ce2(doppler ultrasound)\nE. \u78ba\u5b9a\u8a3a\u65b7\u70ba\u814e\u975c\u8108\u6813\u585e\u5f8c\u61c9\u4f7f\u7528\u6297\u51dd\u8840\u5291(anticoagulant)\u6cbb\u7642\n": "(D)", "101-15.\n\u6709\u4e0042\u6b72\u5973\u6027\uff0c\u5065\u6aa2\u767c\u73fe\u5c3f\u6db2\u4e2d\u86cb\u767d( - )\uff0c\u7d05\u8840\u74035-7/HPF\uff0c\u767d\u8840\u74030-3/ HPF\uff0c\u8868\u76ae\u7d30\u80de0-2/ HPF\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u55ae\u7d14\u6027\u986f\u5fae\u8840\u5c3f(isolated microscopic hematuria)\u53ef\u4ee5\u662f\u814e\u5c0f\u7403\u75be\u75c5\u4e4b\u8868\u73fe\u3002\nB. \u8089\u773c\u6027\u8840\u5c3f(gross hematuria) \u901a\u5e38\u4ee3\u8868\u6709\u6bd4\u8f03\u91cd\u8981\u7684\u814e\u6ccc\u5c3f\u9053\u75be\u75c5\u3002\nC. \u8840\u5c3f\u4f75\u6709\u5c3f\u4e2d\u767d\u8840\u7403 >5/ HPF\u53ca\u83cc\u5c3f(bacteriuria) \u4ee3\u8868\u53ef\u80fd\u6709\u611f\u67d3\u3002\nD. \u5973\u6027\u4e4b\u6025\u6027\u8180\u80f1\u708e\u6216\u5c3f\u9053\u708e\u6709\u6642\u6703\u767c\u751f\u8089\u773c\u6027\u8840\u5c3f\u3002\nE. \u75c5\u4eba\u53ea\u8981\u6709\u4e00\u6b21\u8840\u5c3f\uff08RBC\uff1e2/HPF\uff09\u5c31\u8868\u793a\u814e\u6ccc\u5c3f\u9053\u4e00\u5b9a\u6709\u75c5\u3002\n": "(E)", "101-16.\n\u4e00\u4f4d84\u6b72\u5973\u6027\uff0c\u56e0\u95dc\u7bc0\u75db\u53bb\u85e5\u623f\u8cb7\u85e5\uff0c\u5403\u4e86\u5e7e\u5929\u5f8c\u767c\u751f\u5614\u5410\uff0c\u5728\u6025\u8a3a\u8655\u767c\u73fe\u5c3f\u7d20\u6c2e\uff08BUN\uff09\u70ba84 mg/dl\uff0c\u808c\u9178\u9150\uff08creatinine\uff09\u70ba6.1 mg/dl\u3002\u904e\u53bb\u4e26\u7121\u814e\u81df\u75c5\u53f2\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u53ef\u80fd\u6709\u6025\u6027\u814e\u640d\u50b7\uff08acute kidney injury, AKI\uff09\nB. \u6b62\u75db\u85e5\u53ef\u80fd\u626e\u6709\u91cd\u8981\u89d2\u8272\u3002\nC. \u5927\u591a\u6578\u814e\u81df\u5c08\u5bb6\u6cbb\u7642AKI\u5728BUN 60 mg/dl\u5c31\u958b\u59cb\u505a\u900f\u6790\uff08dialysis\uff09\u4ee5\u907f\u514d\u4f75\u767c\u75c7\uff0c\u592a\u665a\u505a\u6703\u589e\u52a0\u6b7b\u4ea1\u7387\u3002\nD. \u900f\u6790\u65b9\u6cd5\u4e4b\u4f7f\u7528\u8981\u8003\u616e\u7576\u5730\u53ef\u63d0\u4f9b\u7684\u8a2d\u5099\u3002\nE. \u5c0d\u8840\u58d3\u504f\u4f4e\u7684\u75c5\u4eba\uff0c\u7528\u8179\u819c\u900f\u6790\u6bd4\u8840\u6db2\u900f\u6790\u5b89\u5168\u3002\n": "(C)", "101-17.\n\u4e00\u500b35\u6b72\u7537\u6027\uff0c\u5728\u6bcf\u6b21\u611f\u5192\u5f8c\u6703\u767c\u73fe\u8089\u773c\u53ef\u898b\u4e4b\u8840\u5c3f\uff08gross hematuria\uff09\uff0c\u814e\u7a7f\u524c\u8a3a\u65b7\u70baIgA\u814e\u75c5\u8b8a\uff08IgA nephropathy\uff09\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u5e38\u5e38\u4ee5\u814e\u75c5\u75c7\u5019\u7fa4\uff08nephrotic syndrome\uff09\u8868\u73fe\u3002\nB. \u5728\u75c5\u7a0b\u4e2d\u5e38\u5e38\u767c\u751f\u6025\u6027\u814e\u8870\u7aed\u3002\nC. \u5c0d\u5927\u90e8\u4efd\u75c5\u4eba\u800c\u8a00\uff0c\u662f\u4e00\u76f8\u5c0d\u826f\u6027\u4e4b\u75be\u75c5\uff0c\u67095-30%\u6703\u5b8c\u5168\u7de9\u89e3\uff08complete remission\uff09\u3002\nD. \u6709\u76f8\u7576\u9ad8\u6bd4\u4f8b\u7684\u75c5\u4eba\uff08\u7d0440%\uff09\u572810\u5e74\u5167\u6703\u767c\u751f\u814e\u8870\u7aed\u3002\nE. \u5f88\u591a\u5927\u898f\u6a21\u7814\u7a76\u986f\u793a\u5207\u9664tonsil\uff0c\u4f7f\u7528\u985e\u56fa\u9187\u53ca\u9b5a\u6cb9\uff08fish oil\uff09\u53ef\u4ee5\u6539\u5584\u6240\u6709IgA\u814e\u75c5\u8b8a\u4e4b\u75c5\u4eba\u3002\n": "(C)", "101-18.\n\u5728\u503c\u73ed\u6642\u770b\u5230\u4e00\u500b58\u6b72\u5973\u6027\uff0c\u8840\u9209108 mmole/L\uff0c\u75c5\u4eba\u610f\u8b58\u4e0d\u6e05\u695a\uff0c\u5c0d\u6b64\u75c5\u4eba\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u75c5\u4eba\u4e4b\u4f4e\u8840\u9209\u61c9\u8a72\u8d95\u5feb\u6cbb\u7642\u3002\nB. \u9664\u7cfe\u6b63\u5176\u4f4e\u8840\u9209\u5916\u4ea6\u61c9\u627e\u51fa\u539f\u56e0\u5c0d\u75c7\u6cbb\u7642\u3002\nC. \u70ba\u907f\u514d\u767c\u751f\u56e0\u6ef2\u900f\u58d3\u5287\u70c8\u8b8a\u5316\u5f15\u8d77\u4e4b\u8166\u75c5\u8b8a\uff0dosmotic demyelination syndrome\uff08ODS\uff09\uff0c\u7cfe\u6b63\u4e4b\u901f\u5ea6\u6108\u6162\u6108\u4f73\uff0c\u4e0d\u5fc5\u8003\u616e\u63d0\u5347\u8840\u9209\u4e4b\u901f\u7387\u3002\nD. \u6cbb\u7642\u592a\u5feb\u5f15\u8d77\u8166\u90e8\u4e4b\u4f75\u767c\u75c7ODS\u6700\u591a\u767c\u751f\u5728Pons\uff0c\u4f46\u5176\u4ed6\u8166\u90e8\u7d44\u7e54\u4ea6\u53ef\u767c\u751f\u5982\u5c0f\u8166\u3001\u5927\u8166\u76ae\u8cea\u2026\u7b49\u3002\nE. \u82e5\u7cfe\u6b63\u592a\u5feb\u4f7f\u8840\u9209\u904e\u5ea6\u77ef\u6b63\u6642\uff0c\u60f3\u9810\u9632ODS\u6216\u60f3\u9006\u8f49\uff08reverse\uff09ODS\u4e4b\u767c\u751f\uff0c\u53ef\u4ee5\u4f7f\u7528\u975c\u8108\u6ce8\u5c045%\u8461\u8404\u7cd6\u8f38\u6db2\uff0c\u91cd\u65b0\u5f15\u767c\u4f4e\u8840\u9209\u3002\n": "(C)", "101-19.\n\u4e0068\u6b72\u5973\u6027\uff0c\u77e5\u9053\u6709\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u3001\u53ca\u6162\u6027\u814e\u81df\u75c5\uff08CKD\uff09\u5df2\u7d933\u5e74\uff0c\u5176\u8840\u4e2d\u5c3f\u7d20\u6c2e\uff08BUN\uff09\u70ba39mg/dl\uff0c\u808c\u9178\u9150\uff08creatinine\uff09\u70ba2.1mg/dl\u3002\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6709\u7cd6\u5c3f\u75c5\u6216\u6bcf\u5929\u5c3f\u86cb\u767d\u5927\u65bc1\u514b\u4e4bCKD\u75c5\u4eba\uff0c\u8840\u58d3\u61c9\u63a7\u5236\u81f3125/75 mmHg\u3002\nB. \u8840\u7ba1\u5f35\u529b\u7d20\u8f49\u63db\ufffdC\u963b\u65b7\u5291\uff08ACE inhibitor\uff09\u6216\u8840\u7ba1\u5f35\u529b\u7d20\u53d7\u9ad4\u963b\u65b7\u5291\uff08ARB\uff09 \u53ef\u4ee5\u6e1b\u7de9\u814e\u529f\u80fd\u60e1\u5316\u3002\nC. ACE inhibitors\u6216ARB\u5c0d\u6709\u7f3a\u8840\u6027\u814e\u8840\u7ba1\u75be\u75c5\u4e4b\u75c5\u4eba\uff08ischemic renovascular disease\uff09\u8005\u53ef\u5f15\u767c\u6025\u6027\u814e\u640d\u50b7\uff08acute kidney injury\uff09\u3002\nD. ACE inhibitor\u6216ARB\u4e4b\u5916\u518d\u52a0\u7528\u7559\u9240\u5229\u5c3f\u5291\uff08potassium-sparing diuretics \uff09\u5c0d\u75c5\u4eba\u66f4\u6709\u5e6b\u5fd9\u800c\u4e14\u5b89\u5168\uff0c\u6240\u4ee5\u6bcf\u500b\u75c5\u4eba\u90fd\u53ef\u653e\u5fc3\u4f75\u7528\u3002\nE. \u8840\u8102\u80aa\u82e5\u5347\u9ad8\u61c9\u7a4d\u6975\u6cbb\u7642\u3002\n": "(D)", "101-20.\n\u6709\u4e0040\u6b72\u5973\u6027\uff0c\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\u5448\u73fe\uff1apH 7.55\u3001PCO2 50mmHg\u3001HCO3\u203e 42 mEq/L\u3001PO2 94 mmHg\uff0c\u8acb\u554f\u4e0b\u5217\u90a3\u4e9b\u70ba\u53ef\u80fd\u4e4b\u75c5\u56e0\uff1f\r(1)\u4f7f\u7528estrogen\r(2)\u4f7f\u7528amphotericin B\r(3)\u9382\u7f3a\u4e4f\uff08magnesium deficiency\uff09\r(4)\u4f7f\u7528acetazolamide\r(5)\u8f38\u5c3f\u7ba1\u4e59\u72c0\u7d50\u8178\u9020\u53e3\u8853\uff08ureterosigmoidostomy\uff09\nA. (2)+(4)\nB. (4)+(5)\nC. (1)+(3)\nD. (2)+(5)\nE. (2)+(3)\n": "(C)", "101-21.\n\u6709\u4e0051\u6b72\u7537\u6027\uff0c\u4e3b\u8a34\u8173\u816b\u5df1\u7d93\u6578\u5929\uff0c\u6aa2\u67e5\u767c\u73fe\u8840\u9209\uff08Na\uff09\u70ba128mmol/L\uff0c\u5176\u8840\u58d3\u70ba150/92mmHg\uff0c\u5fc3\u8df384/min\uff0c\u5169\u8173\u7686\u6709\u6c34\u816b\uff0c\u5c1a\u672a\u7528\u85e5\u6642\uff0c\u9a57\u5176\u5c3f\u9209\u6fc3\u5ea6\u70ba42mmol/L\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u53ef\u80fd\u4e4b\u539f\u56e0\uff1f\r(1)\u814e\u75c5\u75c7\u5019\u7fa4\uff08nephrotic syndrome\uff09\r(2)\u6025\u6027\u814e\u8870\u7aed\uff08acute renal failure\uff09\r(3)\u809d\u786c\u5316\uff08cirrhosis\uff09\r(4)\u6162\u6027\u814e\u8870\u7aed\uff08chronic renal failure\uff09\r(5)\u5fc3\u81df\u8870\u7aed\uff08cardiac failure\uff09\nA. (1)+(3)\nB. (3)+(5)\nC. (1)+(5)\nD. (2)+(4)\nE. (3)+(4)\n": "(D)", "101-22.\n\u6025\u8a3a\u8655\u4f86\u4e86\u4e00\u4f4d55\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u8840\u4e2d\u9240K\u70ba3.1mEg/L\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u53ef\u80fd\u539f\u56e0\uff1f\r(1)\u4f7f\u7528mannitol\r(2)\u816b\u7624\u5feb\u901f\u5206\u89e3\uff08rapid tumor lysis\uff09\r(3)\u9382\u7f3a\u4e4f\uff08magnesium deficiency\uff09\r(4)\u4f7f\u7528amiloride\r(5)\u9ad4\u6eab\u904e\u4f4e\uff08hypothermia\uff09\nA. (1)+(2)\nB. (3)+(5)\nC. (1)+(4)\nD. (2)+(4)\nE. (2)+(3)\n": "(B)", "102-1.\n\u6162\u6027\u814e\u81df\u75c5(chronic kidney disease, CKD)\u7684\u75c5\u4eba\uff0c\u6703\u767c\u751f\u9aa8\u75c5\u8b8a(osteodystrophy)\uff0c\u4ee5\u4e0b\u6a5f\u8f49\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1)1,25-vitamin D3 deficiency (2)Hypophosphatemia (3)Hypocalcemia (4)Low serum FGF-23 (fibroblast growth factor-23) (5)Klotho deficiency\nA. (1)+(2)+(3)+(4)\nB. (2)+(4)+(5)\nC. (1)+(3)+(5)\nD. (1)+(3)+(4)+(5)\nE. (1)+(3)+(4)\n": "(C)", "102-2.\n\u4e00\u4f4d\u4e2d\u5e74\u5973\u6027\uff0c\u6709\u86cb\u767d\u5c3f(+)\uff0c creatinine 1.8 mg/dL\uff0c\u5026\u6020\uff0c\u8207serum C3 level\u964d\u4f4e\u3002\u5c1a\u672a\u505a\u814e\u81df\u75c5\u7406\u6aa2\u67e5\u524d\uff0c\u6700\u53ef\u80fd\u662f\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u814e\u708e\u75be\u75c5?\nA. Focal segmental glomerulosclerosis (FSGS)\nB. cryoglobulinemia\nC. Henoch-Schonlein purpura\nD. Wegner's granulomatosis\nE. IgA nephropathy\n": "(B)", "102-3.\n\u6709\u95dc\u591a\u56ca\u814e(autosomal dominant polycystic kidney disease, ADPKD)\u7684\u6558\u8ff0\uff0c\u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba?\nA. \u6e90\u81eaPKD2 gene mutation (\u7d04\u4f5480%)\uff0c\u6bd4PKD1 gene mutation (\u7d04\u4f5420%)\u70ba\u591a\nB. \u76f8\u8f03\u5176\u4ed6\u75c5\u56e0\u6240\u5c0e\u81f4\u7684\u6162\u6027\u814e\u81df\u75c5(chronic kidney disease, CKD)\uff0cADPKD\u7684\u7279\u5fb5\u662f\u66f4\u65e9\u767c\u751f\u8ca7\u8840(anemia)\u75c7\u72c0\nC. \u96d6\u7136\u5c11\u6578(4-15%)\u53ef\u80fd\u5408\u4f75cerebral aneurysm, \u4f46\u662f\u5c0d\u65bc\u7121\u75c7\u72c0\u8005\uff0c\u4e0d\u5efa\u8b70\u505aroutine screening\u3002\nD. \u67d0\u4e9bADPKD\u6703\u5408\u4f75\u5fc3\u81df\u74e3\u819c\u7570\u5e38\uff0c\u5176\u4e2d\u4ee5aortic value regurgitation\u6700\u5e38\u898b\u3002\nE. \u9810\u9632ADPKD\u60e1\u5316\uff0c\u8840\u58d3\u63a7\u5236\u5f88\u91cd\u8981\uff0c\u4f46\u61c9\u907f\u514d\u4f7f\u7528ACEI\u6216ARB\u85e5\u7269\u3002\n": "(C)", "102-4.\n\u61f7\u5b55\u5973\u6027\u6cbb\u7642\u9ad8\u8840\u58d3\uff0c\u6216\u662f\u9810\u9632\u8207\u6cbb\u7642pre-eclampsia\u7684\u8840\u58d3\u7570\u5e38\uff0c\u4e0b\u5217\u4f55\u8005\u85e5\u7269\u4e0d\u5efa\u8b70\u4f7f\u7528?\nA. Methyldopa\nB. ACEI \u6216ARB\u985e\u85e5\u7269\nC. Hydralazine\nD. Labetaolol\nE. Pre-eclampsia\u6642\u7d66\u4e88MgSO4\u6216nifedipine\n": "(B)", "102-5.\n\u6709\u95dc\u8179\u819c\u900f\u6790(peritoneal dialysis, PD)\u7684\u6558\u8ff0\uff0c\u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba?\nA. \u8840\u6db2\u900f\u6790(hemodialysis, HD)\u5c0d\u4e2d\u5927\u5206\u5b50\u7684\u6e05\u9664\u7387\uff0c\u6bd4\u8179\u819c\u900f\u6790\u597d\nB. \u8179\u819c\u708e(peritonitis)\u662fPD\u5e38\u898b\u7684\u5408\u4f75\u75c7\uff0c\u6700\u5e38\u898b\u7684\u83cc\u7a2e\u662fPseudomonas species\nC. PD\u767c\u751f\u51fa\u53e3\u611f\u67d3(exit-site infection)\u6642\uff0c\u6700\u5e38\u898b\u7684\u83cc\u7a2e\u662fStaphylococcus aureus\nD. 4.25%\u7684PD\u900f\u6790\u6db2(dialysate)\uff0c\u6bd42.5% dialysate\u53ef\u4ee5\u6709\u66f4\u4f73\u7684\u6bd2\u7d20\u6e05\u9664(clearance)\u8207\u71df\u990a\u88dc\u5145\u6548\u679c\nE. \u8179\u819c\u900f\u6790(PD)\u75c5\u4eba\u7684\u9577\u671f\u5b58\u6d3b\u7387\u6bd4\u8840\u6db2\u900f\u6790(HD)\u75c5\u4eba\u597d\n": "(C)", "102-6.\n\u67d0\u4e2d\u5e74\u7537\u6027\u88ab\u8a3a\u65b7\u6709systemic sclerosis (scleroderma)\uff0c\u8fd1\u5169\u9031\u51fa\u73fe\u9ad8\u8840\u58d3(182/110 mm Hg)\uff0c\u86cb\u767d\u5c3f(+)\uff0c\u8840\u5c3f(2+)\uff0c\u53cacreatinine 2.1 mg/dL (\u4e09\u500b\u6708\u524d\u503c\u70ba1.0 mg/dL)\u3002\u91dd\u5c0d\u8840\u58d3\u63a7\u5236\uff0c\u512a\u5148\u9996\u9078\u85e5\u7269\u70ba:\nA. ACEI \u985e\u964d\u58d3\u5291\nB. \u03b2-blocker\nC. \u03b1-blocker\nD. Direct vasodilator\nE. Diuretics\n": "(A)", "102-7.\n\u5c0dstage II/III\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a\u7684\u75c5\u4eba\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u662f\u6700\u9069\u5408\u7684\u8655\u7f6e\u7b56\u7565\u7d44\u5408?  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1) \u958b\u59cb\u4f7f\u7528erythropoietin (EPO)\u9810\u9632\u8ca7\u8840(anemia) (2)\u4f7f\u7528ACEI/ARB\u63a7\u5236\u8840\u58d3 (3)\u5efa\u8b70\u4f4e\u86cb\u767d\u98f2\u98df(0.8 g/\u6bcfkg\u7406\u60f3\u9ad4\u91cd/day) (4)\u6212\u83f8\u3001\u6e1b\u91cd (5) \u63a7\u5236\u8840\u7cd6\uff0cthe lower the better (6)\u5982\u679c\u6709\u8840\u8102\u7570\u5e38(dyslipidemia)\uff0c\u53ef\u4ee5\u7d66\u4e88\u964d\u8840\u8102\u85e5\u7269(\u5982: statin)\nA. (1)+(2)+(3)+(4)+(5)+(6)\nB. (2)+(4)+(5)\nC. (2)+(3)+(4)+(6)\nD. (1)+(4)+(5)+(6)\nE. (1)+(2)+(3)+(4)+(6)\n": "(C)", "102-8.\n\u521d\u6b21\u88ab\u767c\u73fe\u6709\u9ad8\u8840\u58d3\u7684\u75c5\u4eba\uff0c\u5728screen\u7684\u8a3a\u65b7\u6aa2\u67e5\u9805\u76ee\u4e0a\uff0c\u9664\u4e86\u5efa\u8b70\u8981\u505a: BUN, creatinine, Na, K, Ca, urinalysis\u6aa2\u9a57\u4e4b\u5916\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u662f\u6700\u9069\u5408\u7684\u8a3a\u65b7\u7d44\u5408? (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)(1)total cholesterol (T-Chol), low density lipoprotein (LDL) (2)fasting glucose (AC) level (3)hematocrit (Hct) (4)electrocardiogram (ECG) (5) chest x-ray study (6)renal ultrasonography\nA. (1)+(2)+(3)+(4)+(5)+(6)\nB. (1)+(2)+(3)+(4)\nC. (1)+(2)+(3)+(5)\nD. (1)+(2)+(4)+(6)\nE. (1)+(2)+(6)\n": "(B)", "102-9.\n\u67d054\u6b72\u5973\u6027\uff0c\u6709\u5c3f\u6bd2\u75c7\u72c0(creatinine 4.0 mg/dL)\u3001\u8ca7\u8840(Hct 8.5 g/dL)\u3001\u5026\u6020\u3001\u591c\u5c3f(nocturia)\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u6709metabolic acidosis\uff0c\u8f15\u5ea6\u86cb\u767d\u5c3f(<1.0 g/day)\uff0c\u5c3f\u6db2\u4e2d\u6709WBC cast, granular cast, pyuria\u53caglycosuria\u3002\u75c5\u4eba\u814e\u75c5\u8b8a\u6700\u53ef\u80fd\u7684\u539f\u56e0\u70ba:\nA. Aristolochic acid nephropathy (Chinese herbal nephropathy)\nB. Focal segmental glomerulosclerosis (FSGS)\nC. Membranoproliferative glomerulonephritis (MPGN)\nD. IgA nephropathy\nE. ADPKD (autosomal dominant polycystic kidney disease)\n": "(A)", "102-10.\n\u4e00\u4f4d21\u6b72\u9752\u5e74\uff0c\u5728\u9177\u71b1\u74b0\u5883\u4e2d\u5287\u70c8\u52de\u52d5\uff0c\u51fa\u73fe\u610f\u8b58\u8b6b\u5984\u3001\u62bd\u6410\uff0c\u88ab\u8a3a\u65b7\u70ba\u4e2d\u6691\u3002\u8655\u7f6e\u4e0a\u9700\u6ce8\u610f\u4ee5\u4e0b\u4f75\u767c\u75c7\uff0c\u4f55\u8005\u6700\u5c11\u898b?:\nA. Hyperglycemia\nB. Acute kidney injury\nC. DIC (disseminated intravascular coagulation)\nD. Rhabdomyolysis\nE. Cardiac arrhythmia\n": "(A)", "102-11.\n\u4e00\u4f4d60\u6b72DM\u53ca\u6162\u6027\u814e\u81df\u75c5(chronic kidney disease)\u75c5\u4eba\uff0c\u4e09\u9031\u524d\u7684AC\u8840\u7cd6\u662f160 mg/dL\uff0cHbA1C\u662f8.2%\uff0ccreatinine 2.0 mg/dL\u3002\u56db\u5929\u524d\u958b\u59cb\u6709\u54b3\u55fd\u3001\u63a5\u8457\u6709\u5598\u3001\u547c\u5438\u56f0\u96e3\u3001\u5c3f\u91cf\u6e1b\u5c11\uff0c\u56e0\u6b64\u4f4f\u9662\u3002\u4f4f\u9662\u6642: WBC 12,500/mm3, Hct 28%, BUN 78 mg/dL, creatinine 2.8 mg/dL, AC 190 mg/dL. \u80f8\u90e8X-\u5149\u6aa2\u67e5\u6709\u53f3\u4e0b\u8449\u75c5\u7076\u3002\u52d5\u8108\u8840\u6db2\u6c23\u9ad4\u6aa2\u67e5(ABG): pH 7.22, PO2 92 mm Hg, PCO2 32 mm Hg, HCO3- 10 mEq/L, BE -15 mEq/L. \u5f9e\u75c5\u53f2\u8207ABG\u8cc7\u6599\u4f86\u770b\uff0c\u4ee5\u4e0b\u6700\u9069\u5408\u7684\u8a3a\u65b7?\nA. Simple metabolic acidosis, with well compensation\nB. Simple respiratory acidosis, with well compensation\nC. Metabolic acidosis + respiratory acidosis\nD. Metabolic acidosis + respiratory alkalosis\nE. Respiratory acidosis + metabolic alkalosis\n": "(C)", "102-12.\n\u4e0b\u5217\u814e\u75c5\u8b8a\u7279\u5fb5\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?:\nA. \u5152\u7ae5\u539f\u767c\u6027\u814e\u75c5\u75c7\u5019\u7fa4(primary nephrotic syndrome)\u6700\u5e38\u898b\u7684\u814e\u75c5\u8b8a\u662fminimal change disease\nB. \u6210\u4eba\u539f\u767c\u6027\u814e\u75c5\u75c7\u5019\u7fa4\u6700\u5e38\u898b\u7684\u814e\u75c5\u8b8a\u662ffocal segmental glomerulosclerosis (FSGS)\nC. \u6700\u5bb9\u6613\u4f75\u767c\u814e\u975c\u8108\u963b\u585e(renal vein thrombosis)\u7684\u539f\u767c\u6027\u814e\u75c5\u8b8a\u662fmembranous nephropathy (MN)\nD. \u6700\u5e38\u898b\u7684\u539f\u767c\u6027\u814e\u708e(glomerulonephritis, \u7c21\u7a31GN)\u662fIgA nephropathy\nE. \u548cC\u578b\u809d\u708e(hepatitis C)\u76f8\u95dc\u7684\u814e\u708e\uff0c\u8f03\u5e38\u898b\u662f: membranous nephropathy (MN) \u6216membranoproliferative glomerulonephritis (MPGN)\n": "(B)", "102-13.\n\u4e0b\u5217\u4f55\u8005\u85e5\u7269\u5bb9\u6613\u5f15\u8d77\u6162\u6027\u814e\u75c5\u8b8a\u8207\u6ccc\u5c3f\u9053\u4e0a\u76ae\u7d30\u80de\u764c(uroepithelial carcinoma) (1)Analgesics (2)Chinese herb (3)Calcineurin inhibitors (4)Lithium (5)Lead (\u61c9\u5beb\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(3)+(5)\nB. (2)+(3)+(5)\nC. (2)+(5)\nD. (1)+(2)\nE. (2)+(4)\n": "(D)", "102-14.\n\u67d0\u5973\u6027\u75c5\u4eba\u56e0\u808c\u8089\u7121\u529b\u6c42\u8a3a, \u7d93\u6aa2\u67e5\u767c\u73fe\u8840\u58d3\u6b63\u5e38, \u4f46\u6709\u4f4e\u8840\u9240 (K 3.0 mmol/L) , metabolic alkalosis, high renin \u53cahigh aldosterone level. \u8acb\u554f\u53ef\u80fd\u70ba\u5e95\u4e0b\u4f55\u8005\u75be\u75c5 ? (1)Bartter's syndrome (2)Unilateral renal artery stenosis (3)Liddle's syndrome (4)Gitelman's syndrome (5)Loop diuretics  (\u61c9\u5beb\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)\nB. (1)+(3)+(4)\nC. (1)+(3)+(4)+(5)\nD. (1)+(4)+(5)\nE. (2)+(5)\n": "(D)", "102-15.\n\u67d070\u6b72\u75c5\u4eba\u56e0\u75db\u98a8\u8207\u819d\u95dc\u7bc0\u9000\u5316\u6027\u95dc\u7bc0\u708e\u6642\u5e38\u670d\u7528\u6b62\u75db\u85e5, \u7d93\u6aa2\u67e5serum creatinine\u70ba 2.5 mg/dL, \u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4?\nA. \u4e0d\u9069\u5408\u7e7c\u7e8c\u7d66\u4e88thiazide\u7576\u964d\u8840\u58d3\u85e5.\nB. \u9ad4\u6db2\u4e0d\u8db3\u8207\u6162\u6027\u814e\u81df\u75c5\u5747\u662fAnalgesic nephropathy\u4e4b\u9ad8\u5371\u96aa\u65cf\u7fa4.\nC. \u6838\u78c1\u5171\u632f\u6aa2\u67e5\u70ba\u6700\u5408\u9069\u4e4b\u5f71\u50cf\u6aa2\u67e5.\nD. Acetaminophen\u5f15\u8d77analgesic nephropathy \u7684\u53ef\u80fd\u6027\u6bd4\u8f03\u5c0f\nE. \u56e0analgesic nephropathy\u81f4\u672b\u671f\u814e\u8870\u7aed\u8005,\u7f79\u60a3uroepithelial malignancy \u4e4b\u6a5f\u7387\u589e\u52a0\n": "(C)", "102-16.\n\u67d0\u4f4d\u4e2d\u5e74\u5a66\u5973\u6709\u9ad8\u8840\u58d3\u800c\u4e14\u814e\u81df\u8d85\u97f3\u6ce2\u986f\u793a\u5de6\u5074\u814e\u81df\u8f03\u5c0f(\u9577\u5f918.5\u516c\u5206),\u53f3\u5074(10\u516c\u5206),\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u6aa2\u67e5\u76ee\u524d\u88ab\u8a8d\u70ba\u6bd4\u8f03\u4e0d\u80fd\u78ba\u5207\u986f\u793a\u7570\u5e38?\nA. Captopril renal scintigraphy\nB. Renal Doppler ultrasonography\nC. CT angiography\nD. Magnetic resonance angiography\nE. Digital substraction angiography\n": "(A)", "102-17.\n\u67d060\u6b72\u75c5\u4eba\u5177\u7cd6\u5c3f\u75c5\u5341\u5e74, \u9ad8\u8840\u58d3\u4e09\u5e74, \u73fe\u5728\u5c3f\u6db2\u8a66\u7d19\u6aa2\u67e5\u70ba\u5c3f\u86cb\u767d\u70ba 3+ (300 mg/dL) \u8207serum creatinine 1.4 mg/dL. \u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4?\nA. \u75c5\u4eba\u65bc\u4e09\u5e74\u524d\u5c31\u61c9\u6aa2\u6e2cmicroalbuminuria\u6216\u5c3f\u6db2\u8a66\u7d19\u6aa2\u67e5\nB. \u75c5\u4eba\u5e38\u5728\u60e1\u5316\u5230\u672b\u671f\u814e\u8870\u7aed\u524d, \u5c31\u5148\u5fc3\u8840\u7ba1\u75be\u75c5\u767c\u4f5c\u6216\u6b7b\u4ea1\nC. \u75c5\u4eba\u814e\u529f\u80fd\u53ef\u80fd\u65bc\u4e94\u81f3\u5341\u5e74\u5167\u7e7c\u7e8c\u60e1\u5316\u6210\u672b\u671f\u814e\u8870\u7aed\nD. \u82e5\u5176\u5b50\u5973\u4ea6\u907a\u50b3\u5f97\u7cd6\u5c3f\u75c5, \u5176\u7f79\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a\u4e4b\u6a5f\u7387\u6703\u8f03\u9ad8\nE. \u5176\u814e\u7d72\u7403\u4e4b\u75c5\u7406\u8b8a\u5316\u53ea\u6709\u5c11\u90e8\u5206\u662fKimmelstiel-Wilson nodular lesions\n": "(A)", "102-18.\n\u7576\u61f7\u7591\u6709light chain disease \u6642, \u8acb\u554f\u4f55\u9805\u70ba\u78ba\u5b9a\u8a3a\u65b7\u654f\u611f\u5ea6\u6700\u9ad8(1-4)\u53ca\u5224\u65b7\u9810\u5f8c(5-6) ? (1)Serum protein electrophoresis (2)24hr Urine protein electrophoresis (3)Immunofixation (4)Serum free light chain assay (5)Serum \u03b2-2 microglobulin (6)Serum albumin.\nA. (1)+(2)+(5)\nB. (2)+(5)+(6)\nC. (2)+(3)+(6)\nD. (4)+(5)+(6)\nE. (2)+(3)+(4)+(5)\n": "(D)", "102-19.\n\u8acb\u554f\u9e7c\u5316\u6cbb\u7642, \u5c0d\u4e0b\u5217\u54ea\u7a2e\u814e\u7d50\u6642\u77f3\u6c92\u6709\u5e6b\u5fd9?  (1)Hypocitraturia (2)Hyperuricemia (3)Distal renal tubular acidosis (4)Primary hyperparathyroidism (5) Struvite stones  (\u61c9\u5beb\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)+(5)\nB. (2)+(4)\nC. (4)+(5)\nD. (3)+(4)\nE. (1)+(5)\n": "(C)", "102-20.\n\u95dc\u65bc\u964d\u5c3f\u9178\u85e5\u7269allopurinol\u8207colchicine\u4e4b\u81e8\u5e8a\u4f7f\u7528,\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4?\nA. \u75c5\u4eba\u82e5\u5177HLA-B5801\u8f03\u5bb9\u6613\u5c0dallopurinol\u7522\u751f\u56b4\u91cd\u904e\u654f\u53cd\u61c9\nB. Allopurinol\u6703\u964d\u4f4etheophylline\u4e4bclearance\nC. Allopurinol\u6703\u589e\u52a0\u8207azathioprine\u62166-mercaptopurine\u6bd2\u6027\nD. Thiazide diuretics\u6703\u964d\u4f4eallopurinol\u4e4b\u6bd2\u6027\nE. Clarithromycin\u6703\u589e\u52a0colchicine\u4e4b\u6bd2\u6027\n": "(D)", "102-21.\n\u67d030\u6b72\u5973\u6027\u65bc\u65bc\u61f7\u5b55\u5169\u500b\u6708\u6642\u5f97\u5230\u5c3f\u8def\u611f\u67d3, \u8acb\u554f\u5728\u9078\u64c7\u6297\u751f\u7d20\u6642,\u4e0b\u5217\u4f55\u8005\u4e0d\u9069\u5408\u4f7f\u7528?\nA. Ampicillin\nB. Levofloxacin\nC. Nitrofurantoin\nD. Aminoglycoside\nE. Cephalosporins\n": "(B)", "102-22.\n\u95dc\u65bcscleroderma renal crisis,\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba?\nA. \u767c\u751frenal crisis\u6642, \u8840\u58d3\u6b63\u5e38\u6216\u4e0d\u9ad8\u4ee3\u8868\u9810\u5f8c\u8f03\u4f73\nB. \u82e5\u6709anti-centromere antibodies,\u8868\u793a\u8f03\u5bb9\u6613\u767c\u751frenal crisis.\nC. \u70ba\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u61c9\u4f7f\u7528\u5927\u91cf\u985e\u56fa\u9187\nD. \u53ef\u4ee5\u4f7f\u7528ACEI\u4f86\u9810\u9632renal crisis\u4e4b\u767c\u751f\nE. \u76ae\u819a\u786c\u5316\u5feb\u901f\u9032\u884c\u6216\u5177anti-RNA polymerase I \u8207 III \u6297\u9ad4\u4e4b\u7537\u6027\u75c5\u60a3\u8f03\u5bb9\u6613\u767c\u751frenal crisis.\n": "(E)", "103-1.\n\u4e2d\u5e74\u7537\u6027\uff0c\u6700\u8fd1\u4e09\u500b\u6708\u5728\u9580\u8a3a\u525b\u88ab\u78ba\u8a3a\u6709\u9ad8\u8840\u58d3\u3002\u70ba\u4e86\u89e3\u9ad8\u8840\u58d3\u7684\u75c5\u56e0\u8207\u76f8\u95dc\u5f71\u97ff\uff0c\u9664\u4e86\u4e00\u822c\u75c5\u53f2\u8207\u7406\u5b78\u6aa2\u67e5\u4e4b\u5916\uff0c\u60a8\u6703\u5efa\u8b70\u512a\u5148\u505a\u4ee5\u4e0b\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7be9\u6aa2\uff0c\u4f55\u8005\u9664\u5916?\nA. Hemoglobin or hematocrit\nB. Urinalysis\nC. Fasting glucose level\nD. HbA1C level\nE. Electrocardiogram (ECG) or chest X-ray\n": "(D)", "103-2.\n\u4e00\u4f4d49\u6b72\u7537\u6027\uff0c\u5916\u50b7\u5f8c\u7b2c\u4e09\u5929\u51fa\u73fe\u5c3f\u91cf\u6e1b\u5c11(350 mL/day)\u3002\u814e\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5: \u814e\u81df\u5927\u5c0f\u7121\u7570\u5e38\uff0c\u4e5f\u7121\u6c34\u814e(hydronephrosis)\u3002\u4ee5\u4e0b\u6578\u64da\u4f55\u8005\u652f\u6301ATN (acute tubular necrosis)\uff0c\u800c\u975e\u814e\u524d\u6027\u6025\u6027\u814e\u640d\u50b7(pre-renal acute kidney injury)?\nA. BUN 78 mg/dL, creatinine 1.8 mg/dL\nB. Urine [Na] 41 mEq/L\nC. Urine osmolality 390 mosmol/L\nD. Plasma [Na] 140 mEq/L, plama [creatinine] 1.8 mg/dL, urine [Na] 28 mEq/L, urine [creatinine] 72 mg/dL\nE. urine sediment normal, occasional hyaline cast. No granular or brown cast\n": "(B)", "103-3.\n\u4e00\u4f4d58\u6b72\u5973\u6027\uff0c\u4f8b\u884c\u6027\u5065\u5eb7\u6aa2\u67e5\u6642\u767c\u73fe: \u5c3f\u6db2\u6aa2\u67e5\u5831\u544a\u7570\u5e38\u3002Urinalysis: protein (-), occult blood (2+), RBC 15-20/(HPF, high power field), WBC cast (-), dysmorphic RBC (-), RBC cast (-). \u75c5\u4eba\u81ea\u8ff0\u7121\u5176\u4ed6\u4e0d\u9069\uff0c\u7406\u5b78\u6aa2\u67e5\u4e5f\u7121\u7570\u72c0\u3002\u60a8\u63a5\u8457\u6703\u512a\u5148\u505a\u4ee5\u4e0b\u4f55\u7a2e\u6aa2\u67e5?\nA. Urine cytology test\nB. Check serum cryoglobulin, complement (C3, C4)\nC. Check myoglobulinuria\nD. Arrange renal biopsy\nE. Do urine bacterial culture\n": "(A)", "103-4.\n\u4ee5\u4e0b\u662f\u4e00\u4f4dICU\u75c5\u4eba\u7684\u52d5\u8108\u6c23\u9ad4\u5206\u6790\u8207\u8840\u6db2\u96fb\u89e3\u8cea\u5831\u544a: pH 7.42, PaO2 88 mmHg, PaCO2 67 mmHg, [Na] 140 mEq/L, [K] 3.5 mEq/L, [Cl] 88 mEq/L, HCO3 42 mEq/L\u3002\u4f9d\u64da\u4e0a\u8ff0\u6578\u503c\uff0c\u6700\u7b26\u5408\u4ee5\u4e0b\u4f55\u7a2e\u75c5\u4eba\u72c0\u6cc1?\nA. Sepsis in ICU\nB. Uremia, long-term use of diuretics\nC. COPD with diuretics\nD. Methanol intoxication, with secondary lactic acidosis\nE. Pneumonia, on ventilator support for pulmonary edema\n": "(C)", "103-5.\n\u4ee5\u4e0b\u6709\u95dc\u8179\u819c\u900f\u6790(peritoneal dialysis, \u7c21\u7a31PD)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)  (1)PD\u75c5\u4eba\u767c\u751f\u8179\u819c\u708e(peritonitis)\uff0c\u6700\u5e38\u898b\u7684\u662fStaphylococcus aureus (2)\u8981\u8a3a\u65b7PD\u75c5\u4eba\u767c\u751f\u8179\u819c\u708e(peritonitis)\uff0c\u4e09\u500b\u6700\u4e3b\u8981\u7684\u75c7\u72c0(triad)\u662f: \u8179\u75db(abdominal pain), \u900f\u6790\u6db2\u6df7\u6fc1(cloudy dialysate), \u53ca\u6df7\u6fc1\u7684\u900f\u6790\u6db2\u4e2dWBC\u9700 >100 /\u03bcL (3)PD\u75c5\u4eba\u767c\u751f\u8179\u819c\u708e(peritonitis)\uff0c\u82e5\u662f\u900f\u6790\u6db2\u6df7\u6fc1(cloudy dialysate), \u800c\u6df7\u6fc1\u7684\u900f\u6790\u6db2\u4e2dWBC >100  /\u03bcL\uff0c\u4e14\u4ee5lymphocyte\u70ba\u4e3b(> 50%)\u6642\uff0c\u8981\u8003\u616eTB (tuberculosis)\u6216\u662ffungal peritonitis\r(4)\u8001\u5e74PD\u75c5\u4eba\u767c\u751f\u8179\u819c\u708e(peritonitis)\uff0c\u6700\u5e38\u898b\u7684\u662fPseudomonas species\u83cc\u7a2e (5)PD\u75c5\u4eba\u767c\u751f\u5c0e\u7ba1\u51fa\u53e3(exit-site)\u611f\u67d3\uff0c\u6700\u5e38\u898b\u7684\u662fStaphylococcus epidermidis\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(5)\nC. (1)+(2)+(4)\nD. (1)+(2)+(5)\nE. (2)+(3)\n": "(E)", "103-6.\n\u4e00\u4f4d44\u6b72\u5973\u6027\uff0c\u4e3b\u8ff0\u6700\u8fd1\u516d\u9031\u4f86\u5169\u5074\u811b\u9aa8\u524d(pre-tibial)\u8207\u8173\u8e1d(ankle)\u6709\u9593\u6b47\u6027\u6c34\u816b(edema)\u3002\u508d\u665a\u6642\u8f03\u816b\uff0c\u8173\u62ac\u9ad8\u6216\u65e9\u6668\u7761\u9192\u6642\u6c34\u816b\u6703\u7a0d\u6539\u5584\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5831\u544a\u70ba: albumin 3.0 g/dL, BUN 26 mg/dL, creatinine 1.0 mg/dL, total cholesterol (t-Chol) 284 mg/dL, LDL 168 mg/dL. C3 48 mg/dL (normal range, 75-135 mg/dL)\u3002\u5c3f\u6db2\u6aa2\u67e5\u986f\u793a: protein (2+), occult blood (1+)\u3002\u4f9d\u64da\u4e0a\u8ff0\u6578\u503c\uff0c\u6700\u4e0d\u7b26\u5408\u4ee5\u4e0b\u4f55\u7a2e\u8a3a\u65b7?\nA. \u53ef\u80fd\u662f lupus nephritis\nB. \u53ef\u80fd\u662f post-infectious glomerulonephritis\nC. \u53ef\u80fd\u662f membranous nephropathy\nD. \u53ef\u80fd\u662f cryoglobulinemia\nE. \u53ef\u80fd\u662f membranoproliferative glomerulonephritis\n": "(C)", "103-7.\n\u4e00\u4f4d54\u6b72\u7537\u6027\uff0c\u56e0\u70ba\u8fd1\u4e09\u5468\u4f86\u6709\u547c\u5438\u4e0d\u9069(dyspnea)\u3001\u75f0\u4e2d\u6709\u8840\u7d72(hemoptysis)\u5230\u6025\u8a3a\u5c31\u91ab\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5831\u544a\u70ba: albumin 3.9 g/dL, BUN 46 mg/dL, creatinine 5.8 mg/dL, Hb 9.4 g/dL. \u80f8\u90e8X-\u5149\u986f\u793a: \u5169\u5074\u80ba\u6709\u7030\u6f2b\u578b\u6d78\u6f64(diffuse alveolar infiltration)\u3002\u514d\u75ab\u5b78\u6aa2\u67e5\uff0c\u542b: anti-GBM antibody, ANCA-antibody, C3, C4, ANA\uff0c\u7686\u7121\u660e\u986f\u7570\u5e38\u3002\u4f9d\u64da\u4e0a\u8ff0\u6578\u503c\uff0c\u75c5\u4eba\u7684\u80ba\u90e8\u8207\u814e\u81df\u75c5\u56e0\uff0c\u8f03\u53ef\u80fd\u662f?\nA. Uremic lung\nB. SLE \u5408\u4f75pulmonary-renal syndrome\nC. Wegener's granulomatosis\nD. Goodpasture's syndrome\nE. Microscopic polyarthritis\n": "(A)", "103-8.\n\u4e00\u4f4d70\u6b72\u7537\u6027\uff0c\u904e\u53bb\u75c5\u53f2\u6709\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u3001\u8207\u6162\u6027\u814e\u81df\u75c5(CKD)\u3002\u9810\u5b9a\u5169\u5929\u5f8c\u9032\u884c\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5831\u544a\u70ba: albumin 4.0 g/dL, BUN 42 mg/dL, creatinine 3.1 mg/dL, total cholesterol (t-Chol) 224 mg/dL, LDL 128 mg/dL. \u5c3f\u6db2\u6aa2\u67e5\u986f\u793a: protein (2+)\u3002\u76ee\u524d\u7528\u85e5\u6709: losartan, carvedilol, furosemide, rosuvastatin, aspirin, insulin\u548csaxagliptin\u3002\u4f9d\u64da\u75c5\u4eba\u72c0\u6cc1\uff0c\u70ba\u6e1b\u5c11\u6216\u9810\u9632contrast-induced nephropathy or acute kidney injury (AKI)\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u63aa\u65bd\u6b63\u78ba?  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1)Hydration with isotonic saline, \u53ef\u52a0\u4e0a sodium\rbicarbonate (2)\u56e0\u70baserum creatinine\u9ad8\uff0c\u505a\u5b8c\u5fc3\u5c0e\u7ba1\u7576\u65e5\uff0c\u61c9\u5b89\u6392\u505a\u9810\u9632\u6027\u8840\u6db2\u900f\u6790(prophylactic hemodialysis) (3)\u5c0e\u7ba1\u524d\u4e00\u5929\u8207\u7576\u5929\u5404\u7d66\u4e88N-acetylcysteine (600 mg, bid) (4)\u5c07ARB (losartan)\u63db\u6210cyclosporin-A\uff0c\u4ee5\u6e1b\u5c11\u814e\u6bd2\u6027 (5)\u5982\u679c\u814e\u529f\u80fd\u5c1a\u53ef(< 1.5 mg/dL)\uff0c\u61c9\u8a72\u76e1\u91cf\u5c07insulin\u63db\u56demetformin\uff0c\u53ef\u4ee5\u589e\u52a0\u814e\u81df\u4fdd\u8b77\u4f5c\u7528\u3002\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(3)+(4)+(5)\nC. (1)+(3)+(4)\nD. (1)+(3)+(5)\nE. (1)+(3)\n": "(E)", "103-9.\n\u4e00\u4f4d34\u6b72\u5973\u6027\uff0c\u904e\u53bb\u7121\u91cd\u5927\u75be\u75c5\u6216\u6162\u6027\u75c5\u3002\u4e3b\u8ff0\u6700\u8fd1\u5169\u5929\u6709\u983b\u5c3f\u3001\u6392\u5c3f\u75bc\u75db\u4e0d\u9069(dysuria)\uff0c\u4f46\u662f\u6c92\u6709\u767c\u71d2\u6216\u8170\u75db\u60c5\u5f62\uff0c\u4e5f\u6c92\u6709vaginal discharge\u3002\u4f60\u67e5\u95b1\u75c5\u4f8b\uff0c\u767c\u73fe\u9019\u662f\u5979\u8fd1\u516d\u500b\u6708\u4f86\u7b2c\u4e09\u5ea6\u56e0\u70ba\u76f8\u540c\u4e3b\u8ff0\u5c31\u91ab\u3002\u800c\u4e00\u500b\u6708\u524d\uff0c\u91ab\u5e2b\u66fe\u958b\u4e88trimethoprim-sulfamethoxazole (TMP-SMX)\u4e09\u65e5\u4efd\uff0c\u7576\u6642\u6709\u6548\u4e14\u75c7\u72c0\u75ca\u7652\u3002\u91ab\u5e2b\u5efa\u8b70\u4ee5\u4e0b\u8655\u7f6e\uff0c\u4e0b\u5217\u4f55\u8005\u9664\u5916?\nA. \u4e00\u6a23\u958b\u4e883-5\u65e5\u4efd\u4e4bTMP-SMX \u505a\u75c7\u72c0\u6cbb\u7642\nB. \u5982\u679c\u75c7\u72c0\u672a\u7de9\u89e3\u6216\u60e1\u5316\uff0c\u91cd\u65b0\u505aurine culture\uff0c\u4e26\u4f9d\u7d50\u679c\u9078\u64c7\u6297\u751f\u7d20\u6cbb\u7642\nC. \u5b89\u6392\u505aIVP\u6216\u96fb\u8166\u65b7\u5c64(CT)\u6aa2\u67e5\nD. \u7d66\u4e88\u9810\u9632\u6027\u6297\u751f\u7d20\uff0c\u6bcf\u5929\u7761\u524d\u4f4e\u5291\u91cfTMP-SMX\uff0c\u6216cephalexin\uff0c\u7d043-6\u500b\u6708\u70ba\u671f\u3002\u4e4b\u5f8c\u505c\u85e5\u89c0\u5bdf\nE. \u9f13\u52f5\u591a\u559d\u6c34\u3001\u914d\u5408\u990a\u6210\u9069\u6642\u89e3\u5c3f\u7684\u7fd2\u6163\n": "(C)", "103-10.\n\u4e00\u4f4d28\u6b72\u7537\u6027\uff0c\u4e3b\u8ff0\u5169\u5929\u4f86\u5c3f\u6db2\u984f\u8272\u6df1\u6697(tea-colored urine)\uff0c\u4e14\u611f\u89ba\u5c3f\u91cf\u660e\u986f\u6e1b\u5c11\u4e86\u3002\u75c5\u4eba\u904e\u53bb\u7121\u91cd\u5927\u75be\u75c5\u6216\u6162\u6027\u75c5\uff0c\u7d045\u5929\u524d\u5148\u6709\u611f\u5192\u75c7\u72c0\u3001\u8f15\u5ea6\u767c\u71d2\u3001\u808c\u8089\u8207\u8170\u90e8\u9178\u75db\uff0c\u66fe\u81ea\u884c\u81f3\u85e5\u5c40\u8cb7\u611f\u5192\u6210\u85e5\u670d\u7528\u3002\u4f46\u662f\u7121\u5614\u5410\u3001\u8179\u7009\u3001\u6216\u983b\u5c3f\u7b49\u75c7\u72c0\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe: \u8840\u58d3135/86 mm Hg, \u5589\u56a8\u8f15\u5ea6\u7d05\u816b\uff0c\u547c\u5438\u97f3\u6b63\u5e38\uff0c\u7121\u6c34\u816b\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5: Hb 9.9 g/dL, WBC 9700/mm3, albumin 4.1 g/dL, BUN 38 mg/dL, creatinine 1.9 mg/dL. C3, C4 \u6578\u503c\u7686\u6b63\u5e38\u3002\u5c3f\u6db2\u6aa2\u67e5\u986f\u793a: protein (2+), occult blood (3+)\u3002\u814e\u81df\u8d85\u97f3\u6ce2\u986f\u793a: \u5169\u5074\u814e\u81df\u5927\u5c0f\u6b63\u5e38\uff0c\u7121\u963b\u585e\u60c5\u5f62\u3002\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f?\nA. Membranous nephropathy\nB. IgA nephropathy\nC. Microscopic polyarteritis\nD. Membranoproliferative glomerulonephritis\nE. Focal segmental glomerulosclerosis\n": "(B)", "103-11.\n\u4e00\u4f4d\u6162\u6027\u814e\u81df\u75c5\u4eba\uff0c4\u5e74\u4f86\u6301\u7e8c\u63a5\u53d7\u898f\u5247\u8840\u6db2\u900f\u6790\u6cbb\u7642\u3002\u67d0\u65e5\uff0c\u56e0\u8dcc\u5012\u9aa8\u6298\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u7d93\u8a3a\u65b7\u6709\u9aa8\u8cea\u758f\u9b06\uff0c\u591a\u8655\u8840\u7ba1\u9223\u5316\uff0c\u8207\u76ae\u819a\u8840\u7ba1\u75c5\u8b8a(calciphylaxis)\u3002\u9020\u6210\u4e0a\u8ff0\u75c5\u56e0\u8207\u75c7\u72c0\uff0c\u8207\u4f55\u7a2e\u4e0b\u5217\u6a5f\u8f49\u7121\u95dc?\nA. High parathyroid hormone\nB. High [Calcium] x [Phosphate] product\nC. High fetuin-A\nD. High FGF-23 (fibroblast growth factor)\nE. Vascular wall (media and intima) calcification\n": "(C)", "103-12.\n\u95dc\u65bc\u6162\u6027\u814e\u81df\u75c5(Chronic kidney disease)\u4e4b\u5fc3\u8840\u7ba1\u75be\u75c5(Cardiovascular disease)\uff0c\u5e95\u4e0b\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f (\u8acb\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848\u4e4b\u7d44\u5408) (1)\u4e09\u5230\u56db\u6210\u4ee5\u4e0a\u6162\u6027\u814e\u81df\u75c5\u60a3\u8005\u5728\u9032\u5c55\u81f3\u7b2c\u4e94\u671f\u524d\uff0c\u5df2\u7f79\u60a3\u5fc3\u8840\u7ba1\u75be\u75c5\u6216\u5df2\u56e0\u4e4b\u6b7b\u4ea1 (2)\u53ea\u6709\u5728\u7b2c\u4e09\u81f3\u7b2c\u4e94\u671f\u6162\u6027\u814e\u81df\uff0c\u5fc3\u8840\u7ba1\u75be\u75c5\u624d\u662f\u5c45\u524d\u7684\u7f79\u75c5\u6216\u81f4\u6b7b\u7684\u539f\u56e0 (3)\u900f\u6790\u75c5\u4eba\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u6b7b\u4ea1\u7387\u4e4b\u660e\u986f\u589e\u52a0\uff0c\u4e3b\u8981\u662f\u6025\u6027\u5fc3\u808c\u6897\u585e\u9020\u6210 (4)\u4f4e\u8840\u6e05\u767d\u86cb\u767d\u8840\u75c7\u8207\u900f\u6790\u75c5\u4eba\u4e4b\u6b7b\u4ea1\u7387\u6709\u95dc (5)\u4f4e\u58d3\u529b\u80ba\u6c34\u816b (low-pressure pulmonary edema)\u5e38\u898b\u65bc\u665a\u671f\u6162\u6027\u814e\u81df\u75c5\uff0c\u4fc2\u7531\u80ba\u6ce1\u58c1\u5fae\u8840\u7ba1\u901a\u900f\u5ea6\u589e\u52a0\u6240\u81f4,\u6240\u4ee5\u900f\u6790\u6cbb\u7642\u5e38\u7121\u6548\u679c\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(4)\nC. (1)+(3)+(4)\nD. (1)+(4)\nE. (1)+(4)+(5)\n": "(D)", "103-13.\n\u67d049\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u6162\u6027\u814e\u7d72\u7403\u814e\u708e\u81f4\u5c3f\u6bd2\u75c7\uff0c\u65bc\u8840\u6db2\u900f\u6790\u4e94\u5e74\u5f8c\u63a5\u53d7\u7531\u89aa\u59b9\u59b9\u6350\u8d08\u814e\u81df\u7684\u814e\u81df\u79fb\u690d\u624b\u8853\uff0c\u4f46\u65bc\u79fb\u690d\u624b\u8853\u4e09\u500b\u6708\u5f8c\u767c\u751f\u5c3f\u91cf\u6e1b\u5c11\u53ca\u8840\u6e05\u808c\u9178\u9150\u4e0a\u5347(1.1 mg/dL -> 2.9 mg/dL),\u5728\u8d85\u97f3\u6ce2\u6392\u9664\u7121\u8840\u7ba1\u6216\u5c3f\u9053\u554f\u984c\u5f8c\uff0c\u814e\u81df\u7a7f\u523a\u75c5\u7406\u5982\u5716(A\u3001B\u3001C) \u986f\u793aC4d\u4e4b\u87a2\u5149\u514d\u75ab\u67d3\u8272\u70ba\u967d\u6027\uff0c\u8acb\u554f\u6700\u597d\u5982\u4f55\u8655\u7f6e\uff1f (\u8acb\u9078\u51fa\u6240\u6709\u9069\u7576\u7d44\u5408\u7684\u7b54\u6848)(1)Plasmapheresis (2)Immunoglobulin infusion (3)OKT3 monoclonal antibody (4)Daclizumab (5)Anti-CD20 monoclonal antibody\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)\nC. (2)+(3)+(5)\nD. (1)+(3)+(4)\nE. (1)+(2)+(5)\n": "(E)", "103-14.\n\u67d066\u6b72\u75c5\u4eba\u56e0\u5c3f\u86cb\u767d3+\uff0c\u8840\u6e05\u767d\u86cb\u767d2.9 gm/dL\uff0cBUN 27 mg/dL, Cre 1.5 mg/dL\uff0c \u7d93\u814e\u81df\u7a7f\u523a\u6aa2\u67e5\u70ba\u819c\u6027\u814e\u75c5\u8b8a\uff0c\u5176\u75c5\u7406\u5982\u9644\u5716(A\u3001B\u3001C\u3001D)\uff0c \u8acb\u554f\u5176\u814e\u81df\u75c5\u8207\u4e0b\u5217\u4f55\u8005\u6c92\u6709\u95dc\u806f\uff1f\nA. \u6885\u6bd2\nB. B\u578b\u6216C\u578b\u809d\u708e\nC. \u6297Phospholipase A2 receptor\u6297\u9ad4\nD. \u6297Soluble urokinase plasminogen activator receptor\u6297\u9ad4\nE. \u60e1\u6027\u816b\u7624\n": "(D)", "103-15.\n\u5c31\u5168\u4e16\u754c\u800c\u8a00\uff0c \u8207\u611f\u67d3\u76f8\u95dc\u4e4b\u814e\u7d72\u7403\u708e\u4e2d\uff0c\u6700\u4e3b\u8981\u8207\u6700\u5e38\u898b\u7684\u70ba\u54ea\u5169\u500b\uff1f(1)\u7627\u75be(Malaria) (2)\u8840\u5438\u866b(Schistosomiasis) (3)\u4eba\u985e\u514d\u75ab\u7f3a\u9677\u75c5\u6bd2(HIV) (4)B\u578b\u809d\u708e (5)C\u578b\u809d\u708e\nA. (1)+(2)\nB. (3)+(4)\nC. (4)+(5)\nD. (3)+(4)\nE. (1)+(3)\n": "(A)", "103-16.\n34\u6b72\u7537\u6027\u525b\u53bb\u6771\u5357\u4e9e\u65c5\u904a\u5169\u9031\u4e26\u627f\u8a8d\u5176\u9593\u6709\u6027\u4ea4\u6613\u884c\u70ba\u6578\u6b21\uff0c\u56de\u570b\u4e00\u9031\u5f8c\u51fa\u73fe\u5c0f\u4fbf\u6642\u75bc\u75db\u8207\u5c3f\u9053\u53e3\u6709\u5206\u6ccc\u7269\uff0c\u7d93\u5c3f\u9053\u5206\u6ccc\u7269\u62b9\u7247\u6aa2\u67e5\u6709\u770b\u5230\u767d\u8840\u7403\u5167\u6709\u683c\u862d\u6c0f\u9670\u6027\u4e4b\u96d9\u7403\u83cc\uff0c\u8acb\u554f\u4e0b\u5217\u8005\u70ba\u932f\u8aa4 ?\nA. \u75be\u75c5\u7ba1\u5236\u7f72\u898f\u5b9a\u70ba\u7b2c\u4e09\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\nB. FDA\u5df2\u901a\u904e\u53ef\u7528Nucleic acid amplification tests\u4f86\u78ba\u5b9a\u8a3a\u65b7\nC. \u5f88\u53ef\u80fd\u540c\u6642\u6709\u62ab\u8863\u83cc\u4e4b\u611f\u67d3,\u6545\u6700\u597d\u540c\u6642\u7d66Doxycycline\u6216Azithromycin\u4f86\u6cbb\u7642\nD. \u6b64\u83cc\u56e0\u9ad8\u5ea6\u7a81\u8b8a\u6027,\u5c0e\u81f4\u5176\u6297\u85e5\u6027\u76f8\u7576\u9ad8\nE. CDC\u4e0d\u5efa\u8b70\u7d66\u4e88Quinolone\u985e\u6297\u751f\u7d20\u4f86\u6cbb\u7642\n": "(D)", "103-17.\n20\u6b72\u7537\u6027\u5b78\u751f\u5176\u5144\u5f1f\u8207\u7236\u89aa\u7684\u814e\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u5169\u5074\u814e\u81df\u5747\u6709\u814e\u81df\u56ca\u816b(Renal cysts)\u8207\u8840\u7ba1\u5e73\u6ed1\u808c\u8102\u80aa\u7624(Angiomyolipoma) \uff0c \u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4e2d\u4f55\u8005\u70ba\u932f\u8aa4 ?\nA. \u544a\u8a34\u5b78\u751f\u8207\u5176\u7236\u5144\u5011\u9808\u8981\u5b9a\u671f\u8d85\u97f3\u6ce2\uff0c\u96fb\u8166\u65b7\u5c64\uff0c\u6216\u6838\u78c1\u5171\u632f\u7684\u8ffd\u8e64\u6aa2\u67e5\nB. \u544a\u77e5\u5176\u7236\u5144\u5176\u814e\u529f\u80fd\u6975\u53ef\u80fd\u6703\u8870\u9000\u5230\u9808\u8981\u900f\u6790\u6cbb\u7642\nC. \u7576\u816b\u7624\u5927\u65bc\u4e09\u516c\u5206\u4ee5\u4e0a\uff0c\u5efa\u8b70\u6700\u597d\u8655\u7406\u6389\nD. \u6709\u53ef\u80fd\u4e5f\u6703\u6709CNS\u7684\u554f\u984c\nE. \u6709\u53ef\u80fd\u6703\u6709Pheochromocytoma\n": "(B)", "103-18.\n\u5e95\u4e0b\u95dc\u65bc\u6162\u6027\u814e\u81df\u75c5\u8207Vitamin D\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4 ?\nA. \u6162\u6027\u814e\u81df\u75c5\u75c5\u4eba\u82e5\u8840\u4e2d 25-hydroxyvitamin D\u504f\u4f4e\uff0c\u5176\u5168\u539f\u56e0\u6b7b\u4ea1\u7387(all-cause mortality)\u6703\u589e\u52a0\nB. Fibroblast growth factor-23 (FGF-23)\u6703\u4fc3\u9032\u814e\u81df\u78f7\u7684\u6392\u6cc4\u8207vitamin D\u7684\u88fd\u9020\nC. Vitamin D\u6b20\u7f3a\u6703\u589e\u52a0\u7f79\u60a3\u7cd6\u5c3f\u75c5\uff0c\u5fc3\u81df\u75c5\uff0c\u9ad8\u8840\u58d3\u7b49\u4e4b\u6a5f\u7387\nD. \u6162\u6027\u814e\u81df\u75c5\u56e0Vitamin D\u4e0d\u8db3\uff0c\u6703\u6e1b\u5c11\u526f\u7532\u72c0\u7dda\u4e0aVitamin D receptor\u800c\u4f7f\u526f\u7532\u72c0\u817a\u7d20\u589e\u52a0\nE. Vitamin D \u662f\u5728\u814e\u81df\u8fd1\u7aef\u814e\u5c0f\u7ba1\u76841 alfa-hydroxylase\u5c0725-OH  cholecalciferol\u6d3b\u5316\n": "(B)", "103-19.\n\u4e0b\u5217\u4f55\u8005\u662f\u7a81\u767c\u6027\u591c\u9593\u8840\u7d05\u7d20\u5c3f\u4e2d\u7684\u6700\u7f55\u898b\u7684\u81e8\u5e8a\u8868\u73fe\nA. \u5f8c\u5929\u5f62\u6210\u7684\u6eb6\u8840\u6027\u8ca7\u8840(Acquired hemolytic anemia)\nB. \u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840 (aplastic anemia)\nC. \u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5(Acute myeloid leukemia)\nD. \u975c\u8108\u8840\u6813 (venous thrombosis)\nE. Hemoglobinuria and hemosiderinuria\n": "(C)", "103-20.\n\u95dc\u65bc\u7cd6\u5c3f\u75c5\u4eba\u986f\u5fae\u5c3f\u86cb\u767d\u51fa\u73fe\u4e4b\u610f\u7fa9,\u4e0b\u5217\u4f55\u8005\u70ba\u932f\u8aa4 ?\nA. \u986f\u5fae\u5c3f\u86cb\u767d\u7684\u51fa\u73fe, \u4ee3\u8868\u814e\u7d72\u7403\u8d85\u9ad8\u904e\u6ffe(glomerlar hyperfiltration)\u5df2\u7d93\u5b58\u5728\u4e26\u5f9e\u6b64\u958b\u59cb\u8870\u9000\nB. \u986f\u5fae\u5c3f\u86cb\u767d\u7684\u51fa\u73fe, \u4ee3\u8868\u75c5\u4eba\u767c\u751f\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u7f79\u75c5\u6216\u6b7b\u4ea1\u6a5f\u7387\u5df2\u7d93\u589e\u52a0\nC. \u986f\u5fae\u5c3f\u86cb\u767d\u7684\u51fa\u73fe, \u4ee3\u8868\u81f3\u5c11\u6709\u4e94\u6210\u4ee5\u4e0a\u7684\u75c5\u4eba\u5176\u773c\u5e95\u6709\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u75c5\u8b8a\nD. \u986f\u5fae\u5c3f\u86cb\u767d\u4e4b\u51fa\u73fe, \u4e26\u4e0d\u5177\u907a\u50b3\u6027.\nE. \u986f\u5fae\u5c3f\u86cb\u767d\u7684\u51fa\u73fe, \u4ee3\u8868\u81f3\u5c11\u6709\u4e94\u6210\u4ee5\u4e0a\u7684\u75c5\u4eba\u6709\u9ad8\u8840\u58d3\n": "(D)", "103-21.\n\u95dc\u65bc\u5fc3\u814e\u75c7\u5019\u7fa4\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u70ba\u932f\u8aa4 ?\nA. \u5fc3\u814e\u75c7\u5019\u7fa4\u5f88\u5c11\u767c\u751f\u5728\u5de6\u5fc3\u5ba4\u6536\u7e2e\u529f\u80fd\u6b63\u5e38\u7684\u75c5\u4eba\nB. \u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u53ef\u80fd\u56e0\u814e\u975c\u8108\u58d3\u529b\u589e\u52a0, \u81f4\u4f7f\u814e\u7d72\u7403\u904e\u6ffe\u7387\u4e0b\u964d\nC. \u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u6297\u5229\u5c3f\u6fc0\u7d20(Anti-diuretic hormone,ADH)\u5206\u6ccc\u589e\u52a0\nD. \u6162\u6027\u814e\u81df\u75c5\u4e2d\u7dad\u4ed6\u547dD\u7684\u7f3a\u4e4f\u6703\u9020\u6210\u5fc3\u808c\u80a5\u539a\nE. \u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u8840\u6db2\u4e2dadenosine\u4e0a\u5347,\u6703\u9020\u6210\u814e\u7d72\u7403\u904e\u6ffe\u7387\u4e0b\u964d, \u9209\u56de\u6536\u589e\u52a0\n": "(A)", "103-22.\n\u67d030\u6b72\u5973\u6027\u56e0\u9ad8\u8840\u58d3(BP 210/130 mmHg)\u8207\u4f4e\u8840\u9240(K =2.8 mmol/L), \u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\u70bapH 7.45, PaCO2 53mmHg , HCO3 32.7mEq/L . \u5176\u57fa\u6e96\u7684\u8840\u6f3f\u814e\u7d20\u6d3b\u6027 (Plasma renin activity, PRA  0.07 ng.mL/hr;) \u8840\u6f3f\u7559\u9e7d\u6fc0\u7d20(Plasma aldosterone; PA 43.7 ng/mL);\u7d93\u56db\u5c0f\u6642\u4e8c\u516c\u5347\u751f\u7406\u9e7d\u6c34\u8f38\u6ce8\u5f8c: PRA\u70ba0.2 ng/mL/hr, PA \u70ba19 ng/mL);\u8acb\u554f\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\u4f55?\nA. Diuretic use\nB. Congenital adrenal hyperplasia\nC. Primary aldosteronism\nD. Cushing syndrome\nE. Licorice ingestion\n": "(C)", "104-1.\n24\u6b72\u5973\u6027\u75c5\u4eba\u56e0\u808c\u8089\u62bd\u7b4b\u8207\u5168\u8eab\u4e4f\u529b\u5f71\u97ff\u6253\u96fb\u8166\u8207\u8d70\u8def\u800c\u6c42\u8a3a\u3002\u7406\u5b78\u6aa2\u67e5\u70ba\uff1a\u8840\u58d3 112/70 mmHg; HR 80/min, \u547c\u543814/min,\u5168\u8eab\u808c\u529b\u7d044\u5206\u3002BUN 13.2 mg/dL, Cre 0.9 mg/dL, Uric acid 9.6 mg/dL, Na 136 mmol/L, K 2.6 mmol/L, Cl 85 mmol/L, Ca 2.38 mmol/L, Mg 0.9 mmol/L. Urine K 33.4 mmol/24/h , TTKG 11.74. Blood gas pH 7.53, PaCO2 49.3 mmHg, PaO2 98.0 mmHg, HCO3- 41.2 mEq/L, BE 15.8 mEq/L. Plasma renin activity 25.8 ng/ml/h (normal <5); Plasma aldosterone 64.4 ng/dL (normal <30)., \u814e\u81df\u8d85\u97f3\u6ce2(\u5982\u5716)\u3002\u8acb\u554f\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\r(1) Fanconi syndrome, (2) Bartter syndrome, (3) Gilteman syndrome, (4) \u9577\u671f\u904e\u5ea6\u4f7f\u7528Thiazide, (5) \u9577\u671f\u904e\u5ea6\u4f7f\u7528Loop diuretics.\nA. (1)+(2)\nB. (2)+(5)\nC. (3)+(4)\nD. (2)+(4)\nE. (3)+(5)\n": "(B)", "104-2.\n73\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u6700\u8fd1\u4e94\u5929\u773c\u7736\u5468\u906d\u81ea\u7136\u51fa\u73fe\u7d2b\u6591\uff0c\u81ea\u8ff0\u4e4b\u524d\u7121\u5916\u50b7\u6216\u8dcc\u5012\uff0c\u904e\u53bb\u7121\u7cd6\u5c3f\u75c5\u6216\u9ad8\u8840\u58d3\uff0c\u4e5f\u7121\u670d\u7528\u6b62\u75db\u85e5\u3001\u963f\u65af\u5339\u6797\u3001\u6297\u51dd\u5291\u7b49\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u5168\u8eab\u4ed6\u8655\u76ae\u819a\u7121\u96f7\u540c\u75c7\u72c0\uff0c\u4e0b\u80a2\u7121\u6c34\u816b\u3002\u4f46\u5c3f\u6db2\u6aa2\u67e5\u6709\u5c3f\u86cb\u767d3+,RBC 0-2/HPF\uff0cBUN 30 mg/dL, Cre 1.5 mg/dL, Albumin 3.3 gm/dL\uff0c.\u8d85\u97f3\u6ce2\u986f\u793a\u814e\u81df\u5927\u5c0f\u6b63\u5e38\uff0c\u76ae\u8cea\u56de\u97f3\u5ea6\u7a0d\u589e\u5f37\uff0c\u5176\u4ed6\u7121\u7570\u5e38\u3002\u8acb\u554f\u5728\u5efa\u8b70\u505a\u4fb5\u8972\u6027\u6aa2\u67e5\u524d\uff0c\u6700\u597d\u80fd\u9078\u64c7\u5e95\u4e0b\u54ea\u5e7e\u9805\u6aa2\u67e5\u6bd4\u8f03\u80fd(\u63a5\u8fd1\u767e\u5206\u4e4b\u767e\u7684\u9748\u654f\u5ea6)\u4f86\u78ba\u5b9a\u81c6\u65b7\u4e4b\u6b63\u78ba\u5426\uff1f\r(1) Immunofixation of serum; (2) Immunofixation of urine, (3) Serum protein electrophoresis, (4) Urine Bence Jones Protein detection, (5) Serum immunoglobulin free light chain assay.\nA. (3)+(4)\nB. (1)+(3)+(4)\nC. (2)+(3)+(5)\nD. (1)+(2)+(5)\nE. (3)+(4)+(5)\n": "(D)", "104-3.\n\u8acb\u554f\u5e95\u4e0b\u6240\u5217\u964d\u8840\u58d3\u4e4b\u85e5\u7269\uff0c\u54ea\u4e9b\u53ef\u5e6b\u5fd9\u8f38\u5c3f\u7ba1\u7d50\u77f3\u4e4b\u6392\u51fa\uff1f\r(1) Thiazide, (2) Loop diuretics, (3) Beta blockers, (4) alpha blockers (tamsulosin), (5) calcium blockers (nifedipine)\nA. (1)+(2)\nB. (3)+(4)\nC. (4)+(5)\nD. (1)+(3)\nE. (2)+(5)\n": "(C)", "104-4.\n58\u6b72\u7537\u6027\u75c5\u4eba\u6709\u7cd6\u5c3f\u75c512\u5e74\uff0c\u9ad8\u8840\u58d3\u8207\u8173\u90e8\u6c34\u816b\u7d04\u534a\u5e74\u3002\u7406\u5b78\u6aa2\u67e5 BMI 29\uff0c\u8840\u58d3 154/88 mmHg\uff0c\u811b\u9aa8\u524d\u6c34\u816b +\u3002 \u5c3f\u86cb\u767d 3+, URBC 0-2/HPF\u3002Albumin 3.3 g/dL, BUN 33 mg/dL, Cre 1.8 mg/dL (eGFR 42 ml/min), Na 132 mmol/L, K 5.2 mmol/L, HbA1C 7.3. .\u8acb\u554f\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u662f\u932f\u8aa4\uff1f\r(1) \u56e0\u662f\u6162\u6027\u814e\u81df\u75c5\u7b2c3b\u671f\uff0c\u5c1a\u7121\u9808\u8f49\u8a3a\u81f3\u814e\u81df\u5c08\u79d1\u91ab\u5e2b\u3002(2) \u9ad8\u8840\u58d3\u4e4b\u51fa\u73fe\u4ee3\u8868\u814e\u529f\u80fd\u5c07\u6301\u7e8c\u7e7c\u7e8c\u60e1\u5316\u3002(3) \u82e5\u8840\u7cd6\u80fd\u56b4\u683c\u63a7\u5236\uff0c\u4ea6\u96e3\u4ee5\u964d\u4f4e\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u767c\u751f\u3002(4) \u82e5\u9ad8\u8840\u58d3\u80fd\u56b4\u683c\u63a7\u5236(\u5305\u62ec\u4f7f\u7528ACEI\u6216ARB)\u53ef\u4ee5\u6e1b\u7de9\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a\u8207\u8996\u7db2\u819c\u75c5\u8b8a\u3002(5) \u75c5\u4eba\u8840\u7cd6\u5728\u9ad8\u8840\u58d3\u8207\u5c3f\u86cb\u767d\u51fa\u73fe\u5c07\u66f4\u96e3\u63a7\u5236\u3002\nA. (1)+(3)\nB. (2)+(5)\nC. (2)+(3)\nD. (4)+(5)\nE. (3)+(5)\n": "(A)", "104-5.\n\u8acb\u554f\u6162\u6027\u814e\u81df\u75c5\u4eba\u4e2d\u4f7f\u7528\u5e95\u4e0b\u4e4b\u85e5\u7269\uff0c\u4f55\u8005\u6216\u54ea\u4e9b\u4e0d\u6703\u52a0\u91cd\u8840\u7ba1\u9223\u5316\uff1f\r(1) Calcium containing phosphate binders; (2) non-ion based phosphate binders, (3) Vitamin D, (4)  High calcium dialysate, (5) Warfarin \u3002\nA. (2)\nB. (2)+(3)\nC. (2)+(5)\nD. (2)+(3)+(4)\nE. (2)+(3)+(5)\n": "(A)", "104-6.\n\u8acb\u554f\u5e95\u4e0b\u85e5\u7269\u4f55\u8005\u662f\u4e3b\u8981\u7531\u814e\u81df\u6392\u6cc4\u4e14\u814e\u529f\u80fd\u6b20\u4f73\u6642\u9700\u8abf\u6574\u5291\u91cf\uff0c\u4f46\u5728\u85e5\u7269\u904e\u91cf\u6642\u537b\u7121\u6cd5\u4ee5\u8840\u6db2\u900f\u6790\u4f86\u6392\u9664\uff1f\r(1) Aspirin ; (2) Digoxin ;(3)  Lithium (4)Tobramycin; (5)Vancomycin.\nA. (1)+(2)\nB. (2)+(3)\nC. (2)+(5)\nD. (2)+(4)\nE. (3)+(5)\n": "(C)", "104-7.\n45\u6b72\u5973\u6027\u66fe\u63a5\u53d7\u814e\u81df\u79fb\u690d\uff0c\u6b63\u5728\u670d\u7528 Tacrolimus\u53caSirolimus\uff0c\u6b64\u5916\u6709\u670d\u7528\u907f\u5b55\u85e5\u53ca\u56e0\u51a0\u72c0\u52d5\u8108\u963b\u585e\u66fe\u653e\u652f\u67b6\u800c\u670d\u7528Clopidogrel\uff0c\u8acb\u554f\u6b64\u75c5\u4eba\u5bb9\u6613\u7f79\u60a3\u5e95\u4e0b\u54ea\u4e00\u7a2e\u814e\u81df\u75be\u75c5\uff1f\r(1) Thrombotic thrombocytopenic purpura ; (2) Hemolytic uremic syndrome ; (3) Goodpasture syndrome ; (4) Henoch-Schonlein purpura ; (5)Microscopic polyangitis\nA. (1)+(2)\nB. (3)+(4)\nC. (3)+(5)\nD. (2)+(3)\nE. (2)+(5)\n": "(A)", "104-8.\n63\u6b72\u5973\u6027\u75c5\u4eba\u6709\u9ad8\u8840\u58d3\u3001\u9000\u5316\u6027\u95dc\u7bc0\u708e\u4e4b\u904e\u53bb\u53f2\uff0c\u56e0\u814e\u529f\u80fd\u6b20\u4f73\u6c42\u8a3a\u7d93\u6aa2\u67e5\u6709\u5c3f\u86cb\u767d++\u8207\u5c3f\u7d05\u8840\u74035-10/HPF\u3002\u8840\u6e05\u808c\u9178\u9150 2.2 mg/dL\uff0c\u8840\u7d05\u7d2010 gm/dL\u3002\u8d85\u97f3\u6ce2\u986f\u793a\u5169\u5074\u814e\u81df\u5747\u8f15\u5ea6\u840e\u7e2e\u5404\u7d049\u516c\u5206(\u5982\u5716)\uff0c\u8acb\u554f\u4e0d\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\uff1f\r(1) Myeloma kidney ; (2)nephropathy ; (3)DM nephropathy; (4) Chinese herb nephropathy ; (5)Lithium nephropathy\nA. (1)+(2)\nB. (1)+(3)\nC. (2)+(3)\nD. (3)+(5)\nE. (2)+(5)\n": "(B)", "104-9.\n\u4f9d\u64da\u76ee\u524d\u4e4b\u81e8\u5e8a\u8b49\u64da\uff0c\u65bc\u7b2c\u56db\u671f\u7d05\u6591\u6027\u72fc\u7621\u4e4b\u8a98\u767c\u671f\uff0c\u5efa\u8b70\u5982\u4f55\u9078\u64c7\u514d\u75ab\u6291\u5236\u5291\u800c\u80fd\u6709\u8f03\u4f73\u7642\u6548\u4e14\u8f03\u5c11\u526f\u4f5c\u7528\uff1f\r(1) Monthly i.v. high dose cyclophosphamide;\r(2) Monthly i.v. high dose methylprednisolone,\r(3) Monthly i.v. Rituxumab, anti-CD20 monoclonal antibody.\r(4) Daily oral mycophenolate mofetil\r(5) Daily oral cyclosporine\r(6) Daily oral azathioprine\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(5)\nD. (1)+(3)+(6)\nE. (2)+(5)+(6)\n": "(B)", "104-10.\n\u75c5\u4eba\u56e0Transient Ischemia attack \u6b63\u9577\u671f\u670d\u7528\u4f4e\u5291\u91cfAspirin, \u8acb\u554f\u8207\u4e0b\u5217\u54ea\u4e9b\u85e5\u7269\u6703\u6709\u4ea4\u4e92\u4f5c\u7528\uff1f\r(1) naproxen\r(2) Ibuprofrn\r(3) COX-2 inhibitor\r(4) Acetaminophen\r(5) Diclofenac\nA. (1)+(2)\nB. (1)+(2)+(4)\nC. (2)+(3)+(4)\nD. (2)+(4)+(5)\nE. (2)+(3)+(4)+(5)\n": "(A)", "104-11.\n66\u6b72\u5a66\u4eba\u56e0\u6182\u9b31\u75c7\u541e\u670d\u9223\u96e2\u5b50\u963b\u65b7\u5291\u8207\u4e59\u578b\u4ea4\u611f\u795e\u7d93\u963b\u65b7\u5291(\u4e0d\u77e5\u9053\u5e7e\u7c92)\uff0c\u7d93\u6025\u8a3a\u5f8c\u7be9\u6aa2\u767c\u73fe\u8840\u58d3 70/50 mmHg, \u5fc3\u8df3 45/min\uff0c\u5fc3\u96fb\u5716\u6709AV block \u73fe\u8c61\u3002\u8acb\u554f\u5e95\u4e0b\u54ea\u4e9b\u662f\u4e0d\u9069\u7576\u7684\u7279\u6b8a\u6cbb\u7642\u6216\u8655\u7f6e\uff1f\r(1) \u7d66\u4e88\u5927\u91cf\u751f\u7406\u9e7d\u6c34; (2) Glucacon ; (3) Vasopressors or inotropic agents; (4) Magnesium; (5) Electric pacing ; (6) High dose insulin (with glucose and potassium) ; (7) \u9700\u8981\u96a8\u6642\u6aa2\u6e2c\u8840\u7cd6\u53ca\u9240\u96e2\u5b50\nA. (1)+(2)+(7)\nB. (2)+(6)+(7)\nC. (1)+(4)\nD. (6)+(7)\nE. (1)+(2)+(6)\n": "(C)", "104-12.\n\u4e00\u4f4d30\u6b72\u5973\u6027\uff0c\u904e\u53bb\u6709IgA nephropathy\u8207\u8f15\u5ea6\u86cb\u767d\u5c3f\uff0c\u5b9a\u671f\u5728\u9580\u8a3a\u5c31\u91ab\u3002\u6700\u8fd1\u61f7\u5b55\u4e26\u51fa\u73fe\u9ad8\u8840\u58d3\uff0c\u4ee5\u4e0b\u9ad8\u8840\u58d3\u76f8\u95dc\u85e5\u7269\u8655\u7f6e\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u5408?\nA. \u4f7f\u7528methyldopa\nB. \u4f7f\u7528ACEI \u985e\u964d\u4f4e\u86cb\u767d\u5c3f\uff0c\u9810\u9632\u767c\u751fpre-eclampsia\nC. \u4f7f\u7528 labetalol\nD. \u4f7f\u7528Long-acting nifedipine\nE. \u4f7f\u7528hydralazine\n": "(B)", "104-13.\n\u4e00\u4f4d52\u6b72\u7537\u6027\uff0c\u6709\u4e09\u5e74\u7684nephrotic syndrome\u75c5\u53f2\uff0c\u5b9a\u671f\u5728\u9580\u8a3a\u5c31\u91ab\u3002\u6700\u8fd1\u4e00\u500b\u6708\u51fa\u73fe\u96d9\u4e0b\u80a2\u6c34\u816b\uff0c\u9ad4\u91cd\u589e\u52a0\u4e864\u516c\u65a4\uff0c\u5c3f\u86cb\u767d\u5f9e2.8 g/day\u589e\u52a0\u523010.6 g/day\u3002\u91ab\u5e2b\u61f7\u7591\u6709venous thromboembolism\u5408\u4f75\u75c7\u3002\u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. \u53ef\u80fd\u662f\u767c\u751fdeep vein thrombosis\u6216renal vein thrombosis\nB. \u539f\u56e0\u901a\u5e38\u662fplatelet \u6578\u76ee\u589e\u52a0\u6216antithrombin III activity\u589e\u52a0\u6240\u81f4\nC. \u53ef\u80fd\u539f\u56e0\u662fprotein C\u6216protein S\u6e1b\u5c11\u6240\u81f4\nD. \u901a\u5e38\u5148\u4ee5\u8d85\u97f3\u6ce2\u505a\u7be9\u6aa2(screening test)\uff0c\u5fc5\u8981\u6642\u518d\u5b89\u6392CT \u6216MRI\u6aa2\u67e5\nE. \u4f7f\u7528 heparin \u6216warfarin\u6cbb\u7642\n": "(B)", "104-14.\n\u4e00\u4f4d24\u6b72\u5916\u8868\u5065\u5eb7\u5973\u6027\uff0c\u5065\u5eb7\u6aa2\u67e5\u767c\u73fe: urine protein (2+)\uff0curine occult blood test (2+), Hb 9.4 g/dL\uff0cWBC 7,650/mm3\uff0cserum creatinine 1.8 mg/dL\uff0c\u88dc\u9ad4C3\u8207C4\u8f03\u6b63\u5e38\u503c\u504f\u4f4e\u3002\u75c5\u4eba\u6700\u53ef\u80fd\u662f\u4ee5\u4e0b\u4f55\u7a2e\u814e\u7d72\u7403\u814e\u708e(glomerulonephritis)?\nA. IgA nephropathy\nB. Henoch-Schonlein purpura\nC. Acute poststreptococcal nephritis\nD. Mesangial proliferative glomerulonephritis\nE. Focal segmental glomerulosclerosis (FSGS)\n": "(C)", "104-15.\n\u4e00\u4f4d\u591a\u56ca\u814e(polycystic kidney disease)\u7684\u75c5\u4eba\uff0c\u56e0\u767c\u71d2\u3001\u8170\u75db\u4f4f\u9662\uff0c\u8a3a\u65b7\u70bacystic infection\u3002\u8003\u91cf\u6297\u751f\u7d20\u5c0d\u500b\u5225\u814e\u81df\u56ca\u6ce1(cyst)\u7684\u7a7f\u900f\u6027\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u6297\u751f\u7d20\u8f03\u4e0d\u9069\u7528?\nA. Aminoglycoside\nB. Clindamycin\nC. Ampicillin\u6216Erythromycin\nD. Fluoroquinolone\nE. Metronidazole\n": "(A)", "104-16.\n\u4e00\u4f4d\u4f4f\u9662\u75c5\u4eba\uff0c\u62bd\u8840\u767c\u73fe[Na] 120 mmol/L\uff0c\u91dd\u5c0d\u4f4e\u8840\u9209\u75c7(hyponatremia)\uff0c\u9032\u4e00\u6b65\u6aa2\u67e5\u5c3f\u6db2\u6ef2\u900f\u58d3(urine osmolality) \u5927\u65bc 280 mOsm/L\uff0c\u5c3f\u6db2\u7684\u9209\u96e2\u5b50\u6fc3\u5ea632 mmol/L\u3002\u75c5\u4eba\u7684\u4f4e\u8840\u9209\u75c7\u6700\u53ef\u80fd\u662f\u4ee5\u4e0b\u4f55\u7a2e\u75c5\u56e0?\nA. SIADH (Syndrome of inappropriate antidiuretic hormone secretion)\nB. Primary polydipsia\nC. Liver cirrhosis\nD. Heart failure\nE. Nephrotic syndrome\n": "(A)", "104-17.\n\u4e00\u4f4d54\u6b72\u75c5\u4eba\uff0c\u4e00\u5e74\u524d\u56e0\u70ba\u86cb\u767d\u5c3f\uff0c\u63a5\u53d7\u814e\u81df\u5207\u7247(renal biopsy)\u75c5\u7406\u6aa2\u67e5\uff0c\u8a3a\u65b7\u662fMembranous nephropathy (MN)\uff0c\u4e4b\u5f8c\u6301\u7e8c\u65bc\u9580\u8a3a\u8ffd\u8e64\u3002\u6700\u8fd1\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7d50\u679c(\u548c\u4e00\u5e74\u524d\u985e\u4f3c)\uff0c\u70ba: [Albumin] 3.8 g/dL\uff0c[creatinine] 1.2 mg/dL\uff0c\u86cb\u767d\u5c3f1.6 g/day\u3002\u75c5\u4eba\u6709\u8f15\u5ea6\u9ad8\u8840\u58d3\uff0c\u4f46\u662f\u6c92\u6709\u6c34\u816b\u3002\u73fe\u968e\u6bb5\u91dd\u5c0d\u6b64\u75c5\u4eba\u7684\u8655\u7f6e\uff0c\u4f55\u8005\u8f03\u5408\u9069?\nA. \u4f7f\u7528\u4f4e\u5291\u91cfprednisolone\uff0c\u7d042.5 mg/kg/day\uff0c\u9810\u9632\u75be\u75c5\u60e1\u5316\nB. \u61c9\u8a72\u4f7f\u7528Cyclosporine \u6216 tacrolimus\uff0c\u53ef\u4ee5\u4fc3\u9032\u7de9\u89e3(remission)\nC. \u55ae\u7368\u4f7f\u7528Mycophenolate mofetil (MMF)\uff0c\u53ef\u4ee5\u66f4\u964d\u4f4e\u86cb\u767d\u5c3f\uff0c\u4fdd\u8b77\u814e\u81df\nD. \u5c1a\u7121\u9700\u4f7f\u7528prednisolone\u6216\u5176\u4ed6\u514d\u75ab\u6291\u5236\u5291\uff0c\u53ef\u4ee5\u4f7f\u7528ACEI\u985e\u85e5\u7269\u63a7\u5236\u8840\u58d3\nE. \u61c9\u8a72\u518d\u5b89\u6392\u4e00\u6b21\u814e\u81df\u5207\u7247(renal biopsy)\uff0c\u8ffd\u8e64\u75c5\u7406\u8b8a\u5316\n": "(D)", "104-18.\n\u4e00\u4f4d48\u6b72\u6162\u6027\u814e\u81df\u75c5\u4eba(CKD stage IV, eGFR 18)\uff0c\u56e0\u70ba\u6709\u7591\u4f3c\u8179\u90e8\u816b\u7624\uff0c\u63a5\u53d7\u6838\u78c1\u5171\u632f(MRI, with Gadolinium-contrast)\uff0c\u5169\u65e5\u5f8c\u51fa\u73fe\u5be1\u5c3f(oliguria)\uff0c\u5168\u8eab\u808c\u8089\u8207\u76ae\u819a\u75bc\u75db\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u662f\u767c\u751f\u54ea\u7a2e\u75c5\u72c0?\nA. Acute tubular necrosis\nB. Rhabdomyolysis\nC. Nephrogenic systemic fibrosis\nD. Obstructive acute kidney injury\nE. Dehydration-induced acute kidney injury\n": "(C)", "104-19.\n\u6709\u95dcchronic tubulointerstitial nephritis\u75c5\u4eba\u7684\u5c3f\u6db2\u6aa2\u9a57\uff0c\u4ee5\u4e0b\u6558\u8ff0\u7d44\u5408\u4f55\u8005\u6700\u6b63\u78ba?\r(1) \u7528Hansel stain\u53ef\u4ee5\u898b\u5230eosinophiluria\r(2) \u6c92\u898b\u5230WBC cast\r(3) \u898b\u5230granular cast\r(4) \u86cb\u767d\u5c3f(proteinuria) > 1-2 g/day\r(5) \u6709\u6f5b\u8840\u53cd\u61c9[occult blood test (+)], \u53caWBC 40-50/HPF\uff0c\u4f46\u662f\u75c5\u4eba\u4e26\u7121\u6ccc\u5c3f\u9053\u4e0d\u9069\u75c7\u72c0\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (1)+(3)+(4)\n": "(B)", "104-20.\n\u4e00\u4f4d52\u6b72\u5973\u6027\uff0c\u4e3b\u8a34\u767c\u71d2\u3001\u5641\u5fc3\u5614\u5410\u3001\u80c3\u53e3\u8b8a\u5dee\u548c\u8179\u75db\u6301\u7e8c\u4e86\u4e00\u500b\u661f\u671f\u3002\u75c5\u4eba\u56e0\u7d05\u6591\u6027\u72fc\u7621\u814e\u708e\u53ca\u5c3f\u6bd2\u75c7\uff0c\u63a5\u53d7\u8179\u819c\u900f\u6790\u7d0415\u5e74\u3002\u900f\u6790\u6db2\u5916\u89c0\u6e05\u6f88\uff0c\u8179\u6c34\u5316\u9a57\u767d\u8840\u7403\u5c0f\u65bc100 cells/uL\u3002\u81e8\u5e8a\u4e0a\u51fa\u73fe\u8178\u963b\u585e\u4e4b\u75c7\u72c0\uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64(CT)\u53ef\u770b\u5230\u6709\u8178\u9053\u64f4\u5f35\u53ca\u8178\u58c1\u9223\u5316\uff0c\u4e14\u88ab\u9223\u5316\u7684\u81df\u5c64\u8179\u819c\u5305\u8986\u8d77\u4f86\u3002\u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\r(1) \u53ef\u80fd\u662f\u8179\u819c\u900f\u6790\u767c\u751f\u7d30\u83cc\u6027\u8179\u819c\u708e(bacterial peritonitis), \u6216\u9ef4\u83cc\u6027\u8179\u819c\u708e(fungal peritonitis)\r(2) \u53ef\u80fd\u662f\u767c\u751f\u5305\u56ca\u6027\u8179\u819c\u786c\u5316\u75c7(encapsulating peritoneal sclerosis)\r(3) \u53ef\u4ee5\u7528tamoxifen\uff0c\u6216\u514d\u75ab\u6291\u5236\u5291(\u5982\u985e\u56fa\u9187\uff0ccorticosteroid)\u6cbb\u7642\r(4) \u53ef\u4ee5\u7528\u4e59\u578b\u963b\u65b7\u5291(beta-blocker)\u6cbb\u7642\r(5) \u4f7f\u7528\u9ad8\u7cd6\u6fc3\u5ea6\u900f\u6790\u6db2\uff0c\u589e\u52a0\u704c\u6d17\u6b21\u6578\uff0c\u53ef\u9810\u9632\u8179\u8154\u5167\u6cbe\u9ecf\uff0c\u4e26\u88dc\u5145\u71df\u990a\nA. (1)+(2)+(5)\nB. (1)+(3)+(5)\nC. (2)+(3)\nD. (2)+(3)+(4)\nE. (2)+(3)+(5)\n": "(C)", "104-21.\n\u4e00\u4f4d51\u6b72\u7537\u6027\uff0c\u8eab\u6750\u5fae\u80d6\uff0c\u5169\u500b\u6708\u524d\u4f8b\u884c\u6027\u5065\u6aa2\u767c\u73fe\u6709\u9ad8\u8840\u58d3(152/94 mm Hg)\u3002\u75c5\u4eba\u81f3\u4f60\u7684\u9580\u8a3a\u5c31\u91ab\uff0c\u6e2c\u5f97\u8840\u58d3\u503c148/90 mm Hg\uff0c\u4f9d\u71672015\u5e74\u51fa\u7248\u7684\u53f0\u7063\u9ad8\u8840\u58d3\u6307\u5f15\uff0c\u9664\u4e86\u6aa2\u67e5serum creatinine\uff0curinalysis\u7b49\uff0c\u53calipid parameters\u4e4b\u5916\uff0c\u5efa\u8b70\u5b89\u6392\u4ee5\u4e0b\u5be6\u9a57\u5ba4\u4f8b\u884c\u6aa2\u67e5\uff0c\u4f55\u8005\u9664\u5916?\nA. Renal ultrasonography\nB. Hemoglobin or hematocrit\nC. Serum uric acid level\nD. Fasting glucose level\nE. Electrocardiogram (ECG) or chest X-ray\n": "(A)", "104-22.\n\u4f4e\u8840\u9240\u7684\u539f\u56e0\u53ef\u4ee5\u5927\u81f4\u6b78\u985e\u70baThyrotoxic periodic paralysis (TPP)\u8207hypokalemic non-periodic paralysis (HNPP)\u5169\u985e\u3002\u9019\u4e9b\u75c5\u4eba\u5728\u88dc\u5145\u9240\u7684\u8f38\u6db2\u6cbb\u7642\u4e2d\uff0c\u8840\u6e05\u9240\u6fc3\u5ea6\u6709\u6642\u53cd\u800c\u66f4\u4f4e\uff0c\u9019\u7a31\u4e4b\u70ba\"Paradoxical hypokalemia\". \u4ee5\u4e0b\u6709\u95dcParadoxical hypokalemia\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\nA. \u4e00\u822c\u800c\u8a00\uff0c\u7576\u8981\u77ef\u6b63\u4f4e\u8840\u9240\uff0cTPP\u6bd4HNPP\u7684\u75c5\u4eba\u9700\u8981\u88dc\u5145\u66f4\u591a\u7684\u9240\nB. \u4e00\u822c\u800c\u8a00\uff0c\u7576\u77ef\u6b63\u4f4e\u8840\u9240\u6642\uff0cTPP\u6bd4HNPP\u7684\u75c5\u4eba\u66f4\u5e38\u767c\u751frebound hyperkalemia.\nC. \u4e00\u822c\u800c\u8a00\uff0c\u7576\u77ef\u6b63\u4f4e\u8840\u9240\u6642\uff0cTPP\u6bd4HNPP\u7684\u75c5\u4eba\u66f4\u5e38\u767c\u751fParadoxical hypokalemia\nD. TPP\u7684\u75c5\u4eba\u767c\u751fParadoxical hypokalemia\u7684\u539f\u56e0\uff0c\u901a\u5e38\u8207\u9ad4\u6db2\u5bb9\u7a4d\u4e0d\u8db3(hypovolemia)\u6216renin-aldosterone \u6d3b\u6027\u904e\u9ad8\u6709\u95dc\nE. HNPP\u7684\u75c5\u4eba\u767c\u751fParadoxical hypokalemia\u7684\u539f\u56e0\uff0c\u901a\u5e38\u8207\u8840\u58d3\u9ad8\u6709\u95dc\uff0c\u6240\u4ee5\u53ef\u4ee5\u4f7f\u7528beta-blocker\u4f86\u9810\u9632\n": "(B)", "105-1.\n54\u6b72\u80a5\u80d6\u7537\u5b50(BMI 27.6)\uff0c\u56e0\u9ad8\u8840\u58d3\u4e00\u76f4\u63a7\u5236\u4e0d\u4f73\u800c\u88ab\u8f49\u8a3a\uff0c\u5176\u964d\u58d3\u85e5\u7269\u958b\u59cb\u6709Verapamil\u3001Metoprolol\u3001Clonidine\uff0c\u5f8c\u4f86\u8abf\u6574\u6210Amlodipine\u3001Atenolol\u3001Valsartan\u3001Doxazosin\u3001Minoxidil\u4e94\u7a2e\uff0c\u4f46\u662f\u8840\u58d3\u4ecd\u7136\u5728160-180/100-110 mmHg\u3002\u4ed6\u5e38\u56e0\u982d\u75db\u8207\u95dc\u7bc0\u9178\u75bc\u670d\u7528Ibuprofen\uff0c\u6700\u8fd1\u6aa2\u6e2c\u8840\u6e05\u808c\u9178\u9150\u70ba2.9mg/dL\uff1b\u53e6\u5916\u6709\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\uff0c\u56e0\u914d\u6234\u5100\u5668\u7761\u89ba\u4e0d\u8212\u670d\uff0c\u6c92\u6709\u6bcf\u5929\u63a5\u53d7continuous positive airway pressure (CPAP)\u6cbb\u7642\u3002\r\u70ba\u4e86\u80fd\u5c07\u8840\u58d3\u597d\u597d\u63a7\u5236\uff0c\u8acb\u554f\u5e95\u4e0b\u8655\u7f6e\u54ea\u4e9b\u70ba\u6b63\u78ba\uff1f\r1. \u61c9\u8a72\u6539\u7528Selective COX2  inhibitor\uff0c\u5c0d\u8840\u58d3\u8f03\u7121\u5f71\u97ff\u3002\r2. \u61c9\u8a72\u5b89\u639224\u5c0f\u6642\u52d5\u614b\u8840\u58d3\u76e3\u6e2c(24 hour ambulatory blood pressure monitor) \u7684\u6aa2\u67e5\u3002\r3. \u61c9\u8a72\u52a0\u4e0a\u5229\u5c3f\u5291\u4e4b\u4f7f\u7528\u4ee5\u53ca\u7be9\u6aa2\u5176\u4ed6\u6b21\u767c\u6027\u9ad8\u8840\u58d3\u3002\r4. \u61c9\u8a72\u6e1b\u91cd\u53ca\u5f37\u8abf\u6bcf\u5929\u4f7f\u7528CPAP\u6cbb\u7642\u3002\r5. \u61c9\u8a72\u63a8\u85a6\u505a\u814e\u52d5\u8108\u4ea4\u611f\u795e\u7d93\u71d2\u707c\u8853\u6cbb\u7642\u3002\nA. 1+2+3\nB. 1+3+4\nC. 1+3+5\nD. 2+3+4\nE. 1+2+3+4\n": "(D)", "105-2.\n63\u6b72\u7537\u6027\u75c5\u4eba\u5169\u5929\u524d\u63a5\u53d7\u8180\u80f1\u93e1\u6aa2\u67e5\uff0c\u9010\u6f38\u51fa\u73fe\u754f\u5bd2\u767c\u71d2\u3001\u89e3\u5c3f\u4e0d\u6613\u3001\u89e3\u5c3f\u75bc\u75db\u3001\u983b\u5c3f\u3001\u6703\u9670\u8655\u7a0d\u5fae\u4e0d\u9069\uff1b\u9ad4\u6eab\u651d\u6c0f38.3\u5ea6\u3001\u5176\u4ed6\u751f\u547d\u73fe\u8c61\u7a69\u5b9a\uff0cCostophrenic angle\u7121\u6572\u64ca\u75db\u3001\u5c3f\u9053\u53e3\u7121\u5206\u6ccc\u7269\uff1b\u5c3f\u6db2\u6aa2\u67e5\u670910 WBC/HPF\u3001Nitrite 1+, Leukocyte esterase 1+\uff1b\u62bd\u8840\u6aa2\u67e5\u814e\u529f\u80fd\u6b63\u5e38\uff0cPSA \u5347\u9ad8\u81f325ng/ml\u3002\r\u8acb\u554f\u5e95\u4e0b\u54ea\u4e9b\u6558\u8ff0\u662f\u6b63\u78ba\u7684\uff1f\r1.\u61c9\u8a72\u8981\u505a\u5c3f\u6db2\u8207\u8840\u6db2\u7d30\u83cc\u57f9\u990a\r2. \u56e0\u70ba\u5c3f\u6db2Nitrite\u5448\u967d\u6027\uff0c\u6975\u53ef\u80fd\u662fPseudomonas\u611f\u67d3\r3. \u61c9\u8a72\u5b89\u6392\u814e\u81df\u8180\u80f1\u651d\u8b77\u817a\u8d85\u97f3\u6ce2\u6aa2\u67e5\r4..\u53ef\u7d66\u4e88\u53e3\u670dFluoroquinolone\u4e8c\u81f3\u56db\u9031\r5. \u53ef\u7d66\u4e88\u53e3\u670dNitrofuratoin\u4e8c\u81f3\u56db\u9031\nA. 1+2+4\nB. 1+3+4\nC. 2+3+4\nD. 1+3+5\nE. 2+3+5\n": "(B)", "105-3.\n58\u6b72\u7537\u6027\u75c5\u4eba\u6709\u9ad8\u8840\u58d3\u3001\u9ad8\u8840\u8102\u3001\u6162\u6027\u814e\u81df\u75c5\u3001\u75db\u98a8(\u8fd1\u534a\u5e74\u767c\u4f5c\u4e09\u6b21\uff0c\u6700\u5f8c\u4e00\u6b21\u70ba\u4e09\u5468\u524d\uff0c\u5728\u624b\u6307\u3001\u8173\u8dbe\u3001\u624b\u8098\u3001\u8033\u6735\u7b49\u591a\u8655\u95dc\u7bc0\u6709Subcutaneous tophi)\u3002\u76ee\u524d\u62bd\u8840\u6aa2\u67e5\u8840\u6e05\u808c\u9178\u91502.1 mg/dL(eGFR 33)\uff1b\u5c3f\u9178 9 mg/dL\u3002\u5176\u76ee\u524d\u670d\u7528\u85e5\u7269\u6709Thiazide\u3001Losartan\u3001Amlodipine\u3001Fenofibrate\u3001 low dose aspirin\u3002\r\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u8655\u7f6e\u70ba\u6070\u7576\uff1f\r1.\u958b\u59cb\u4f7f\u7528Allopurinol\u6216Febuxostat\uff0c\u4f46\u9808\u964d\u4f4e\u5291\u91cf\u3002\r2.\u505c\u7528Thiazide\uff0c\u56e0\u70ba\u6703\u52a0\u5c3f\u9178\u800c\u4e14\u589e\u52a0Allopurinol\u7684\u6bd2\u6027\u3002\r3. Losartan\u3001Amlodopine\u3001 Low dose aspirin \u5747\u6703\u4fc3\u9032\u5c3f\u9178\u6392\u6cc4\u3002\r4.\u5df2\u975e\u6025\u6027\u75db\u98a8\u671f\uff0c\u4e0d\u5fc5\u518d\u4f7f\u7528Colchicine\u3002\r5.\u6b64\u75c5\u4eba\u964d\u4f4e\u5c3f\u9178\u4e4b\u9810\u671f\u76ee\u6a19\u70ba6 mg/dL\u4ee5\u4e0b\u3002\nA. 1+2+3\nB. 2+3+5\nC. 1+2+5\nD. 1+3+5\nE. 1+4+5\n": "(C)", "105-4.\n62\u6b72\u5973\u59d3\uff0c\u904e\u53bb\u7121\u9ad8\u8840\u58d3\u6216\u7cd6\u5c3f\u75c5\uff0c\u8fd1\u4e94\u5e74\u96d9\u624b\u624b\u6307\u78b0\u51b7\u6c34\u6703\u8b8a\u7d05\u7d2b\uff0c\u6700\u8fd1\u56db\u500b\u6708\u9010\u6f38\u51fa\u73fe\u4ee5\u4e0b\u75c7\u72c0\uff1a\u9762\u5b54\u8207\u624b\u6307\u6d6e\u816b\u3001\u541e\u56a5\u4e0d\u9806\u3001\u8aaa\u8a71\u9072\u7de9\u3001\u4e0b\u80a2\u816b\u8139\u3001\u8840\u58d3\u8b8a\u9ad8\u3001\u547c\u5438\u6025\u4fc3\u3001\u547c\u5438\u56f0\u96e3\u3001\u7aef\u5750\u547c\u5438\u3002BP160/83 mmHg, Urine protein 3+, RBC 40-50/HPF;Hb 7.4 gm/dL,Alb 2.8 gm/dL,Cre 2.8 mg/dL(\u534a\u5e74\u524d1.2 mg/dL) \u3002( \u5982\u5716\u793a)\r\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\nA. \u99ac\u4e0a\u4f4f\u9662\u4e26\u958b\u59cb\u985e\u56fa\u9187\u7684\u6cbb\u7642\u3002\nB. \u82e5\u5728\u767c\u75c5\u524d\u7d66\u4e88ACE inhibitor\uff0c\u5373\u53ef\u6709\u6548\u5730\u9810\u9632\u6b64\u75c5\u4e4b\u767c\u4f5c\u3002\nC. \u82e5\u75c5\u4eba\u6c92\u6709\u51fa\u73fe\u9ad8\u8840\u58d3(\u5373Normotensive)\uff0c\u5176\u75c5\u60c5\u8207\u9810\u5f8c\u6703\u8f03\u597d\u3002\nD. \u82e5\u75c5\u4eba\u4e4bautoantibody against topoisomerase I (Scl70)\u5448\u967d\u6027\uff0c\u5176\u9810\u5f8c\u8f03\u597d\u3002\nE. \u82e5\u5169\u5e74\u5f8c\u4ecd\u7121\u6cd5\u812b\u96e2\u900f\u6790\u6cbb\u7642\uff0c\u53ef\u5efa\u8b70\u75c5\u4eba\u63a5\u53d7\u814e\u81df\u79fb\u690d\uff0c\u56e0\u70ba\u5176\u5b58\u6d3b\u7387\u9084\u597d\u4e14\u5f88\u5c11\u5fa9\u767c\u3002\n": "(E)", "105-5.\n\u8ffd\u8e64\u7cd6\u5c3f\u75c5\u75c5\u4eba\u8840\u7cd6\u63a7\u5236\u60c5\u5f62\u7684\u7cd6\u5316\u8840\u8272\u7d20(Glycosylated hemoglobin, HbA1C)\uff0c\u8acb\u554f\u6709\u54ea\u4e9b\u72c0\u6cc1\u6703\u5047\u6027\u589e\u9ad8(fasle high)?\r1. Hemolytic anemia\r2. Iron dficiency anemia.\r3. High dose Vitamin A or C\r4. Chronic kidney disease\r5. Chronic liver dsease.\nA. 1+2\nB. 1+3\nC. 2+4\nD. 3+5\nE. 4+5\n": "(C)", "105-6.\n\u95dc\u65bc\u651d\u8b77\u817a\u7279\u5b9a\u6297\u539f(Prostate specific antigen,PSA)\u4e4b\u6e2c\u91cf\u8207\u7be9\u6aa2\uff0c\u5e95\u4e0b\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\r1. PSA\u4e4b\u7be9\u6aa2\u5177\u6975\u4f73\u4e4b\u654f\u611f\u5ea6(Sensitivity)\u8207\u7279\u7570\u6027(Specificity)\u3002\r2. PSA\u4e4b\u8840\u4e2d\u6fc3\u5ea6\u8ddf\u651d\u8b77\u817a\u764c\u4e4b\u767c\u751f\u6a5f\u7387\u53ca\u9810\u5f8c\u7121\u660e\u986f\u76f8\u95dc\u3002\r3. PSA\u4e4b\u7be9\u6aa2\u5efa\u8b70\u53ea\u5728\u5e74\u9f6155\u523069\u6b72\u7684\u7537\u6027\uff0c\u624d\u6709\u5229\u591a\u65bc\u5f0a\u3002\r4. PSA\u4e4b\u7be9\u6aa2\u5efa\u8b70\u53ea\u5728\u9810\u4f30\u58fd\u547d\u6709\u8d85\u904e15\u5e74\u7684\u7537\u6027\u624d\u9700\u8003\u616e\u3002\r5. PSA\u4e4b\u7be9\u6aa2\u82e5\u5305\u62ec\u6e2c\u91cffree PSA\uff0c\u53ef\u589e\u52a0\u6e2c\u5f97\u651d\u8b77\u817a\u764c\u7684\u6a5f\u7387\u3002\nA. 1+2\nB. 2+5\nC. 1+2+3\nD. 2+3+4\nE. 3+4+5\n": "(E)", "105-7.\n\u7576\u7d2b\u6591\u75c7Purpura \u51fa\u73fe\u6642\uff0c\u5176\u91cd\u8981\u7684\u9451\u5225\u8a3a\u65b7\u70ba\u662f\u5426Palpable\uff0c \u8acb\u554f\u5e95\u4e0b\u90a3\u4e9b\u814e\u81df\u75be\u75c5\u51fa\u73fe\u7684purpura\u662f\u70baPalpable?\r1. Uremia\r2. Thrombotic thrombocytopenic purpura\r3. Henoch- Schonlein Purpura\r4. Waldenstrom's hypergammaglobulinemic purpura\r5. Polyarteritis nodosa\nA. 1+3\nB. 2+4\nC. 2+3+4\nD. 1+3+5\nE. 3+5\n": "(E)", "105-8.\n65\u6b72\u5973\u6027\u56e0\u814e\u75c5\u75c7\u5019\u7fa4(\u819c\u6027\u814e\u75c5\u8b8a)\u904e\u53bb\u66fe\u63a5\u53d7\u985e\u56fa\u9187\u8207\u5229\u5c3f\u5291\u5df2\u6709\u4e94\u5e74\u6642\u9593\uff0c\u4f46\u76ee\u524d\u70ba\u7de9\u89e3\u72c0\u6cc1\uff0c\u985e\u56fa\u9187\u4ecd\u7dad\u6301(Prednisolone 10mg QD)\uff0c\u8acb\u554f\u95dc\u65bc\u75c5\u4eba\u9aa8\u8cea\u758f\u9b06\u65b9\u9762\uff0c\u5e95\u4e0b\u8655\u7f6e\u90a3\u4e9b\u8996\u70ba\u6070\u7576\uff1f\r1. \u985e\u56fa\u9187\u5291\u91cf\u5f88\u4f4e\u4e0d\u6703\u6709\u5f71\u97ff\uff0c\u4e0d\u5fc5\u8003\u616e\u505c\u7528\u3002\r2. \u61c9\u8a72\u78ba\u5b9a\u6bcf\u5929\u6709\u53e3\u670d\u8db3\u91cf\u7684\u9223\u7247\u8207\u7dad\u4ed6\u547dD\u3002\r3. \u53ef\u8003\u616e\u7d66\u4e88Bisphosphonate\u4f86\u9810\u9632\u9aa8\u6298\u3002\r4. \u61c9\u8a72\u4e0d\u7528\u6bcf\u5e74\u5b89\u6392\u6aa2\u6e2c\u9aa8\u5bc6\u5ea6(DXA)\u4e4b\u6aa2\u67e5\r5. \u5982\u6709\u9aa8\u8cea\u758f\u9b06\uff0c\u53ef\u8003\u616e\u65bd\u6253\u5408\u6210\u7684\u526f\u7532\u72c0\u817a\u7d20\u3002\nA. 1+2\nB. 1+2+3\nC. 1+2+4\nD. 1+4+5\nE. 2+3+5\n": "(E)", "105-9.\n30\u6b72\u7537\u6027\u521d\u6b21\u53c3\u52a0\u99ac\u62c9\u677e\u8cfd\u8dd1\u5f8c\u4e0d\u652f\u5012\u5730\uff0c\u808c\u8089\u75e0\u75bc\u4e14\u5c3f\u6db2\u5448\u68d5\u7d05\u8272\uff0c\u9001\u81f3\u6025\u8a3a\u521d\u6b65\u6aa2\u67e5\u91cf\u5f97\u9ad4\u6eab\u70ba38.8\u5ea6(\u651d\u6c0f)\uff0c\u8840\u58d3\u6b63\u5e38\uff0c\u5c3f\u6db2\u8a66\u7d19\u6aa2\u67e5\u6709\u6f5b\u88402+\u4f46\u96e2\u5fc3\u6c89\u6e23\u7121\u7d05\u8840\u7403\uff0c\u808c\u9178\u91501.3mg/dL\uff0cCPK 13000u/L \u8acb\u554f\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\r1. \u50cf\u71b1\u4e2d\u6691\uff0c\u56e0\u6b64\u767c\u751f\u6025\u6027\u814e\u8870\u7aed\u6a5f\u7387\u5927\u3002\r2.\u5fc5\u9808\u4f9d\u9760\u8840\u6db2\u6216\u5c3f\u6db2myoglobin\u7684\u5b9a\u91cf\u6aa2\u67e5\u624d\u53ef\u78ba\u5b9a\u662f\u6a6b\u7d0b\u808c\u6eb6\u89e3\u75c7\u3002\r3.\u5176\u4e0a\u8ff0\u5c3f\u6db2\u8a66\u7d19\u6aa2\u67e5\u7d50\u679c\u4ee3\u8868\u53ef\u80fd\u6703\u767c\u751f\u6025\u6027\u814e\u8870\u7aed\u3002\r4.\u61c9\u8a72\u7a4d\u6975\u88dc\u5145\u5927\u91cf\u9ad4\u6db2\uff0c\u7dad\u6301\u5c3f\u6db23ml/kg/hr\uff0c\u76f4\u5230\u5c3f\u6db2\u8a66\u7d19\u6f5b\u8840\u53cd\u61c9\u5448\u9670\u6027\u3002\r5.\u5982\u679c\u5c3f\u6db2pH<6.5\uff0c\u4e00\u5b9a\u8981\u9ede\u6ef4\u52a0\u4e0aBicarbonate\u9e7c\u5316\u5c3f\u6db2\u3002\nA. 1+2+3\nB. 1+3+4\nC. 2+4+5\nD. 3+4+5\nE. 1+4+5\n": "(B)", "105-10.\nWhich patient may have the highest risk and progression of CKD ?\nA. CKD stage 1, with normal albuminuria\nB. CKD stage 3b, with normal albuminuria\nC. CKD stage 2, with severely increased albuminuria\nD. CKD stage 3a, with moderately increased albuminuria\nE. CKD stage 3, no matter the status of albuminuria, will have similar risk of CKD progression\n": "(D)", "105-11.\nSystemic diseases may induce thrombotic microangiopathy in the kidney, with the pathological picture of secondary focal segmental glomerulosclerosis.  Which does not belong to this category ?\nA. hemolytic-uremic syndrome (HUS)\nB. Hepatitis B virus infection\nC. Malignant hypertension\nD. Antiphospholipid syndrome\nE. Radiation nephropathy after bone marrow transplantation\n": "(B)", "105-12.\nA 38-year-old woman who had been diagnosed as membranous nephropathy with heavy proteinuria (4.5 g/day). One day she presented with flank pain, tenderness, hematuria, and rapid decline in renal function.  Which is the most likely diagnosis ?\nA. Renal stone with urinary tract infection\nB. Renal vein thrombosis\nC. Renal artery stenosis\nD. Malignant hypertension\nE. Thrombotic microangiopathy\n": "(B)", "105-13.\nSeveral nutrients have been implicated to increase risk for nephrolithiasis formation. Except ?\nA. Higher intake of animal protein\nB. Higher intake of potassium-rich or magnesium-rich food\nC. Higher sodium intake\nD. Vitamin C supplement is associated with an increased risk of calcium oxalate stone\nE. Higher consumption of sugar-sweetened carbonated beverage\n": "(B)", "105-14.\nA 48 y/o male was found to develop acute renal failure after 7 days of drug therapy. His clinical presentation were: fever, rash, peripheral eosinophilia, and oliguric renal failure, but without proteinuria. Which statement is correct?\r1.A possible etiology of acute interstitial nephritis (AIN)\r2.His manifestation is compatible with nonsteroidal anti-inflammatory drug (NSAID)-induced AIN\r3.Peripheral blood eosinophilia is common in most of AIN patients\r4.Urinary eosinophils are sensitive and specific for diagnosis of AIN, therefore, this testing is highly recommended\r5.Renal biopsy is generally not required for diagnosis of AIN\nA. 1+3+4+5\nB. 1+5\nC. 1+3+4\nD. 1+2\nE. 1+2+3+4+5\n": "(B)", "105-15.\nWhich statement regarding Lithium-associated nephropathy is not correct ?\nA. Most of the patients presented as oliguric acute renal failure\nB. Prolonged (>10-20 years) lithium use, or those experienced repeated episodes of toxic lithium levels, may develop chronic tubulointerstitial nephritis\nC. The most prudent approach is to monitor lithium levels frequently and adjust dosing to avoid toxic levels\nD. In patients with significant proteinuria, ACEI or ARB treatment should be helpful\nE. typical findings on renal biopsy are interstitial fibrosis and tubular atrophy\n": "(A)", "105-16.\nWhich statement regarding mineral metabolism in CKD is correct?\r1.increased production of parathyroid hormone\r2.reduced production of fibroblast growth factor-23 (FGF-23)\r3.increased renal excretion of phosphate\r4.reduced produce of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]\r5.reduction in serum calcium\nA. 1+3+4+5\nB. 1+2+4\nC. 1+2+3+4\nD. 1+2+4+5\nE. 1+4+5\n": "(E)", "105-17.\nPrimary glomerular diseases with reduced complement levels is:\nA. Cryoglobulinemia\nB. Minimal-change disease\nC. IgA nephropathy\nD. focal segmental glomerular sclerosis\nE. Wegener's granulomatosis\n": "(A)", "105-18.\nWhich test has the highest sensitivity of screening renovascular hypertension ?\nA. Duplex ultrasonography\nB. Computed tomography angiography\nC. Captopril renogram\nD. Magnetic resonance angiography (MRA)\nE. Captopril plus diuretics renogram\n": "(D)", "105-19.\nFor diagnosis of acute renal failure, which urinary indices indicating prerenal azotemia rather than acute tubular necrosis or obstruction ?\nA. Urine Na > 40 mEq/L\nB. Urine osmolarity < 400\nC. Urine/plasma creatinine ratio < 20\nD. Renal failure index < 1\nE. FENa > 2%\n": "(D)", "105-20.\nA 52-year-old man with a 20-year history of cigarette smoking is admitted to the hospital because of cough and weakness. On admission, his serum electrolyte levels are: serum [Na] 112 mEq/L; [K] 4.5 mEq/L; [Cl] 80 mEq/L; and HCO3-, 26 mEq/L. The BUN was 8 mg/dL , serum creatinine 0.8 mg/dL and serum uric acid 3.0 mg/dL. These data are most consistent with which of the following?\nA. SIADH (syndrome of inappropriate antidiuretic hormone secretion)\nB. Congestive heart failure\nC. Cirrhosis and ascites\nD. Severe salt and water depletion\nE. Adrenal insufficiency\n": "(A)", "105-21.\nA 28 y/o young male visited your outpatient clinic with an elevated blood pressure of 148/100 mmHg. He denies taking any medications, but has a family history of hypertension. His laboratory values were: [Na] 140 mEq/L, [K] 3.1 mEq/L, [Cl] 98 mEq/L, BUN 25 mg/dL, Creatinine 0.9 mg/dL, Glucose: 85 mg/dL. The arterial blood gas (ABG) test reveals: Arterial pH: 7.48, PCO2: 46 mm Hg, HCO3-: 34 mEq/L. What is the most appropriate characterization of his acid-base disorder?\nA. Metabolic alkalosis\nB. Metabolic alkalosis and respiratory acidosis\nC. Respiratory alkalosis and metabolic acidosis\nD. Metabolic alkalosis and respiratory alkalosis\nE. Respiratory alkalosis\n": "(A)", "105-22.\n\u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD, hemodialysis)\uff0c\u6709\u95dc\u8179\u819c\u900f\u6790(PD, peritoneal dialysis)\u7684\u6558\u8ff0\u8207\u9577\u671f\u5408\u4f75\u75c7\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. PD\u75c5\u4eba\u4f7f\u7528\u9ad8\u7cd6\u900f\u6790\u6db2\u662f\u70ba\u4e86\u8981\u9054\u5230\u900f\u6790\u6e05\u9664\u5c3f\u6bd2\u7d20(uremic toxin)\u7684\u6548\u679c\nB. PD\u75c5\u4eba\u5bb9\u6613\u51fa\u73fehypertriglyceridemia\uff0c\u662f\u56e0\u70ba\u4f7f\u7528\u9ad8\u7cd6\u900f\u6790\u6db2\nC. \u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD)\uff0c\u8179\u819c\u900f\u6790(PD)\u75c5\u4eba\u8f03\u5bb9\u6613\u767c\u751f\u8179\u819c\u708e(peritonitis)\nD. \u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD)\uff0c\u8179\u819c\u900f\u6790(PD)\u75c5\u4eba\u6bcf\u65e5\u86cb\u767d\u8cea\u6d41\u5931\u91cf\u8f03\u9ad8\nE. \u76f8\u8f03\u65bc\u8179\u819c\u900f\u6790(PD)\uff0c\u8840\u6db2\u900f\u6790(HD)\u75c5\u4eba\u8f03\u51fa\u73fe\u900f\u6790\u4e2d\u4f4e\u8840\u58d3\n": "(A)", "106-1.\n\u4e00\u4f4d48\u6b72\u5973\u6027\uff0c\u60a3\u6709bipolar affective disorder\uff0c\u9577\u671f\u670d\u7528\u92f0\u9e7d(Lithium)\u8fd1\u5341\u5e74\u3002\u6700\u8fd1\u51fa\u73fe:  polyuria \u548c polydipsia\u3002 \u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u75c5\u4eba\u53ef\u80fd\u662f Lithium intoxication\nB. \u75c7\u72c0\u53ef\u80fd\u662f central diabetes insipidus (DI)\nC. \u6162\u6027 Lithium nephropathy\u53ef\u4f34\u96a8\u6709\u86cb\u767d\u5c3f\nD. \u53ef\u4f34\u96a8\u51fa\u73fe hypernatremia\nE. Lithium \u82e5\u5f15\u8d77\u6162\u6027\u814e\u75c5\u8b8a\u6703\u6709 interstitial fibrosis \u548c tubular atrophy\n": "(B)", "106-2.\n\u4e00\u4f4d62\u6b72\u5973\u6027\uff0c\u56e0\u7d93\u5e38\u982d\u75db\u8207\u95dc\u7bc0\u75e0\u75db\uff0c\u81ea\u884c\u670d\u7528\u591a\u7a2e\u6b62\u75db\u85e5\uff0c\u6709aspirin, caffeine, acetaminophen\u53ca\u4e0d\u540c\u7a2e\u985e\u7684 NSAID (non-steroid anti-inflammatory drug)\u7b49\uff0c\u6df7\u5408\u8457\u4f7f\u7528\u3002\u6700\u8fd1\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u6709\u814e\u529f\u80fd\u4e0d\u5168\u8207\u86cb\u767d\u5c3f(2+)\u3002\u4ee5\u4e0b\u6558\u8ff0\u7684\u75c7\u72c0\u6216\u8a3a\u65b7\uff0c\u4f55\u8005\u6700\u6b63\u78ba?\nA. \u75c5\u4eba\u7684\u8a3a\u65b7\u7b26\u5408 renal infarction and cortical necrosis\nB. \u75c5\u4eba\u7684\u8a3a\u65b7\u6700\u53ef\u80fd\u662f glomerulosclerosis\nC. \u5176\u4ed6\u53ef\u80fd\u4f34\u96a8\u51fa\u73fe polyuria and metabolic alkalosis\u75c7\u72c0\nD. \u672c\u8a3a\u65b7\u53ef\u80fd\u4f34\u96a8\u51fa\u73fe papillary necrosis and papillary calcification\nE. \u4e0a\u8ff0\u85e5\u7269\u4e2d\uff0c\u6700\u53ef\u80fd\u5f15\u8d77\u6b64\u75c5\u75c7\u7684\u662facetaminophen\n": "(D)", "106-3.\n\u4e00\u4f4d42\u6b72\u7537\u6027\uff0c\u56e0\u767c\u73fe\u6700\u8fd1\u6578\u6b21\u91cf\u5230\u8840\u58d3\u5347\u9ad8(148/88 mmHg)\uff0c\u800c\u81ea\u884c\u5230\u91ab\u9662\u5c31\u8a3a\u3002\u91dd\u5c0d\u521d\u6b21\u5c31\u91ab\uff0c\u4e14\u591a\u6b21\u7d00\u9304\u8b49\u5be6\u78ba\u6709\u9ad8\u8840\u58d3\u7684\u75c5\u4eba\uff0c\u6703\u5b89\u6392\u512a\u5148\u505a\u4ee5\u4e0b\u8a55\u4f30(initial evaluation)\uff0c\u4ee5\u4e0b\u4f55\u8005\u6700\u4e0d\u5177\u512a\u5148\u6027?\nA. Urinalysis\nB. Serum BUN and creatinine\nC. Serum uric acid\nD. Fasting blood glucose, total cholesterol and LDL cholesterol\nE. Hematocrit\n": "(C)", "106-4.\n\u9577\u671f\u7cd6\u5c3f\u75c5\u6703\u5f15\u8d77\u591a\u7a2e\u814e\u81df\u75c5\u8b8a\uff0c\u5305\u62ec: \u86cb\u767d\u5c3f\u3001\u814e\u529f\u80fd\u4e0d\u5168\u3001\u611f\u67d3\u75c7\uff0c\u6216\u814e\u5c0f\u7ba1\u9178\u8840\u75c7(renal tubular acidosis, \u7c21\u7a31RTA)\u8207\u4ee3\u8b1d\u6027\u9178\u8840\u75c7\u3002\u6709\u95dc\u9019\u7a2eRTA\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\nA. \u6b64\u7a2eRTA\u7684\u7279\u9ede\u662f\u51fa\u73fehyperkalemia\nB. \u6700\u5e38\u5f15\u8d77\u7684\u662ftype II RTA\nC. \u6b64\u7a2eRTA\u5f15\u8d77\u7684\u9178\u8840\u75c7\uff0c\u901a\u5e38serum pH\u503c\u6703\u5f88\u4f4e\uff0c\u9700\u8981\u975c\u8108\u6ce8\u5c04\u88dc\u5145bicarbonate\nD. \u6b64\u7a2eRTA\u662f\u56e0\u70ba\u8840\u4e2daldosterone\u6fc3\u5ea6\u5f88\u9ad8\u6240\u5f15\u8d77\nE. \u4e3b\u8981\u75c5\u8b8a\u662f\u5728collecting tubule\uff0c\u7121\u6cd5\u6392\u51fa\u6c2b\u96e2\u5b50(hydrogen ion)\n": "(A)", "106-5.\n\u4e00\u4f4d62\u6b72\u5973\u6027\uff0c\u9577\u671f\u670d\u7528amitriptyline\u6cbb\u7642\u6182\u9b31\u75c7(depression)\uff0c\u6700\u8fd1\u56e0stroke\u4f4f\u9662\u3002\u75c5\u4eba\u7121\u541e\u56a5\u56f0\u96e3\uff0c\u98f2\u98df\u6b63\u5e38\uff0c\u4e5f\u6c92\u6709\u6c34\u816b\u3002\u4f4f\u9662\u4e00\u9031\u5f8c\u62bd\u8840\u6aa2\u67e5\u767c\u73feserum [Na] 126 mEq/L\uff0cosmolality 262 mOsm/kg\u3002urine [Na] 40 mEq/L\uff0curine osmolality 398 mOsm/kg\u3002\u75c5\u4ebahyponatremia\u7684\u539f\u56e0\uff0c\u6700\u53ef\u80fd\u662f?\nA. \u767c\u751fRenal sodium loss and dehydration\nB. \u767c\u751fExtra-renal loss of sodium, and fluid overload\nC. \u767c\u751f lung cancer\nD. \u767c\u751f SIADH (syndrome of inappropriate anti-diuretic hormone secretion)\nE. \u767c\u751f stroke-induced central diabetes insipidus (DI)\n": "(D)", "106-6.\n\u4e00\u4f4d22\u6b72\u5973\u6027\uff0c\u6709\u4e09\u5e74SLE (Systemic Lupus Erythematosus)\u75c5\u53f2\uff0c\u4f46\u6c92\u6709\u898f\u5247\u670d\u85e5\u3002\u6700\u8fd1\u4e00\u9031\u51fa\u73fe\u5598\u3001\u6c34\u816b\u3001\u5c3f\u91cf\u6e1b\u5c11\uff0c\u9ad4\u91cd\u589e\u52a0\u8fd17\u516c\u65a4\u3002\u4f4f\u9662\u8840\u58d3154/94 mmHg\uff0c\u62bd\u8840\u6aa2\u67e5: BUN 98 mg/dL\uff0ccreatinine 3.6 mg/dL, urine protein (4+)\u3002\u56e0\u70ba\u6025\u6027\u814e\u640d\u50b7(acute kidney injury, AKI)\uff0c\u5b89\u6392\u75c5\u4eba\u63a5\u53d7\u814e\u81df\u751f\u6aa2(renal biopsy)\uff0c\u4ee5\u4e0b\u75c5\u7406\u8b8a\u5316\uff0c\u4f55\u8005\u6700\u4e0d\u53ef\u80fd?\nA. Focal segmental glomerulosclerosis (FSGS)\nB. Diffuse proliferative nephritis with diffuse subendothelial deposit\nC. Membranous glomerulonephritis with subepithelial immune complex deposit\nD. Global endocapillary proliferation, crescent formation\nE. Glomerular necrotizing lesion, may present with vascular lesion\n": "(A)", "106-7.\n\u4e00\u4f4d48\u6b72\u7537\u6027\uff0c\u904e\u53bb\u6709C\u578b\u809d\u708e\uff0c\u5b9a\u671f\u5728\u9580\u8a3a\u8ffd\u8e64\u3002\u6700\u8fd1\u4e00\u500b\u6708\u4f86\uff0c\u51fa\u73fe\u86cb\u767d\u5c3f\uff0c\u811b\u524d\u8207\u8db3\u8e1d\u6c34\u816b\uff0c\u9ad4\u91cd\u7565\u589e\u52a0\u8fd13\u516c\u65a4\uff0c\u8840\u58d3150/92 mmHg\u3002\u62bd\u8840\u6aa2\u67e5: \u6709\u8840\u6e05\u88dc\u9ad4(complement, C3\u8207C4)\u504f\u4f4e\u60c5\u5f62\u3002\u56e0\u70ba\u4e0d\u660e\u539f\u56e0\u814e\u75c5\uff0c\u5b89\u6392\u75c5\u4eba\u63a5\u53d7\u814e\u81df\u751f\u6aa2(renal biopsy)\u3002\u4ee5\u4e0b\u75c5\u7406\u8b8a\u5316\uff0c\u4f55\u8005\u6700\u53ef\u80fd?\nA. Membranoproliferative glomerulonephritis (MPGN)\nB. Membranous nephropathy (MN)\nC. IgA nephropathy\nD. Focal segmental glomerulosclerosis (FSGS)\nE. Henoch-Schonlein purpura (HSP)\n": "(A)", "106-8.\n\u4e00\u4f4d46\u6b72\u7537\u6027\uff0c\u904e\u53bb\u7d93\u5e38\u6709\u9f3b\u7ac7\u708e\u75c7\u72c0\uff0c\u6700\u8fd1\u4e00\u500b\u6708\u4f86\uff0c\u51fa\u73fe\u80f8\u60b6\u3001\u6c23\u5598\u3001\u54b3\u55fd\u3001\u5580\u8840\u3002\u4f4f\u9662\u5f8c\u5c3f\u6db2\u6aa2\u67e5\u6709: hematuria, \u8207 RBC cast\u3002\u62bd\u8840\u6aa2\u67e5: antineutrophil cytoplasmic antibody (ANCA)\u967d\u6027\u53cd\u61c9\u3002\u75c5\u4eba\u5982\u679c\u63a5\u53d7\u814e\u81df\u751f\u6aa2(renal biopsy)\uff0c\u6700\u53ef\u80fd\u7684\u81e8\u5e8a\u8a3a\u65b7\u8207\u75c5\u7406\u8b8a\u5316\u662f:\nA. Goodpasture's syndrome\nB. Granulomatosis with polyangiitis (Wegener's granulomatosis)\nC. Polyarteritis nodosa (PNA)\nD. Microscopic polyangitis (MPA)\nE. Behcet's syndrome\n": "(B)", "106-9.\n\u5c3f\u6db2\u6c89\u6e23(cast, sediment)\u6aa2\u9a57\uff0c\u6709\u6642\u5019\u4e5f\u53ef\u4ee5\u63d0\u4f9b\u91cd\u8981\u7684\u8a0a\u606f\uff0c\u5e6b\u52a9\u81e8\u5e8a\u8a3a\u65b7\u3002\u4ee5\u4e0b\u6709\u95dc\u5404\u7a2e\u75be\u75c5\u8207urine cast\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. Dysmorphic RBC\u8207erythrocyte casts\u901a\u5e38\u8868\u793ahematuria\u4f86\u81ea\u65bcglomerulus\nB. \u5287\u70c8\u904b\u52d5\u53c8\u9ad4\u6db2\u4e0d\u8db3(dehydration)\u5f8c\u7684\u5c3f\u6db2\u7570\u5e38\uff0c\u53ef\u80fd\u6703\u51fa\u73fehyaline cast\nC. Granular cast\u901a\u5e38\u8868\u793a\u6709tubular injury \u6216 chronic kidney disease\nD. Allergic interstitial nephritis\u6703\u51fa\u73fe WBC cast \u6216 urine eosinophil, \u4f46\u5f88\u5c11\u51fa\u73fe RBC cast\nE. \u7cd6\u5c3f\u75c5(DM)\u75c5\u4eba\u82e5\u5408\u4f75\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a\uff0c\u7d93\u5e38\u6703\u4f34\u96a8\u51fa\u73feRBC cast\n": "(E)", "106-10.\n\u4e00\u4f4d64\u6b72\u7537\u6027\uff0c\u63a5\u53d7\u51a0\u72c0\u52d5\u8108\u7e5e\u9053\u624b\u8853\u5f8c\u7b2c\u4e8c\u5929\uff0c\u51fa\u73fe\u5be1\u5c3f(oliguria)\uff0c\u814e\u529f\u80fd\u7570\u5e38\u3002\u75c5\u4eba\u7684\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u81e8\u5e8a\u6558\u8ff0\uff0c\u6700\u7b26\u5408\u624b\u8853\u5f8c\u767c\u751fpre-renal azotemia (AKI)\u7684\u81e8\u5e8a\u8a3a\u65b7?\nA. Hypotension or cardiogenic shock\nB. Functional excretion of sodium is 3.5%\nC. Urine sodium is 40 mEq/L\nD. BUN/creatinine ratio is 10\nE. Low urine specific gravity (< 1.015), and active urinary sediment (+)\n": "(A)", "106-11.\n\u4e00\u4f4d44\u6b72\u7537\u6027\uff0c\u6709\u80ba\u7d50\u6838(pulmonary tuberculosis)\u63a5\u53d7rifampin\u8207isoniazid\u6cbb\u7642\u3002\u67d0\u65e5\u56e0\u610f\u8b58\u6a21\u7cca\uff0c\u547c\u5438\u6025\u4fc3\uff0c\u56db\u80a2\u6709\u8f15\u5fae\u986b\u6296\u62bd\u6410\u60c5\u5f62\uff0c\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u62bd\u8840\u6aa2\u67e5:\u52d5\u8108\u6c23\u9ad4\u5206\u6790\u3001\u8840\u6e05\u96fb\u89e3\u8cea\u5982\u4e0b: ABG: pH 7.26\uff0cHCO3- 11 mEg/L\uff0cPCO2 21 mmHg ; glucose 160 mg/dL, BUN 34 mg/dL, Cr 1.8 mg/dL ; Na 133 mEq/L , K 6.1 mEq/L, Cl 94mEq/L\u3002\u7531\u4ee5\u4e0a\u6578\u64da\u5206\u6790\uff0c\u6700\u7b26\u5408\u4ee5\u4e0b\u4f55\u7a2e\u8a3a\u65b7? (1)Metabolic acidosis\uff1b(2)Respiratory acidosis\uff1b(3)adequate secondary (respiratory or renal) compensation\uff1b(4)inadequate secondary (respiratory or renal)\rcompensation\uff1b(5)normal anion gap\uff1b(6)increased or high anion gap\nA. (1)+(3)+(5)\nB. (1)+(3)+(6)\nC. (1)+(4)+(5)\nD. (1)+(4)+(6)\nE. (2)+(4)+(6)\n": "(B)", "106-12.\n\u67d045\u6b72\u7537\u6027\u5df2\u6709\u9ad8\u8840\u58d35\u5e74\uff0c\u6700\u8fd1\u6aa2\u67e5\u6709\u8840\u5c3fRBC 10-20/HPF\u3001Cre 1.2 mg/dL\u3001\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u5169\u5074\u814e\u81df\u9577\u5f91\u8d85\u904e15\u516c\u5206(\u5982\u5716)\u53ca\u5404\u6709\u56ca\u816b\u6578\u76ee\u8d85\u904e\u5341\u500b\uff1b\u5bb6\u65cf\u53f2\u70ba\u7236\u89aa\u81ea60\u6b72\u958b\u59cb\u8840\u6db2\u900f\u6790\uff0c\u4e0d\u66fe\u9871\u5167\u51fa\u8840\uff0c\u7236\u89aa\u7684\u814e\u81df\u8d85\u97f3\u6ce2\u4ea6\u6709\u96f7\u540c\u7684\u767c\u73fe\u3002\r\u8acb\u554f\u95dc\u65bc\u5176\u814e\u81df\u75be\u75c5\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba\uff1f(1)\u6bcf\u5e74\u5b9a\u671f\u8ffd\u8e64\u814e\u529f\u80fd\uff0c\u5373\u70ba\u9810\u4f30\u65e5\u5f8c\u662f\u5426\u9700\u8981\u900f\u6790\u6cbb\u7642\u4e4b\u6700\u654f\u611f\u65b9\u6cd5\uff1b(2)\u82e5\u5176\u592a\u592a\u61f7\u5b55\u53ef\u505a\u7522\u524d\u7be9\u6aa2\uff0c\u5176\u5b50\u5973\u907a\u50b3\u6b64\u814e\u81df\u75be\u75c5\u7684\u6a5f\u6703\u70ba50%\uff1b(3) \u4ee5\u5f71\u50cf\u5b78\u6aa2\u67e5\u4f30\u7b97\u5176\u814e\u81df\u9ad4\u7a4d\uff0c\u82e5\u8d85\u904e600\u7acb\u65b9\u516c\u5206\uff0c\u5176\u814e\u529f\u80fd\u6975\u53ef\u80fd\u6301\u7e8c\u9010\u5e74\u60e1\u5316\uff1b(4) \u96d6\u7121\u75c7\u72c0\uff0c\u61c9\u6bcf\u5e74\u5b89\u6392\u8166\u90e8\u8840\u7ba1Magnetic resonance angiography\u7684\u6aa2\u67e5\uff1b(5)\u5b9c\u5efa\u8b70\u505c\u6b62\u670d\u7528\u542b\u5973\u6027\u8377\u723e\u8499\u4e4b\u907f\u5b55\u85e5\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (2)+(4)\nD. (4)+(5)\nE. (2)+(3)+(5)\n": "(E)", "106-13.\n\u67d050\u6b72\u53f0\u96fb\u54e1\u5de5\u65bc\u98b1\u98a8\u5f8c\u66fe\u81f3\u6c34\u707d\u5730\u5340\u8655\u7406\u5012\u584c\u96fb\u7dda\u687f\uff0c\u7d0410\u5929\u5f8c\u51fa\u73fe\u9ad8\u71d2\u3001\u982d\u75db\u3001\u808c\u8089\u75e0\u75db\u3001\u54b3\u55fd\u5e36\u8840\u3001\u547c\u5438\u6025\u4fc3\uff0c\u4f4f\u9662\u6aa2\u67e5\u5f8c\u767c\u73fe\uff1a\u7d50\u819c\u4e0b\u51fa\u8840(\u5982\u5716\u4e00)\u3001\u9ec3\u75b8\u3001\u814e\u529f\u80fd\u5931\u5e38\u3001\u4f4e\u8840\u9240\u7b49\u3002\u80f8\u90e8X\u5149(\u5982\u5716\u4e8c)\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u6b63\u78ba\uff1f(1)\u6b64\u75c5\u70ba\u4ee5\u52d5\u7269\u70ba\u5bbf\u4e3b\u4e4b\u5bc4\u751f\u87f2\u6240\u5f15\u8d77\uff1b(2)\u5fc5\u9808\u7b49\u5f85\u75c5\u539f\u9ad4\u4e4b\u8840\u6db2\u57f9\u990a\u7d50\u679c\u70ba\u967d\u59d3\uff0c\u65b9\u80fd\u78ba\u5b9a\u8a3a\u65b7\u8207\u958b\u59cb\u6cbb\u7642\uff1b(3)\u767c\u75c5\u5341\u5929\u5f8c\u9ad4\u5167\u5df2\u7522\u751f\u6297\u9ad4\uff0c\u4f46\u5c3f\u6db2\u4e2d\u4ecd\u53ef\u80fd\u6709\u75c5\u539f\u9ad4\u4e4b\u5b58\u5728\uff1b(4)\u6b64\u75c5\u5373Weil's disease\uff0c\u6709\u9ad8\u6b7b\u4ea1\u7387\u4e4b\u5371\u96aa\uff1b(5)\u6b64\u75c5\u9760\u81e8\u5e8a\u8a3a\u65b7\uff0c\u9808\u7acb\u5373\u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u3002\nA. (2)+(3)+(4)\nB. (1)+(2)+(4)\nC. (1)+(3)+(4)\nD. (3)+(4)+(5)\nE. (1)+(4)+(5)\n": "(D)", "106-14.\n\u67d070\u6b72\u75c5\u4eba\u5df2\u7d93\u6b63\u5728\u670d\u7528\u5229\u5c3f\u5291\u53caValsartan\uff0c\u8acb\u554f\u4e0b\u5217NSAIDs\u4e2d\u54ea\u4e00\u500b\u6700\u4e0d\u6703\u5f71\u97ff\u9019\u5169\u7a2e\u964d\u58d3\u85e5\u4e4b\u6548\u679c\uff1f\nA. Acetaminophen\nB. Etoricoxib\nC. Diclofenac\nD. Celecoxib\nE. Nimesulide\n": "(A)", "106-15.\n\u67d040\u6b72\u7537\u6027\u7121\u7cd6\u5c3f\u75c5\u6216\u9ad8\u8840\u58d3\u75c5\u53f2\u3001\u904e\u53bb\u5e38\u6709\u9593\u6b47\u6027\u80a2\u9ad4\u75bc\u75db\u3001\u76ae\u819a\u75c5\u8b8a(\u5982\u5716)\u3001\u4e0d\u6613\u6d41\u6c57\u3001\u5c3f\u86cb\u767d(++)\u3001\u814e\u529f\u80fd\u5931\u5e38(Cre 3.0 mg/dL)\uff0c\u5176\u5bb6\u65cf\u53f2\u70ba\u5169\u4f4d\u5144\u9577\u5144\u5206\u5225\u6b7b\u65bc\u5fc3\u81df\u8870\u7aed\u53ca\u8166\u8840\u7ba1\u610f\u5916\u53ca\u8840\u6db2\u900f\u6790\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f(1) \u61c9\u70baGaucher disease\uff1b(2)\u5b9c\u5b89\u6392\u773c\u79d1\u3001\u5fc3\u81df\u65b9\u9762\u6aa2\u67e5\uff1b(3)\u5176\u59ca\u59b9\u61c9\u8a72\u90fd\u4e0d\u6703\u6709\u75c7\u72c0\uff1b(4)\u5c3f\u6db2\u6aa2\u67e5\u53ef\u51fa\u73fe \"Maltese crosses\"\u7684\u6c89\u6fb1\u7269\uff1b(5) \u814e\u81df\u75c5\u7406\u591a\u70bafocal segmental glomerulosclerosis(FSGS)\u3002\nA. (1)+(3)\nB. (2)+(3)\nC. (3)+(5)\nD. (1)+(3)+(5)\nE. (2)+(4)+(5)\n": "(E)", "106-16.\n\u7167\u9867\u6162\u6027\u814e\u81df\u75c5\u7684\u75c5\u4eba\uff0c(1)\u65bc\u4f55\u6642\u671f \u61c9\u8f49\u4ecb\u7d66\u814e\u81df\u5c08\u79d1\u91ab\u5e2b\uff0c(2)\u65bc\u4f55\u671f\u61c9\u8ddf\u75c5\u4eba\u4ecb\u7d39\u814e\u81df\u66ff\u4ee3\u6cbb\u7642 (\u8840\u6db2\u900f\u6790\u3001\u8179\u819c\u900f\u6790\u3001\u814e\u81df\u79fb\u690d)\uff1f\rI-\u7b2c\u4e00\u671f\uff1bII:\u7b2c\u4e8c\u671f\uff1bIII\uff1a\u7b2c\u4e09\u671f\uff1bIV\uff1a\u7b2c\u56db\u671f\uff1a Va : \u7b2c\u4e94\u671f\u900f\u6790\u524d\nA. (1)I\uff1b (2) III\nB. (1) I\uff1b (2) Va\nC. (1)III\uff1b(2) IV\nD. (1)IV\uff1b(2) Va\nE. (1)Va\uff1b(2)Va\n": "(C)", "106-17.\n\u95dc\u65bc\u6162\u6027\u814e\u81df\u75c5\u4e4b\u86cb\u767d\u98f2\u98df\u9650\u5236 \uff0c\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u4e0d\u6b63\u78ba\uff1f\nA. \u7576\u51fa\u73fe\u5c3f\u6bd2\u75c7\u72c0\u6642\uff0c\u86cb\u767d\u98f2\u98df\u9650\u5236\u6700\u4f4e\u70ba\u86cb\u767d\u8cea\u6bcf\u59290.6\u516c\u514b/\u516c\u65a4(\u7406\u60f3\u9ad4\u91cd)\u53ca\u71b1\u91cf\u6bcf\u592930 kcal/\u516c\u65a4(\u7406\u60f3\u9ad4\u91cd)\u3002\nB. \u4f4e\u86cb\u767d\u98f2\u98df\u9650\u5236\u672c\u8eab\u78ba\u5be6\u53ef\u4ee5\u6e1b\u7de9\u814e\u529f\u80fd\u60e1\u5316\uff0c\u56e0\u5176\u53ef\u6e1b\u4f4e\u5c3f\u6bd2\u75c7\u72c0\u8207\u5ef6\u7de9\u958b\u59cb\u900f\u6790\u6cbb\u7642\u4e4b\u6642\u9593\u3002\nC. \u4f4e\u86cb\u767d\u98f2\u98df\u53ef\u7531\u6e2c\u91cf\u9ad4\u91cd\u8b8a\u5316\u3001\u8840\u6e05\u767d\u86cb\u767d\u300124\u5c0f\u6642urea nitrogen\u6392\u6cc4\u91cf\u7b49\u4f86\u5224\u65b7\u4f4e\u86cb\u767d\u98f2\u98df\u9650\u5236\u662f\u5426\u9069\u5ea6\u3002\nD. \u9ad8\u86cb\u767d\u98f2\u98df\u5e38\u4e5f\u6703\u589e\u52a0\u78f7\u8207\u9209\u4e4b\u651d\u53d6\uff0c\u800c\u62b5\u92b7angiotensin-converting enzyme inhibitor (ACEi)\u8207angiotensin-receptor blocker (ARB)\u4e4b\u814e\u81df\u4fdd\u8b77\u4f5c\u7528\u3002\nE. \u4f4e\u86cb\u767d\u98f2\u98df\u63a7\u5236\u9700\u88dc\u5145\u6c34\u6eb6\u6027\u7dad\u751f\u7d20\u3002\n": "(B)", "106-18.\n\u95dc\u65bc\u8840\u58d3\u4e4b\u6e2c\u91cf\uff1a \u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u61c9\u9f13\u52f5\u5c45\u5bb6\u8840\u58d3\u76e3\u6e2c(Home blood pressure monitoring)\uff0c\u6bcf\u5929\u6e2c\u91cf\u8207\u7d00\u9304\u4e8c\u81f3\u4e09\u56de\u3002\nB. \u9ad8\u8840\u58d3\u6cbb\u7642\u7684\u76ee\u6a19\uff1a\u4e00\u822c\u75c5\u60a3\u70ba\u5c45\u5bb6\u8840\u58d3\u5e73\u5747\u8981\u4f4e\u65bc135/85 mmHg\uff1b\u6162\u6027\u814e\u81df\u75c5\u5247\u4f4e\u65bc130/80 mmHg\u3002\nC. \u6d3b\u52d5\u5f0f\u8840\u58d3\u76e3\u6e2c(Ambulatory blood pressure monitoring)\u7684\u6b63\u5e38\u503c\uff1a\u767d\u5929\u5e73\u5747\u4f4e\u65bc135/85 mmHg:\uff1b\u591c\u9593\u5e73\u5747\u4f4e\u65bc130/80 mmHg\u3002\nD. \u8207\u8a3a\u9593\u8840\u58d3\u6e2c\u91cf\u76f8\u8f03\uff0c\u6d3b\u52d5\u5f0f\u8840\u58d3\u6e2c\u91cf\u66f4\u80fd\u9810\u6e2c\u5fc3\u808c\u6897\u585e\u6216\u4e2d\u98a8\u3002\nE. \u5c31\u6d3b\u52d5\u5f0f\u8840\u58d3\u76e3\u6e2c\u800c\u8a00\uff0c\u82e5\u8207\u767d\u5929\u7684\u8840\u58d3\u76f8\u6bd4\u8f03\uff0c\u591c\u9593\u9ad8\u8840\u58d3\u6703\u589e\u52a0\u5fc3\u8840\u7ba1\u7684\u8ca0\u64d4\uff0c\u70ba\u5fc3\u8840\u7ba1\u75be\u75c5\u9810\u5f8c\u4e4b\u5f37\u70c8\u56e0\u5b50\u3002\n": "(C)", "106-19.\n\u95dc\u65bc\u9aa8\u9ad3\u79fb\u690d\u814e\u75c5\u8b8a(Bone marrow transplant nephropathy)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\nA. \u5e38\u5728\u79fb\u690d\u5f8c\u767e\u65e5\u5167\u767c\u751f\nB. \u8207Cyclosporine\u6709\u95dc\nC. \u8207Sirolimus\u6709\u95dc\nD. \u8207Radiation\u6709\u95dc\nE. \u9808\u7a4d\u6975\u505a\u8840\u6f3f\u7f6e\u63db\u6cbb\u7642\u3002\n": "(D)", "106-20.\n\u4e0b\u5217\u54ea\u4e00\u500b\u514d\u75ab\u6291\u5236\u85e5\u7269\uff0c\u53ef\u80fd\u5f15\u8d77\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u3001\u53ca\u814e\u81df\u75c5(Thrombotic microangiopathy) \u4e09\u7a2e\u75be\u75c5\uff1f\nA. Prednisolone\nB. Cyclosporine\nC. Tacrolimus\nD. Sirolimus\nE. Mycophenolate mofetil\n": "(C)", "106-21.\n\u67d050\u6b72\u7537\u6027\u6709\u9152\u7cbe\u6210\u766e\u75c5\u53f2\uff0c\u88ab\u767c\u73fe\u8eba\u5728\u65c5\u9928\u623f\u9593\u5730\u677f\u4e0a\u800c\u88ab\u9001\u81f3\u6025\u8a3a\u8655\u3002\u8840\u58d3120/66 mmHg\uff0c\u5fc3\u8df3\u6bcf\u5206\u9418100\u4e0b\uff0c\u547c\u5438\u6bcf\u5206\u941830\u4e0b\u3002\u62bd\u8840\u6aa2\u67e5\uff1aSerum Na 140 mEq/L\uff0cK 5.8 mEq/L\uff0cCl 103 mEq/L\uff0cBUN 25 mg/dL\uff0cCre 1.4 mg/dL\uff0cAC glucose 150 mg/L\uff0c pH 7.16\uff0c PaCO2 23 mmHg, HCO3- 8 mEq/L\uff0cSerum osmolarity 332 mOsm/L\uff0c\u8840\u4e2d\u9152\u7cbe\u6fc3\u5ea6\u70ba\u9670\u6027\u3002\u8acb\u554f\u80fd\u70ba\u5e95\u4e0b\u4f55\u8005\uff1f\nA. Diabetic ketoacidosis\nB. Starvation ketoacidosis\nC. Alcohol ketoacidosis\nD. Methanol intoxication\nE. Salicylates\n": "(D)", "106-22.\n\u95dc\u65bc\u6025\u6027\u814e\u81df\u50b7\u5bb3(Acute kidney injury; AKI) \u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e\uff1f\nA. \u7d55\u5927\u591a\u6578\u6025\u6027\u814e\u81df\u50b7\u5bb3\u5728\u91ab\u9662\u5167\u767c\u751f\uff0c\u5c24\u5176\u5728\u52a0\u8b77\u75c5\u623f\u3002\nB. \u6025\u6027\u814e\u81df\u50b7\u5bb3\u4e2d\u5927\u591a\u6578\u70baPrerenal AKI\u3002\nC. NSAIDs\u3001ACEi\u3001ARB\u7b49\u5bb9\u6613\u5f15\u8d77Prerenal AKI\u3002\nD. \u793e\u5340\u578b\u6025\u6027\u814e\u81df\u5bb3\u5927\u90e8\u5206\u70baPrerenal AKI\u3002\nE. \u4f4e\u8840\u6e05\u767d\u86cb\u767d\u5bb9\u6613\u597d\u767cPrerenal AKI\u3002\n": "(E)", "107-1.\n\u91dd\u5c0d\u65b0\u8a3a\u65b7\u7684\u78ba\u8a3a\u9ad8\u8840\u58d3\u7684\u75c5\u4eba\uff0c\u5efa\u8b70\u512a\u5148\u505a\u521d\u671f\u8a55\u4f30(initial evaluation)\uff0c\u5305\u62ec: BUN, creatinine, urinalysis\uff0c\u53ca\u4ee5\u4e0b\u9805\u76ee\uff0c\u4f55\u8005\u9664\u5916?\nA. Serum lipid panel\nB. Electrocardiogram (ECG)\nC. Fasting plasma glucose\nD. Serum potassium, calcium\nE. Serum uric acid level\n": "(E)", "107-2.\n\u4e00\u4f4d55\u6b72\u5973\u6027\uff0c\u4e3b\u8a34\u9577\u671f\u6709\u95dc\u7bc0\u75bc\u75db\u3001\u4e7e\u773c\u75c7\u3001\u53ca\u4f7f\u7528NSAID\u7684\u7fd2\u6163\u3002\u67d0\u65e5\u56e0\u75b2\u52de\u7121\u529b\u81f3\u6025\u8a3a\u5c31\u8a3a\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe: serum creatinine 1.0 mg/dL, Na 139 mEq/L, K 3.3 mEq/L, Cl 115 mEq/L, ABG: pH 7.26, HCO3- 14 mEq/L. \u5c3f\u6db2\u6aa2\u67e5: pH 7.0, glucose (-), protein (-), \u5c3f\u6db2\u96fb\u89e3\u8cea: Na 35 mEq/L, K 40.0 mEq/L, Cl 18 mEq/L  \u75c5\u4eba\u7684\u9178\u8840\u75c7(acidosis)\uff0c\u6700\u7b26\u5408\u4ee5\u4e0b\u54ea\u4e00\u500b\u8a3a\u65b7?\nA. Chronic diarrhea\nB. Type 1 RTA (renal tubular acidosis)\nC. Type 2 RTA (renal tubular acidosis)\nD. Type 4 RTA (renal tubular acidosis)\nE. Diabetic keto-acidosis\n": "(B)", "107-3.\n\u67d0\u4f4dCKD stage 5\u7684\u75c5\u4eba\uff0c[Ca] 8.7 mg/dL, [P] 6.8 mg/dL\u3002 \u4e0b\u5217\u6709\u95dc\u814e\u6027\u9aa8\u75c5\u8b8a\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. Hyperphosphatemia stimulates increasing plasma level of PTH (parathyroid hormone)\nB. Low serum [Ca] level, and reduced FGF-23 (fibroblast growth factor 23)production contribute to renal bone disease\nC. Nephron loss reduces synthesis of 1,25-Vitamin D3\nD. Low level of 1,25-Vitamin D3 results in lower intestine resorption of Ca\nE. Phosphate retention contributes to hypo[Ca]\n": "(B)", "107-4.\n\u4e00\u4f4d70\u6b72\u5973\u6027\uff0c\u904e\u53bb\u6c92\u6709CAD\u6216DM\u75c5\u53f2\uff0c\u4e5f\u6c92\u6709\u898f\u5247\u5c31\u91ab\u3002\u6700\u8fd1\u56e0\u70ba\u5026\u6020\u3001\u80c3\u53e3\u4e0d\u4f73\u4f86\u8a3a\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u767c\u73fe: serum creatinine 6.2 mg/dL, eGFR 14 mL/min\uff0cHb 11.4 g/dL, serum ferritin 500 ng/mL\u3002\u4e0b\u5217\u8655\u7f6e\uff0c\u4f55\u8005\u6700\u9069\u5b9c?\nA. \u7d66\u4e88ESA (erythropoiesis stimulating agent)\uff0c\u5c07Hb \u63d0\u5347\u81f3\u76ee\u6a19\u503c13-14 g/dL\nB. Check serum level of erythropoietin\nC. Give intravenous iron for anemia\nD. Give oral iron dose for correcting anemia\nE. Measure blood level of transferrin saturation\n": "(E)", "107-5.\n\u4e00\u4f4d48\u6b72\u5973\u6027\uff0c\u8a3a\u65b7\u6709high grade lymphoma\uff0c\u9810\u5b9a\u63a5\u53d7cytotoxic chemotherapy\u3002\u75c5\u4eba\u76ee\u524d\u7684serum creatinine level\u662f2.1 mg/d\u3002\u70ba\u4e86\u9810\u9632\u767c\u751ftumor lysis syndrome\u53ca\u814e\u81df\u60e1\u5316\uff0c\u4e0b\u5217\u8655\u7f6e\uff0c\u4f55\u8005\u6700\u9069\u5b9c?\nA. Give allopurinol or febuxostat, if not contraindicated, for preventing hyperuricemia\nB. Give acetylcysteine for preventing acute kidney injury\nC. Give large amount of 5% glucose water solution for volume expansion\nD. Give 1,25-activated Vitamin D3 for preventing hyperphosphatemia\nE. Arrange dialysis immediately after chemotherapy for preventing occurrence of chronic interstitial nephritis\n": "(A)", "107-6.\n\u4e0b\u5217\u8655\u7f6e\u6709\u52a9\u65bc\u6e1b\u7de9\u591a\u56ca\u814e(adult polycystic kidney)\u75c5\u4eba\u7684\u814e\u529f\u80fd\u60e1\u5316\uff0c\u4f55\u8005\u9664\u5916?\nA. \u4f7f\u7528ACEI \u6216 ARB\uff0c\u63a7\u5236\u8840\u58d3\u5728130-140/80-90 mmHg\u4e4b\u4e0b\nB. \u4f7f\u7528vasopressin antagonist (tolvaptan), \u6216\u5efa\u8b70\u9069\u7576\u589e\u52a0\u6bcf\u65e5\u98f2\u6c34\u91cf (> 3 L/day)\nC. \u5982\u679c\u6709cyst infection, \u4f7f\u7528lipid-soluble antibiotics, \u5982: quinolones, \u56e0\u70bacyst penetration \u4f73\uff0c\u6548\u679c\u8f03\u597d\nD. \u9650\u5236\u4f4e\u9e7d(low salt, < 5 g/day)\u98f2\u98df\nE. \u4f7f\u7528\u4f4e\u86cb\u767d\u98f2\u98df (low protein diet, < 0.6 g/kg/day)\n": "(E)", "107-7.\n\u4e00\u4f4d72\u6b72\u7537\u6027\uff0c\u56e0\u70ba\u9ad8\u8840\u58d3\uff0c\u86cb\u767d\u5c3f\uff0c\u4e0b\u80a2\u8f15\u5ea6\u6c34\u816b\uff0c\u4f86\u9580\u8a3a\u5c31\u8a3a\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5:  serum creatinine1.8 mg/dL, \u6709proteinuria (2+), hematuria (-), \u9032\u4e00\u6b65\u505aurine protein electrophoresis\u6709monoclonal band (+)\uff0cC3\u8207C4 \u7686\u6b63\u5e38\u3002\u4f4f\u9662\u505a\u814e\u81df\u751f\u6aa2(renal biopsy)\u767c\u73fe\u6709\u7269\u8cea\u6c89\u6fb1\u5728glomerulus\uff0ctubule\u90e8\u5206\u6b63\u5e38\u3002\u4ee5\u7279\u6b8a\u67d3\u8272\uff0c\u5448\u73feCongo red (-) \u3002\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba:\nA. Amyloidosis\nB. Light-chain deposit disease\nC. Myeloma cast nephropathy\nD. Fibrillary glomerulonephritis\nE. Type II cryoglobulinemia\n": "(B)", "107-8.\n\u9577\u671f\u8840\u6db2\u900f\u6790(hemodialysis)\u7684\u75c5\u4eba\uff0c\u70ba\u505a\u597d\u9632\u8b77\uff0c\u9810\u9632\u611f\u67d3\uff0c\u9664\u4e86\u6aa2\u6e2cHIV \uff0cviral hepatitis (B and C) profile\u4e4b\u5916\uff0c\u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba? (1). \u5c0d\u65bc HBV (-)\u7684\u75c5\u4eba\uff0c\u5efa\u8b70\u65bd\u6253 HBV vaccine (2).\u5efa\u8b70\u6bcf\u4e94\u5e74\u5167\uff0c\u61c9\u65bd\u6253 23\u50f9/13\u50f9 pneumococcal vaccine (3). \u5efa\u8b70\u6bcf\u5e74\u6d41\u611f\u5b63\u7bc0\uff0c\u61c9\u65bd\u6253  inactivated influenza vaccine (4). \u5efa\u8b70\u65bd\u6253 Herpes Zoster vaccine\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(3)\nC. (1)+(2)\nD. (1)+(3)\nE. (2)+(3)+(4)\n": "(B)", "107-9.\n56\u6b72\u7537\u6027\uff0c\u7121\u7cd6\u5c3f\u75c5\uff0c\u6709\u8f15\u5ea6\u9ad8\u8840\u58d3\uff0cBMI 26Kg/\u33a1\uff0cserum creatinine 3.2 mg/dL\uff0ceGFR 18 mL/min\uff0c\u5c0d\u65bcCKD\u5c1a\u672a\u900f\u6790\u7684\u75c5\u4eba\uff0c\u86cb\u767d\u8cea\u651d\u53d6\u91cf\uff0c\u4ee5\u4e0b\u5efa\u8b70\uff0c\u4f55\u8005\u6700\u5408\u9069?\nA. 1.4-1.5 g/kg/day\nB. 1.2-1.4 g/kg/day\nC. 1.0-1.2 g/kg/day\nD. 0.6-0.8 g/kg/day\nE. < 0.4-0.6 g/kg/day\n": "(D)", "107-10.\n\u6162\u6027\u814e\u81df (CKD) \u60a3\u8005\u61c9\u907f\u514d\u6216\u5c0f\u5fc3\u4f7f\u7528OTC (over-the-counter)\u85e5\u7269,\u4f46\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u4e0b\u53ef\u4ee5\u4f7f\u7528?\nA. NSAID as analgesics\nB. Aspirin for CV protection\nC. Ephedrine for weight reduction\nD. MgO for constipation\nE. Aluminum hydroxide long-term use as antacid\n": "(B)", "107-11.\n\u4e00\u4f4d39\u6b72\u5973\u6027\uff0c\u672c\u8eab\u7121DM\uff0c\u9019\u6b21\u662f\u7b2c\u4e00\u6b21\u61f7\u5b55\u3002\u5728\u61f7\u5b55\u7b2c26\u9031\u6642\u51fa\u73fe\u9ad8\u8840\u58d3(150/96 mmHg)\uff0c\u6709\u96d9\u4e0b\u80a2\u8db3\u8e1d\u9644\u8fd1\u6c34\u816b\u3002\u5c3f\u6db2\u8a66\u7d19(dipstick)\u6aa2\u67e5\u6709\u86cb\u767d\u5c3f (2+)\uff0c\u56e0\u6b64\u88ab\u8f49\u4ecb\u4f86\u5167\u79d1\u9580\u8a3a\u3002\u6b32\u5b89\u6392\u9451\u5225\u8a3a\u65b7\uff0c\u4e0b\u5217\u9078\u9805\uff0c\u4f55\u8005\u6700\u9069\u5b9c? (1). Liver function test (AST, ALT) (2). Check platelet count (3). Check anti-phospholipid antibody titer (4).Arrange CT/MRI for central vein thrombosis (5). Give ACEI/ARB for hypertension control and for renal protection\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)\nC. (1)+(4)+(5)\nD. (1)+(3)+(5)\nE. (3)+(4)\n": "(B)", "107-12.\n\u4e00\u4f4d48\u6b72\u88ab\u65b0\u8a3a\u65b7\u6709\u9ad8\u8840\u58d3\u7684\u7537\u6027\uff0c\u672c\u8eab\u7121DM\u3002\u670d\u7528\u91ab\u5e2b\u7d66\u4e88\u7684ACEI\u964d\u8840\u58d3\u85e5\u7269\uff0c\u5169\u500b\u6708\u5f8c\u8fd4\u8a3a\uff0c\u767c\u73feserum creatinine\u5f9e 1.4 mg/dL\u4e0a\u5347\u81f32.6 mg/dL\u3002\u91cd\u65b0\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u8179\u90e8\u5728\u809a\u81cd\u53f3\u5074\u90e8\u4f4d\u6709\u56c9\u97f3(bruit)\u3002\u6b32\u5b89\u6392\u9451\u5225\u8a3a\u65b7\uff0c\u4e0b\u5217\u9078\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba? (1). \u5982\u679c\u6aa2\u67e5\u75c5\u4eba\u7684renin, aldosterone level\uff0c\u9810\u671frenin\u61c9\u8a72\u504f\u4f4e\uff0c\u800caldosterone\u6703\u5f88\u9ad8 (2). \u53ef\u5b89\u6392duplex Doppler \u6216CT/MRI\u6aa2\u67e5renal artery (3). \u61c9\u8a72\u63a5\u8457\u5b89\u6392\u505a\u5c0e\u7ba1\u6aa2\u67e5renal vein sampling (4). \u5982\u679c\u6aa2\u67e5\u8840\u6e05[K]\uff0c\u7d93\u5e38\u6703\u4f34\u96a8\u6709\u9ad8\u8840\u9240(hyperkalemia) (5).\r\u5982\u679c\u6aa2\u67e5\u5c3f\u6db2catecholamines\uff0c\u6703\u767c\u73fe\u5c3f\u6db2catecholamines\u5347\u9ad8\nA. (1)+(2)\nB. (1)+(3)+(4)\nC. (3)+(4)+(5)\nD. (2)\nE. (1)+(2)+(5)\n": "(D)", "107-13.\n\u9580\u8a3a\u8f49\u8a3a48\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u4e3b\u8a34\u70ba\u534a\u5e74\u524d\u4f4e\u5291\u91cf\u80ba\u90e8\u96fb\u8166\u65b7\u5c64\u610f\u5916\u767c\u73fe\u5de6\u908a\u814e\u4e0a\u817a\u67092\u516c\u5206\u5927\u5c0f\u4e4b\u7d50\u7bc0\uff0c\u904e\u53bb\u7121\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u8acb\u554f\u95dc\u65bc\u814e\u4e0a\u817a\u7624\u4e4b\u4e0b\u5217\u6558\u8ff0\uff0c\u4f55\u9805\u70ba\u6b63\u78ba\uff1f(1). \u82e5\u7121\u9ad8\u8840\u58d3\u6216\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u75c7\u72c0\uff0c\u5c31\u4e0d\u7528\u505a\u8377\u723e\u8499\u65b9\u9762\u7684\u7be9\u6aa2 (2). \u7531\u5f71\u50cf\u5b78\u6aa2\u67e5\uff0c\u82e5\u5927\u65bc4\u516c\u5206\u60e1\u6027\u816b\u7624\u4e4b\u53ef\u80fd\u6027\u8f03\u9ad8 (3). \u82e5\u70ba\u814e\u4e0a\u817a\u76ae\u8cea\u764c\uff0c\u5927\u90e8\u5206\u6703\u88fd\u9020\u904e\u591a\u7684\u985e\u56fa\u9187 (4). \u82e5 Low CT density <10 HU in unenhanced CT \u8207 Contrast washout after 15 min. >50%\uff0c\u5247\u70ba\u826f\u6027\u5076\u898b\u7624(Incidentaloma)\u4e4b\u6a5f\u7387\u8f03\u5927 (5). MRI\u70ba\u9996\u9078\u6aa2\u67e5\u9805\u76ee\uff0c\u56e0\u80fd\u6bd4\u96fb\u8166\u65b7\u5c64\u63d0\u4f9b\u66f4\u591a\u8cc7\u8a0a\nA. (1)+(2)+(4)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)\nD. (2)+(3)+(5)\nE. (2)+(4)+(5)\n": "(C)", "107-14.\n\u4ee5\u4e0b\u4e0d\u540c\u6642\u671f\u7684\u6162\u6027\u814e\u81df\u75c5(CKD)\u60a3\u8005\uff0c\u9996\u5ea6\u62bd\u8840\u6e2c\u5f97\u9ad8\u81bd\u56fa\u9187\u8840\u75c7 (CHO 260 mg/dL,HDL 30 mg/dL, LDL 160 mg/dL)\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u5efa\u8b70\u7d66\u4e88Statin\uff1f (1). \u5e74\u9f6155\u6b72\u4e4b\u7b2c\u4e8c\u671fCKD\u60a3\u8005 (2). \u5e74\u9f6155\u6b72\uff0c\u5c1a\u672a\u958b\u59cb\u900f\u6790\u4e4b\u7b2c\u4e94\u671fCKD \u60a3\u8005 (3). \u5e74\u9f6140\u6b72\uff0c\u6709\u5c3f\u86cb\u767d\u8207\u7cd6\u5c3f\u75c5\u4e4b\u7b2c\u56db\u671fCKD\u60a3\u8005 (4). \u5e74\u9f6140\u6b72\u3001\u958b\u59cb\u900f\u6790\u6cbb\u7642\u5169\u5e74\u4e4b\u7b2c\u4e94\u671fCKD\u60a3\u8005 (5). \u5e74\u9f6140\u6b72\u3001\u814e\u81df\u79fb\u690d\u6210\u529f\u5169\u5e74\u4e4b\u7b2c\u4e8c\u671fCKD\u60a3\u8005\nA. (3)+(4)+(5)\nB. (2)+(4)+(5)\nC. (4)+(5)\nD. (2)+(4)\nE. (4)\n": "(E)", "107-15.\n\u5c3f\u5931\u7981\u70ba\u8001\u4eba\u5e38\u898b\u4e4b\u56f0\u64fe\u554f\u984c\uff0c\u8acb\u554f\u5e95\u4e0b\u54ea\u4e9b\u5e38\u898b\u7684\u85e5\u7269\u53ef\u80fd\u52a0\u91cd\u591c\u5c3f\u800c\u5118\u91cf\u907f\u514d\uff1f (1). Doxazocin (2). Dihydropyridine calcium-channel blockers (3). NSAIDs (4). Thiazolidinediones (5). Anthistamines\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (2)+(3)+(4)\nD. (2)+(3)+(5)\nE. (1)+(3)+(5)\n": "(C)", "107-16.\n\u95dc\u65bc\u6d3b\u52d5\u5f0f\u8840\u58d3\u91cf\u6e2c(Ambulatory blood pressure mesurement)\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u96b1\u533f\u578b\u9ad8\u8840\u58d3(Masked hypertension)\u4e4b\u5fc3\u8840\u7ba1\u75be\u75c5\u98a8\u96aa\u660e\u986f\u4f4e\u65bc\u8a3a\u9593\u6216\u5c45\u5bb6\u4e4b\u6301\u7e8c\u6027\u9ad8\u8840\u58d3\nB. \u591c\u9593\u578b\u9ad8\u8840\u58d3(Nocturnal hypertension)\u662f\u6bd4\u767d\u5929\u9ad8\u8840\u58d3\u6216\u8a3a\u9593\u9ad8\u8840\u58d3\u66f4\u5f37\u4e4b\u5fc3\u8840\u7ba1\u75be\u75c5\u98a8\u96aa\u9810\u5f8c\u56e0\u5b50\nC. \u96b1\u533f\u578b\u9ad8\u8840\u58d3\u5e38\u898b\u65bc\u7537\u6027\u3001\u8001\u4eba\u3001\u7cd6\u5c3f\u75c5\nD. \u8001\u4eba\u5e38\u898b\u6709\u767d\u888d\u9ad8\u8840\u58d3(White coat hypertension) \u6216\u96b1\u533f\u578b\u9ad8\u8840\u58d3\nE. \u6162\u6027\u814e\u81df\u75c5\u7279\u5225\u5e38\u898b\u6709\u591c\u9593\u9ad8\u8840\u58d3\u8207\u96b1\u533f\u578b\u9ad8\u8840\u58d3\n": "(A)", "107-17.\n55\u6b72\u75c5\u4eba\uff0c\u7cd6\u5c3f\u75c5\u4e03\u5e74\u75c5\u53f2\u6bcf\u5929\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u63a7\u5236\uff0c\u4eca\u5e74\u56e0\u51fa\u73fe\u5c3f\u86cb\u767d\u8207\u9ad8\u8840\u58d3\u958b\u59cb\u670d\u7528 Thiazide/Valsartan\uff0c\u8fd1\u5169\u500b\u6708\u53c8\u80c3\u9178\u9006\u6d41\u670d\u7528Proton pump inhibitor\uff0c\u9019\u6b21\u9580\u8a3a\u75c5\u4eba\u62b1\u6028\u5bb9\u6613\u624b\u8db3\u62bd\u6410(tetany)\uff0c\u8acb\u6b64\u65b0\u75c7\u72c0\u53ef\u80fd\u8ddf\u54ea\u4e00\u96fb\u89e3\u8cea\u4e4b\u7570\u5e38\u76f8\u95dc\uff1f\nA. \u4f4e\u9209\u8840\u75c7\nB. \u4f4e\u9240\u8840\u75c7\nC. \u4ee3\u8b1d\u6027\u9e7c\u4e2d\u6bd2\nD. \u4f4e\u9382\u8840\u75c7\nE. \u4f4e\u9223\u8840\u75c7\n": "(D)", "107-18.\n\u5728\u665a\u671f\u6162\u6027\u814e\u81df\u75c5\u6216\u900f\u6790\u75c5\u4eba\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805 \u8207\u5176\u9ad8\u51fa\u8a31\u591a\u7684\u5fc3\u8840\u7ba1\u75be\u75c5\u6216\u6b7b\u4ea1\u98a8\u96aa\u4e0d\u898b\u5f97\u6709\u76f4\u63a5\u76f8\u95dc\uff1f\nA. \u4f4e\u8840\u58d3 (Low blood pressure)\nB. \u66fe\u6709\u6025\u6027\u5fc3\u808c\u6897\u585e (Documented AMI)\nC. \u5fc3\u81df\u8870\u7aed (Congestive heart failure)\nD. \u5de6\u5fc3\u5ba4\u80a5\u539a (Left ventricular hypertrophy)\nE. \u64f4\u5f35\u578b\u5fc3\u808c\u80a5\u539a (Dilated cardiomyopathy)\n": "(B)", "107-19.\n\u95dc\u65bc\u814e\u81df\u7d30\u80de\u764c(Renal cell carcinoma)\uff0c\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u814e\u81df\u7d30\u80de\u764c\u4e2d\u4ee5Clear cell carcinoma\u70ba\u6700\u591a\u800c\u4e14\u6700\u6703\u8f49\u79fb\nB. Clear cell carcinoma\u70ba von Hippel-Lindau gene \u4e4b \"loss of function\" mutation\nC. \u7d04\u756530%\u814e\u81df\u7d30\u80de\u764c\u767c\u73fe\u6642\u5df2\u6709\u8f49\u79fb\uff0c\u800c\u814e\u81df\u5207\u9664\u624b\u8853\u5f8c\u4ecd\u670920-30%\u6703\u6709\u8f49\u79fb\u5fa9\u767c\nD. \u814e\u81df\u7d30\u80de\u764c\u5c24\u5176\u662fClear cell carcinoma\u767c\u73fe\u6642\u6709\u8f49\u79fb\uff0c\u4ecd\u61c9\u5efa\u8b70\u505a\u7f79\u764c\u5074\u4e4b\u5168\u90e8\u6216\u5c40\u90e8\u814e\u81df\u5207\u9664\nE. \u5e38\u4f34\u6709Paraneoplastic syndrome\uff0c\u5305\u62ec\u6709\u809d\u81df\u8f49\u79fb\u53ca\u809d\u529f\u80fd\u7570\u5e38\u4e4bStauffer's syndrome\n": "(E)", "107-20.\n68\u6b72\u7537\u6027 \u7121\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u3001\u5fc3\u808c\u7f3a\u6c27\u7b49\u75c5\u53f2\uff0c\u8fd1\u516d\u500b\u6708\u9010\u6f38\u51fa\u73fe\u547c\u5438\u56f0\u96e3\u3001\u884c\u52d5\u56f0\u96e3\u3001\u7ad9\u7acb\u6642\u982d\u6688\u3001\u4e0b\u80a2\u6c34\u816b\u3001\u4e0b\u80a2\u6709\u9ebb\u6728\u53ca\u75bc\u75db\u611f\u89ba\u7570\u5e38\u3002 \u7d93\u6aa2\u67e5\uff1a\u8840\u58d3102/70 mmHg\u3001\u8108\u535a96/min\u3001\u547c\u543820/min\u3001\u80f8\u90e8Cardiac dullness\u589e\u52a0\u3001\u547c\u5438\u97f3\u6e1b\u5c11\uff0c\u8179\u90e8\u6709shifting dullness\uff0c\u4e0b\u80a2\u56b4\u91cd\u6c34\u816b\u81f3\u819d\u84cb\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u4e0b\u80a2\u5c0d\u89f8\u6478\u8207\u9707\u52d5\u4e4b\u611f\u89ba\u6709\u4e0b\u964d\u3002\u62bd\u8840\u6aa2\u67e5\uff1aHb 10.2 gm/dL, Albumin 2.4 gm/dL, Cre 1.6 mg/dL, CHO 280 mg/dL, HbA1C 5.9%, Urine Protein/ Creatinine ratio 4800 mg/g, \u53caUrine\u6709Bence Jones protein\u7684\u5b58\u5728\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u9032\u4e00\u6b65\u6aa2\u67e5immunofixation of serum and urine\u53caserum immunoglobulin free light chain assay\uff0c\u78ba\u5b9a\u70ba \u03ba \u6216 \u03bb light chain \u8207\u5176\u91cf\nB. \u5efa\u8b70\u53ef\u5148\u505a\u76ae\u4e0b\u8102\u80aa\u8207\u9aa8\u9ad3\u7a7f\u523a\uff0c\u78ba\u5b9a\u662f\u5426\u6709Amyloidosis \u4ee5\u53ca\u9aa8\u96a8\u5167plasma cell \u7684\u767e\u5206\u6bd4\nC. \u8a3a\u65b7\u4e0a\u9084\u662f\u9700\u8981\u505a\u814e\u81df\u5207\u7247\uff0c\u4e26\u514d\u75ab\u67d3\u8272\u8b49\u660e\u6709light chain\u7684\u5b58\u5728\nD. \u6b64\u75c5\u63a5\u53d7\u81ea\u9ad4\u9020\u8840\u5e79\u7d30\u80de\u9aa8\u9ad3\u79fb\u690d\u4e26\u4e0d\u6703\u6bd4\u50b3\u7d71\u5316\u7642\u6548\u679c\u597d\nE. \u75c5\u4eba\u7d50\u5c40(outcome)\u6c7a\u5b9a\u65bc\u814e\u529f\u80fd\u662f\u5426\u60e1\u5316\u81f3\u900f\u6790\u6cbb\u7642\n": "(E)", "107-21.\n\u67d050\u6b72\u7537\u6027\u4f86\u9662\u524d\u4e94\u5929\u525b\u9a0e\u8173\u8e0f\u8eca\u74b0\u5cf6\u7d50\u675f\uff0c\u4e3b\u8a34: \u8f15\u5fae\u5641\u5fc3\u3001\u5169\u8173\u808c\u8089\u75e0\u75bc\u7121\u529b\u3001\u5c0f\u4fbf\u5448\u53ef\u6a02\u984f\u8272\u5df2\u5169\u5929\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3130/80 mmHg\uff0c\u8108\u640f 82/min\uff0c\u547c\u543818/min\uff0c\u80f8\u90e8\u8179\u90e8\u7121\u6059\uff0c\u5169\u5074\u5c0f\u817f\u5927\u817f\u6709\u58d3\u75db\u53ca\u808c\u8089\u8f15\u5fae\u7121\u529b~+4\u3002\u62bd\u8840\u6aa2\u67e5\uff1a WBC 10200/ul, Hb 11.6g/dL,BUN 128mg/dL, Cre 6.7mg/dL, Na 138mmol/L, K 5.6mmol/L, ABG pH 7.26, HCO3- 16mEq/L. CK 25000 U/L, AST 703U/L, ALT 238 U/L, Bil-T 1.2 mg/dL, LDH 2013 U/dL, Haptoglobin 58 mg/dL, \u5c3f\u6aa2 pH 5.8, protein (2+), OB(3+), RBC 2-5/HPF, WBC\r0-3/HPF.\u814e\u81df\u8d85\u97f3\u6ce2\u986f\u793a\u5169\u5074\u814e\u81df\u5747\u70ba10\u516c\u5206\u5de6\u53f3\uff0c\u7121\u840e\u7e2e\u73fe\u8c61\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u5176AKI\u70ba\u7531Hypovolemia\u4e4bprerenal AKI\uff0c\u6240\u4ee5\u6cbb\u7642\u4e0a\u4ee5Hydration\u70ba\u4e3b\nB. \u61c9\u4e5f\u8981\u6aa2\u67e5\u8840\u6e05\u9223\u8207\u78f7\u6fc3\u5ea6\uff0c\u56e0\u5e38\u6703\u6709\u4f4e\u9223\u8840\u75c7\u8207\u9ad8\u78f7\u8840\u75c7\nC. \u61c9\u6301\u7e8c\u7d66\u4e88\u751f\u7406\u9e7d\u6c34\u81f3\u5c11\u6bcf\u5c0f\u6642200\u6beb\u5347\u4ee5\u4e0a\uff0c\u81f3\u5c3f\u8a66\u7d19\u6f5b\u8840\u8b8a\u6210\u9670\u6027\u70ba\u6b62\nD. \u82e5\u5c3f\u6db2pH<6.5\uff0c\u53ef\u8003\u616e\u5728\u751f\u7406\u9e7d\u6c34\u4e2d\u52a0\u5165Sodium bicarbonate\nE. \u5982\u679c\u51fa\u73fe\u5be1\u5c3f\u3001\u9ad8\u8840\u9240\u4f75EKG\u8b8a\u5316\u3001\u56b4\u91cd\u9178\u4e2d\u6bd2\uff0c\u5c31\u61c9\u5373\u65e9\u7dca\u6025\u8840\u6db2\u900f\u6790\u6cbb\u7642\n": "(A)", "107-22.\n\u4ee5\u4e0b\u662f\u4e00\u4f4dICU\u75c5\u4eba\u7684\u52d5\u8108\u6c23\u9ad4\u5206\u6790\u8207\u8840\u6db2\u96fb\u89e3\u8cea\u5831\u544a: pH 7.42, PaO2 88 mmHg, PaCO2 67 mmHg, [Na] 140 mEq/L, [K] 3.5 mEq/L, [Cl] 88 mEq/L, HCO3 42 mEq/L\u3002\u4f9d\u64da\u4e0a\u8ff0\u6578\u503c\uff0c\u6700\u7b26\u5408\u4ee5\u4e0b\u4f55\u7a2e\u75c5\u4eba\u72c0\u6cc1?\nA. Sepsis in ICU\nB. Uremia, long-term use of diuretics\nC. COPD with diuretics\nD. Methanol intoxication, with secondary lactic acidosis\nE. Pneumonia, on ventilator support for pulmonary edema\n": "(C)", "108-1.\n\u6162\u6027\u814e\u81df\u75c5(CKD)\u75c5\u4eba\u5e38\u5408\u4f75\u6709\u9223\u78f7\u7570\u5e38\uff0c\u4ee5\u4e0b\u6709\u95dc\u6cbb\u7642\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u63a1\u7528\u4f4e\u78f7\u98f2\u98df(low phosphate diet)\uff0c\u6709\u52a9\u65bc\u9810\u9632\u526f\u7532\u72c0\u817a\u9ad8\u80fd\u75c7(secondary hyperparathyroidism)\nB. \u4f7f\u7528\u6d3b\u6027\u7dad\u4ed6\u547dD(\u5982: calcitriol)\u53ef\u4ee5\u6291\u5236\u526f\u7532\u72c0\u817a\u7d20(parathyroid hormone)\u5206\u6ccc\uff0c\u526f\u4f5c\u7528\u4e4b\u4e00\u662f\u5f15\u8d77\u9ad8\u8840\u9223(hypercalcemia)\nC. \u4f7f\u7528calcimimetic agent(\u5982: cinacalcet)\u53ef\u4ee5\u6291\u5236\u526f\u7532\u72c0\u817a\u7d20(parathyroid hormone)\u5206\u6ccc\uff0c\u526f\u4f5c\u7528\u4e4b\u4e00\u662f\u5f15\u8d77\u9ad8\u8840\u9223(hypercalcemia)\nD. \u4f7f\u7528\u78f7\u7d50\u5408\u5291(\u5982: \u5404\u5f0f\u9223\u7247)\u53ef\u4ee5\u6291\u5236\u526f\u7532\u72c0\u817a\u7d20(parathyroid hormone)\u5206\u6ccc\uff0c\u526f\u4f5c\u7528\u4e4b\u4e00\u662f\u5f15\u8d77\u9ad8\u8840\u9223(hypercalcemia)\nE. \u4f7f\u7528sevelamer\u6216lanthanum\uff0c\u53ef\u4ee5\u6291\u5236\u8178\u80c3\u9053\u5c0d\u78f7\u7684\u5438\u6536\uff0c\u4f46\u4e0d\u6703\u5f15\u8d77\u9ad8\u8840\u9223(hypercalcemia)\n": "(C)", "108-2.\n\u9ad8\u8840\u58d3\u7684\u75c5\u4eba\u521d\u6b21\u5c31\u91ab\u6642\uff0c\u61c9\u5b89\u6392\u512a\u5148\u505a\u4ee5\u4e0b\u8a55\u4f30(initial evaluation)\uff0c\u4f55\u8005\u9664\u5916?\nA. Hematocrit\nB. Serum uric acid level\nC. ECG (electrocardiogram)\nD. Urinalysis \u6216 urine albumin excretion\nE. Serum BUN and Cr, Sodium, potassium\n": "(B)", "108-3.\n\u59b3(\u4f60)\u662f\u5167\u79d1\u91ab\u5e2b\uff0c\u4e00\u4f4d\u5e74\u8f15\u9ad8\u8840\u58d3\u75c5\u4eba\u61f7\u5b5520\u9031\uff0c\u8f49\u4ecb\u5230\u59b3(\u4f60)\u7684\u9580\u8a3a\u8ffd\u8e64\u3002\u4ee5\u4e0b\u91dd\u5c0d\u61f7\u5b55\u9ad8\u8840\u58d3\u7684\u6cbb\u7642\u5efa\u8b70\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. \u8a72\u5b55\u5a66\u7684\u8840\u58d3\u63a7\u5236\u76ee\u6a19\uff0c\u5efa\u8b70\u4e0d\u9ad8\u65bc140/90 mmHg\nB. \u53ef\u7d66\u4e88\u4f4e\u5291\u91cf(80-100 mg/day)aspirin\uff0c\u9810\u9632\u767c\u751f\u5b50\u7672\u524d\u75c7(pre-eclampsia)\nC. \u8840\u58d3\u85e5\uff0c\u5efa\u8b70\u4ee5ACEI\u6216ARB\u985e\u512a\u5148\nD. \u8840\u58d3\u85e5\uff0c\u53ef\u4ee5\u4f7f\u7528labetalol\nE. \u8840\u58d3\u85e5\uff0c\u53ef\u4ee5\u4f7f\u7528nifedipine\n": "(C)", "108-4.\n\u81e8\u5e8a\u4e0a\u53ef\u4ee5\u4f7f\u7528eGFR\u8207urine ACR(albumin creatinine ratio)\u4f86\u5224\u65b7\u814e\u81df\u75c5\u7684\u56b4\u91cd\u7a0b\u5ea6\uff0c\u8207\u8a55\u4f30\u9032\u5c55\u5230\u672b\u671f\u814e\u81df\u75c5(ESRD)\u7684\u5371\u96aa\u5ea6\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u60c5\u6cc1\u6700\u56b4\u91cd?\nA. eGFR 30 (ml/min/1.73 m2)\uff0c urine ACR<30 mg/g\nB. eGFR 60 (ml/min/1.73 m2)\uff0c urine ACR>300 mg/g\nC. eGFR 50 (ml/min/1.73 m2)\uff0c urine ACR 30-300 mg/g\nD. eGFR 70 (ml/min/1.73 m2)\uff0c urine ACR<30 mg/g\nE. eGFR 40 (ml/min/1.73 m2)\uff0c urine ACR 30-300 mg/g\n": "(E)", "108-5.\n\u4e0d\u660e\u539f\u56e0\u7684\u6025\u6027\u814e\u640d\u50b7(AKI)\uff0c\u5c3f\u6db2\u6aa2\u67e5\u767c\u73fe: protein (2+), RBC cast (+), WBC cast (-), WBC 0-5/HPF, eosinophil (-), bacteria (-), Muddy brown cast (-), FENa > 1% \u75c5\u4eba\u767c\u751fAKI\u6700\u53ef\u80fd\u7684\u75c5\u56e0\u70ba:\nA. Glomerulonephritis (GN) or vasculitis\nB. Interstitial nephritis\nC. Acute tubular necrosis (ATN)\nD. Pyelonephritis or papillary necrosis\nE. Renal arterial or vein occlusion\n": "(A)", "108-6.\n\u4e00\u4f4d36\u6b72\u5973\u6027\uff0c\u4e3b\u8a34\u5065\u5eb7\u6aa2\u67e5\u767c\u73fe\u8840\u5c3f(hematuria)\u3002\u9580\u8a3a\u518d\u4e00\u6b21\u5c3f\u6db2\u6aa2\u67e5\u767c\u73fe: protein (3+), O.B. (2+), dysmorphic RBC (+), RBC cast (+)\u3002\u57fa\u65bc\u9019\u4e9b\u8cc7\u6599\uff0c\u59b3(\u4f60)\u6703\u5b89\u6392\u4ee5\u4e0b\u9032\u4e00\u6b65\u6aa2\u67e5\uff0c\u4f55\u8005\u6700\u4e0d\u5408\u9069?\nA. IVP (intravenous pyelography)\u6216RP (retrograde pyelography)\nB. \u505aserology tests, \u5305\u62ec: ant-GBM Ab, ANCA, ASLO (anti-strytolysin O)\nC. \u6aa2\u6e2c\u8840\u4e2d complement levels (C3, C4), cryoglobulin\nD. Renal sonography, \u5fc5\u8981\u6642\u8003\u616erenal biopsy\nE. Urine cytology test\n": "(A)", "108-7.\n\u4e00\u4f4d\u75c5\u4eba\u4e3b\u8a34\u983b\u5c3f\uff0c\u800c\u4e14\u6bcf\u6b21\u5c3f\u91cf\u90fd\u5f88\u591a\u3002\u75c5\u4eba\u4e26\u672a\u4f7f\u7528\u5229\u5c3f\u5291\uff0c\u8eab\u9ad4\u6aa2\u67e5: \u8840\u58d3\u6b63\u5e38\uff0c\u7121\u7570\u72c0\u3002\u6536\u96c624\u5c0f\u6642\u5c3f\u6db2\u7d50\u679c\u5982\u4e0b: \u7e3d\u5c3f\u91cf 3600 mL/day, urine osmolality 550 mOsm/kg\u3002\u75c5\u4eba\u7684\u6aa2\u67e5\u6578\u503c\uff0c\u6700\u7b26\u5408\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u591a\u5c3f\u75c7\u7684\u8a3a\u65b7:\nA. \u767c\u751fsolute diuresis\nB. Primary polydipsia\nC. \u767c\u751f central diabetes insipidus (DI)\nD. \u767c\u751f nephrogenic diabetes insipidus (DI)\nE. \u767c\u751f SIADH (syndrome of inappropriate anti-diuretic hormone secretion)\n": "(A)", "108-8.\n\u4e0b\u5217\u539f\u767c\u6027\u814e\u75c5\u8b8a\u5f15\u8d77\u7684\u814e\u75c5\u75c7\u5019\u7fa4(nephrotic syndrome)\uff0c\u54ea\u4e00\u7a2e\u6700\u5bb9\u6613\u5408\u4f75\u814e\u975c\u8108\u6813\u585e(renal vein thrombosis)?\nA. Focal segmental glomerulosclerosis (FSGS)\nB. IgA nephropathy\nC. Membranous nephropathy (MN)\nD. Minimal change disease (MCD)\nE. Type I MPGN (membranoproliferative glomerulonephritis)\n": "(C)", "108-9.\n\u6162\u6027\u814e\u81df\u75c5(CKD)\u75c5\u4eba\u7684\u98f2\u98df\uff0c\u5efa\u8b70\u53ef\u4f75\u7528\u4f4e\u86cb\u767d\u98f2\u98df(low protein diet, LPD)\uff0c\u4ee5\u4fdd\u8b77\u814e\u529f\u80fd\uff0c\u6e1b\u7de9CKD\u60e1\u5316\u3002\u4ee5\u4e0b\u5c0d\u65bcLPD\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. CKD\u98f2\u98df\u6cbb\u7642\u6307\u5f15\u6240\u8b02\u7684LPD\uff0c\u5efa\u8b70\u6bcf\u65e5\u86cb\u767d\u8cea\u651d\u53d6\u7d040.6-0.8 g/kg/day\nB. LPD\u53ef\u4ee5\u8b93\u814e\u5c0f\u7403\u5165\u7403\u5c0f\u52d5\u8108(afferent arteriole)\u6536\u7e2e\uff0c\u964d\u4f4e\u814e\u5c0f\u7403\u5167\u58d3\u529b(intra-glomerular pressure)\uff0c\u6e1b\u7de9CKD\u60e1\u5316\nC. LPD\u53ef\u4ee5\u589e\u5f37\u814e\u5c0f\u7403\u51fa\u7403\u5c0f\u52d5\u8108(efferent arteriole)\u64f4\u5f35\u7684\u6a5f\u8f49\uff0c\u964d\u4f4e\u814e\u5c0f\u7403\u5167\u58d3\u529b(intra-glomerular pressure)\uff0c\u6e1b\u7de9CKD\u60e1\u5316\nD. LPD\u8981\u642d\u914d\u71b1\u91cf\u9650\u5236\uff0c\u5efa\u8b70 < 30 Kcal/kg/day\uff0c\u9019\u6a23\u624d\u80fd\u6709\u6548\u6539\u5584\u6e1b\u7de9CKD\u60e1\u5316\nE. LPD\u53ef\u4ee5\u6e1b\u5c11\u542b\u6c2e(nitrogen, N)\u4ee3\u8b1d\u7269\u7522\u751f\uff0c\u964d\u4f4e\u76f8\u95dcuremic toxins, \u5982: p-cresol sulfate\u7522\u751f\n": "(D)", "108-10.\n\u9810\u9632contrast-induced acute kidney injury (AKI)\uff0c\u4ee5\u4e0b\u6cbb\u7642\u7b56\u7565\u7d44\u5408\uff0c\u4f55\u8005\u6b63\u78ba? (1)\u9069\u7576\u7684volume expansion, \u5efa\u8b70\u512a\u5148\u9078\u64c7isotonic saline (2)\u52a0\u4e0aurinary alkalization, \u6548\u679c\u548c\u55ae\u7d14\u4f7f\u7528isotonic saline\u6548\u679c\u7121\u5dee\u5225 (3)\u73fe\u5728\u7684\u6307\u5f15\u5efa\u8b70: routine \u7d66\u4e88 N-acetylcysteine\uff0c\u53ef\u4ee5\u6709\u6548\u9810\u9632AKI\u767c\u751f (4)\u5982\u679c\u75c5\u4eba\u6b63\u5728\u4f7f\u7528metformin, \u5efa\u8b70\u4e0d\u8981\u96a8\u610f\u7d42\u6b62\u505c\u7528\uff0c\u4ee5\u907f\u514d\u767c\u751flactic acidosis (5)\u5982\u679c\u75c5\u4eba\u6b63\u5728\u4f7f\u7528diuretics, \u6216Angiotensin-converting enzyme inhibitors (ACEI) \u6216angiotensin-receptor blockers (ARB), \u5efa\u8b70\u8981\u66ab\u505c\u4f7f\u7528\uff0c\u4ee5\u9810\u9632\u767c\u751fAKI\nA. (1)+(2)\nB. (1)+(2)+(3)\nC. (1)+(2)+(3)+(4)\nD. (1)+(2)+(3)+(5)\nE. (1)+(2)+(5)\n": "(A)", "108-11.\n\u91dd\u5c0d\u591a\u56ca\u814e(autosomal dominant polycystic kidney disease, ADPKD)\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u6cbb\u7642\u7b56\u7565\u53ef\u4ee5\u9810\u9632\u814e\u7d72\u7403\u904e\u6ffe\u7387(GFR)\u4e0b\u964d? (1)Low salt diet (2)Cyclic adenosine monophosphate (cAMP) raising agent, \u4f8b\u5982 dipyridamole (3)Vasopressin-receptor antagonist, \u4f8b\u5982: somatostatin (4)Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor blockers (ARB) (5)Water restriction, to prevent cyst growth\nA. (1)+(2)+(3)+(4)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)+(5)\nD. (1)+(3)+(5)\nE. (2)+(3)+(5)\n": "(B)", "108-12.\n\u4ee5\u4e0b\u7684\u7cd6\u5c3f\u75c5\u6cbb\u7642\u85e5\u7269\uff0c\u54ea\u4e00\u985e\u53ef\u4ee5\u6709\u6548\u9810\u9632\u814e\u75c5\u8b8a\u7684\u767c\u751f? (1)Insulin (2)Metformin (3)Biguanides (4)Dipeptidyl peptidase 4 (DPP-4) inhibitors (5)glucagon-like peptide 1 (GLP-1) agonist (6)sodium-glucose cotransporter 2 (SGLT2) inhibitors\nA. (5)+(6)\nB. (1)+(5)+(6)\nC. (3)+(5)+(6)\nD. (3)+(4)+(5)+(6)\nE. (1)+(2)+(5)+(6)\n": "(A)", "108-13.\n63\u6b72\u7537\u6027\u75c5\u4eba\u56e0 Chronic kidney disease stage 3 (eGFR 50ml/min/1.73m^2)\uff0c\u814e\u75c5\u75c7\u5019\u7fa4(\u814e\u81df\u5207\u7247\u75c5\u7406\u70ba\u5c40\u90e8\u786c\u5316\u578b\u814e\u708e)\u3001\u9ad8\u8840\u58d3\u3001\u9000\u5316\u6027\u95dc\u7bc0\u708e\u7b49\u75be\u75c5\u670d\u7528\u5e95\u4e0b\u85e5\u7269\uff0c\u4f46\u662f\u904e\u53bb\u534a\u5e74\u8840\u9240\u90fd\u7dad\u6301\u57285.5-6.0 mmol/L\u4e4b\u9593\uff0c\u8acb\u554f\u9ad8\u8840\u9240\u53ef\u80fd\u8207\u5e95\u4e0b\u85e5\u7269\u6709\u95dc? (1)ARB (2)Doxazosin (3)Cyclosporin (4)Predinisolone (5)COX-2 inhibitor.\nA. (1)+(3)+(4)\nB. (1)+(3)+(5)\nC. (1)+(2)+(4)\nD. (1)+(2)+(5)\nE. (1)+(4)+(5)\n": "(B)", "108-14.\n\u95dc\u65bc\u814e\u81df\u66ff\u4ee3\u7642\u6cd5\uff0c\u5e95\u4e0b\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\nA. \u65e9\u9ede\u958b\u59cb\u900f\u6790(eGFR 10-14 ml/min/1.73m^2) \u8ddf\u665a\u9ede\u958b\u59cb\u900f\u6790 (5-7 ml/min/1.73m2)\u5728\u6b7b\u4ea1\u7387\u6709\u986f\u8457\u5dee\u7570\nB. \u589e\u52a0\u6bcf\u6b21\u8840\u6db2\u900f\u6790\u4e2d\u5c3f\u7d20\u6c2e\u7684\u6e05\u9664\u7387\uff0c\u53ef\u4ee5\u6539\u5584\u6b7b\u4ea1\u7387\nC. \u6bcf\u9031\u4e09\u6b21\u7684\u8840\u6db2\u900f\u6790\u6539\u70ba\u6bcf\u9031\u516d\u6b21\uff0c\u53ef\u4ee5\u6e1b\u5c11\u6b7b\u4ea1\u7387\nD. \u4f4e\u767d\u86cb\u767d\u8840\u75c7\u70ba\u900f\u6790\u75c5\u4eba\u4e4b\u91cd\u8981\u4e0d\u826f\u9810\u5f8c\u56e0\u5b50\nE. \u8840\u6db2\u900f\u6790\u6539\u70ba\u8179\u819c\u900f\u6790\u53ef\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\n": "(D)", "108-15.\n\u67d0\u7537\u6027\u6709\u9ad8\u8840\u58d3\u75c5\u4eba\uff0c\u56e0\u4e0b\u80a2\u6c34\u816b\u516d\u500b\u6708\uff0c\u7d93\u6aa2\u67e524\u5c0f\u6642\u5c3f\u86cb\u767d\u70ba5\u516c\u514b\uff0c\u8840\u6e05\u767d\u86cb\u767d3 gm/L\uff0cCreatinine 1.7 mg/dL\uff0c\u7d93\u814e\u81df\u7a7f\u523a\u5207\u7247\u75c5\u7406\u5831\u544a\u70ba\u7b2c\u4e8c\u671f\u819c\u6027\u814e\u708e\u3002\u8acb\u554f\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u5b9c? (1)\u61c9\u6aa2\u6e2c\u8840\u6e05Anti-M-Phospholipase A2 recptor (Anti-PLA2R) antibody titer (2)\u53ef\u7531\u814e\u81df\u5207\u7247\u4e2d\u814e\u7d72\u7403\u5e95\u819c\u4e4b\u589e\u539a\u8207\u767c\u708e\u7d30\u80de\u4e4b\u6d78\u6f64\u591a\u5be1\u5f97\u77e5\u5176\u9810\u5f8c (3)\u82e5\u75c5\u4ebaAnti-PLA2R antibody titer\u4e0d\u9ad8\uff0c\u5c31\u8868\u793a\u5176\u5c31\u6703\u81ea\u884c\u7de9\u89e3 (4)\u82e5\u75c5\u4ebaAnti-PLA2R antibody titer\u6709\u9ad8\uff0c\u5c31\u61c9\u5efa\u8b70\u63a5\u53d7\u514d\u75ab\u6291\u5236\u7642\u6cd5 (5)\u82e5\u75c5\u4ebaAnti-PLA2R antibody\rtiter\u6709\u9ad8\u4e14\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\uff0c\u5efa\u8b70\u9084\u662f\u7e7c\u7e8c\u8ffd\u8e64\u6b64\u6297\u9ad4\u4e4btiter\u3002\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(4)+(5)\nC. (1)+(4)+(5)\nD. (1)+(2)+(3)\nE. (1)+(3)+(4)\n": "(C)", "108-16.\n\u95dc\u65bc\u53f0\u7063\u814e\u81df\u79fb\u690d\u7684\u73fe\u6cc1\uff0c\u4f55\u8005\u70ba\u932f\uff1f\nA. \u53f0\u7063\u814e\u81df\u79fb\u690d\u75c5\u4eba\u7b2c\u4e00\u3001\u4e94\u3001\u5341\u5e74\u7684\u5b58\u6d3b\u7387\u8207\u7f8e\u570b\u76f8\u7576\nB. \u53f0\u7063\u814e\u81df\u79fb\u690d\u75c5\u4eba\u4e94\u3001\u5341\u5e74\u5b58\u6d3b\u7387\u6bd4\u53f0\u7063\u900f\u6790\u7684\u75c5\u4eba\u660e\u986f\u9ad8\u5f88\u591a\nC. \u53f0\u7063\u814e\u81df\u79fb\u690d\u5f8c\u6b7b\u4ea1\u539f\u56e0\u6392\u540d\u4f9d\u5e8f\u70ba\u5fc3\u8840\u7ba1\u75be\u75c5\u3001\u611f\u67d3\u3001\u60e1\u6027\u816b\u7624\nD. \u53f0\u7063\u814e\u81df\u79fb\u690d\u5f8c\u60e1\u6027\u816b\u7624\u767c\u751f\u7387\u70ba\u6b63\u5e38\u4eba\u76843-5\u500d\uff0c\u4e14\u9010\u5e74\u589e\u52a0\nE. \u53f0\u7063\u814e\u81df\u79fb\u690d\u5f8c\u816b\u7624\u8ddf\u5916\u570b\u4e00\u6a23\u4ee5\u6dcb\u5df4\u764c\u5c45\u591a\n": "(E)", "108-17.\n\u8acb\u554f\u5728\u5e95\u4e0b\u90a3\u4e00\u7a2e\u72c0\u6cc1\u505a\u5927\u91cf\u8f38\u6db2\u6cbb\u7642\uff0c\u4ecd\u8981\u5c0f\u5fc3\u53ef\u80fd\u6703\u9020\u6210\u7f3a\u8840\u6027\u814e\u50b7\u5bb3\uff1f\nA. \u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2 Diabetic ketoacidosis\nB. \u6a6b\u7d0b\u808c\u6eb6\u89e3\u75c7 Rhabdomyolysis\nC. \u71d2\u50b7 Burns\nD. \u5c3f\u8def\u963b\u585e\u88ab\u89e3\u9664\u5f8c\u5c3f\u91cf\u589e\u52a0  Post-obstruction diuresis\nE. \u986f\u5f71\u5291\u7d66\u4e88\u5f8c After administration of constrast medium\n": "(C)", "108-18.\n\u95dc\u65bc\u814e\u81df\u79fb\u690d\u5f8c\u591a\u7624\u6027\u75c5\u6bd2(Polyomaviruses BK virus) \u611f\u67d3\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u932f\uff1f\nA. \u901a\u5e38\u5728\u814e\u81df\u79fb\u690d\u4e00\u500b\u6708\u5f8c\u624d\u767c\u751f\nB. \u7d66\u4e88Acyclovir\u53ef\u4ee5\u6709\u6548\u5730\u9810\u9632\u5176\u767c\u751f\nC. \u65e9\u671f\u767c\u73fe\u8207\u964d\u4f4e\u8abf\u6574\u514d\u75ab\u6291\u5236\u85e5\u7269\u6975\u70ba\u9069\u7576\u4e4b\u8655\u7f6e\nD. BK \u75c5\u6bd2\u611f\u67d3\u53ef\u898b\u65bc\u814e\u81df\u79fb\u690d\nE. BK\u75c5\u6bd2\u53ef\u5728\u75c5\u4eba\u7684\u5c3f\u6db2\u8207\u8840\u6db2\u4e2d\u6aa2\u6e2c\u6216\u57f9\u990a\u51fa\u4f86\n": "(B)", "108-19.\n65\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u904e\u53bb\u7121\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\uff0c\u4e00\u5e74\u524d\u5065\u6aa2\u5c3f\u6db2\u814e\u529f\u80fd\u5747\u6b63\u5e38\uff0c\u4f46\u6700\u8fd1\u516d\u9031\u5c3f\u6db2\u984f\u8272\u8b8a\u6df1\uff0c\u8173\u8e1d\u6c34\u816b\uff0c\u8d70\u8def\u6703\u5fae\u5598\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3 152/98 mmHg\uff0c\u4e0b\u80a2\u6c34\u816b\u81f3\u5c0f\u817f\u524d\u811b\u9aa8\u8655\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\uff1a\u5c3f\u86cb\u767d3+\uff0cOB 3+\uff0cURBC 50-70/HPF\uff0cHb 10g/dL\uff0cBUN 53 mg/dL\uff0cCre 3.6 mg/dL\uff0c\u514d\u75ab\u5b78\u6aa2\u67e5C-ANCA (+) \u4e14titer\u9ad8\u904e\u6b63\u5e38\u503c\uff0c\u8acb\u554f\u5176\u814e\u81df\u5207\u7247\u4e4b\u75c5\u7406\u5831\u544a\u6bd4\u8f03\u53ef\u80fd\u70ba\u5e95\u4e0b\u4f55\u8005? (1)Goodpasture syndrome (2)Wegner granulomatosis (3)Eosonophilic granulomatosis (4)Churg-Strauss disease (5)Microscopic polyangitis.\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (2)+(4)+(5)\nE. (1)+(3)+(5)\n": "(B)", "108-20.\n\u95dc\u65bc\u8001\u5e74\u6642\uff0c\u814e\u81df\u6ccc\u5c3f\u7cfb\u7d71\u4e4b\u9000\u5316\uff0c\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u932f\u8aa4\uff1f\nA. \u814e\u7d72\u7403\u904e\u6ffe\u7387\u6bcf\u5e74\u8870\u90001%\uff0c\u81f370\u6b72\u6642\u5e73\u5747\u7d04\u70ba70 ml/min/1.73m2\u5de6\u53f3\nB. \u814e\u81df\u5c3f\u6db2\u6700\u5927\u6fc3\u7e2e\u80fd\u529b\u4e0b\u964d\uff0c\u4e14\u591c\u9593\u5c3f\u91cf\u589e\u52a0\nC. \u8180\u80f1\u4fbf\u5bb9\u6613\u8e81\u52d5\uff0c\u4e14\u8180\u80f1\u6536\u7e2e\u529b\u4e0b\u964d\nD. \u8180\u80f1\u9918\u5c3f\u91cf\u589e\u52a0\uff0c\u4e14\u8180\u80f1\u5bb9\u91cf\u6e1b\u5c11\nE. \u903c\u5c3f\u808c\u904e\u5ea6\u53cd\u61c9(Detrusor overactivity)\u662f\u5c3f\u5931\u7981\u6700\u5e38\u898b\u4e4b\u539f\u56e0\n": "(D)", "108-21.\n36\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u4e3b\u8a34\u6700\u8fd1\u5169\u9031\u6709\u7d93\u5e38\u53e3\u6e34\u3001\u5c3f\u91cf\u589e\u52a0\u53ca\u51fa\u73fe\u982d\u75db\u73fe\u8c61\u3002\u7406\u5b78:\u8840\u58d3\u6b63\u5e38\uff0c\u76ae\u819a\u5f48\u529b\u6b63\u5e38\u3002\u7d93\u521d\u6b65\u6aa2\u9a57\u5f97\u814e\u529f\u80fd\u5c3f\u8a66\u7d19\u6aa2\u67e5\u5747\u6b63\u5e38\uff0c\u4f46 [Na+] 155 mmol/L; plasma osmolarity 330 mOsm/L\u3002\u8acb\u554f\u5e95\u4e0b\u4e4b\u81e8\u5e8a\u8655\u7f6e\uff0c\u4f55\u9805\u70ba\u932f\u8aa4\uff1f\nA. \u61c9\u5148\u5728\u4e0d\u9650\u6c34\u72c0\u6cc1\u4e0b\uff0c\u8acb\u75c5\u4eba\u8490\u96c624\u5c0f\u6642\u4e4b\u5c3f\u6db2\u4e26\u8a18\u9304\u5c3f\u91cf\nB. \u598224\u5c0f\u6642\u5c3f\u91cf\u8d85\u904e50 ml/Kg\uff0c\u800c\u4e14Urine osmolarity < 300 mOsm/L\uff0c\u6709\u53ef\u80fd\u662fDiabete insipidus.(DI)\nC. \u61c9\u8981\u5148\u6392\u9664Hypokalemia\u53caHypercalcemia\nD. \u53ef\u6253 DDAVP\uff0c\u770bPlasm osmolarity\u4e4b\u8b8a\u5316\u4f86\u5224\u5b9a\u662fcentral\u6216Nephrogenic DI\nE. \u6cbb\u7642\u6642\uff0c\u6bcf\u5929 [Na+] \u4e4b\u4e0b\u964d\u91cf\u6700\u597d\u4e0d\u8981\u8d85\u904e 10 mmol/L\n": "(D)", "108-22.\n\u757670\u6b72\u75c5\u4eba\u56e0\u814e\u75c5\u75c7\u5019\u7fa4\u53caCre 2.0 mg/dL\uff0c\u9032\u4e00\u6b65\u7d93\u6aa2\u67e5Serum and urine immunofixation \u3001 Free light chain assay\u3001\u814e\u81df\u7a7f\u523a\u5f8c\u5df2\u78ba\u5b9a\u662f Renal AL Amyloidosis\u3002\u8acb\u554f\u63a5\u4e0b\u4f86\u4e4b\u81e8\u5e8a\u8655\u7f6e\uff0c\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u932f\u8aa4\uff1f\nA. \u5efa\u8b70\u9032\u4e00\u6b65\u505aBone marrow biopsy\nB. \u7e7c\u7e8c\u8ffd\u8e64Free light chain assay \u505a\u70ba\u75c5\u60c5\u8207\u6cbb\u7642\u4e4b\u6307\u6a19\nC. \u82e5\u4e5f\u6709Cardiac involvement\uff0c\u4e5f\u61c9\u8ffd\u8e64Troponin\u8207 N-termial pro-BNP\nD. \u6b64\u75c5\u4eba\u5c31\u662f\u63a5\u53d7\u5316\u5b78\u7642\u6cd5\uff0c\u7d42\u7a76\u9084\u662f\u6703\u6b7b\u65bcRenal failure\nE. \u75c5\u4eba\u63a5\u53d7\u81ea\u9ad4\u9020\u8840\u5e79\u7d30\u80de\u79fb\u690d\u4e0d\u898b\u5f97\u6703\u6bd4\u5316\u7642\u597d\n": "(D)", "109-67.49\u6b72\u7537\u6027\u56e0\u8fd1\u5e7e\u5e74\u91cd\u8986\u6392\u51fa\u5c3f\u8def\u7d50\u77f3 \uff0c\u6b64\u5916\uff0c\u660e\u986f\u7121\u5176\u4ed6\u81e8\u5e8a\u75c7\u72c0\u8207\u7cfb\u7d71\u75be\u75c5 \uff0c\u7d93\u6aa2\u67e5\u6709\u8840\u6e05\u808c\u9178\u9150 1.4 \nmg/dL (eGFR 57 ml /min/1.73m2)\u3001\u9ad8\u8840\u9223(13mg/dL)\u3001\u53ca\u9ad8\u526f\u7532\u72c0\u817aiPTH (150 \npg/mL)\uff0ctechnetium -99m sestamibi scintigraphy (MIBI)\u986f\u793a\u5728\u53f3\u7532\u72c0\u817a\u8655\u4f4d\u7f6e\u6709intense uptake \uff0c\u8acb\u554f\u5176\n\u4e4b\u8655\u7f6e\u4f55\u8005\u70ba\u6b63\u78ba \uff1f\n(1) \u5efa\u8b70\u5b9c\u4f4e\u9223\u9ad8\u78f7\u7684\u98f2\u98df  \n(2) \u5efa\u8b70\u5b9c\u4f7f\u7528Thiazide\u9810\u9632\u5c3f\u8def\u7d50\u77f3\n(3) \u5efa\u8b70\u5b9c\u4f7f\u7528Biphosphate\u9810\u9632\u9aa8\u8cea\u758f\u9b06 \n(4) \u5efa\u8b70\u5b9c\u4f7f\u7528cinacalcet\u964d\u4f4e\u8840\u9223\u6fc3\u5ea6\n(5) \u5efa\u8b70\u5b9c\u63a5\u53d7\u526f\u7532\u72c0\u817a\u5207\u9664   \nA.(1)+(2)+(3)+(4)+(5)\nB.(1)+(3)+(5)\nC.(1)+(2)+(3)+(4)\nD.(2)+(3)+(4)\nE.(3)+(4)+(5)\n": "[E]", "109-68.\u65bc\u6162\u6027\u814e\u75c5\u4e4b\u5206\u671f\u4e2d \uff0c\u5e95\u4e0b\u54ea\u4e9b\u70ba\u53ef\u80fd\u8fc5\u901f\u56b4\u91cd\u60e1\u5316 (\u5373\u7d05\u8272\u8b66\u6212 )\u7684\u72c0\u6cc1\uff1furinary albumin to creatinine \nratio (UACR)\n(1) eGFR 45 -59 + UACR 100 mg /g \n(2) eGFR 45 -59 + UACR > 300 mg /g\n(3) eGFR 30 -44 + UACR < 30 mg /g \n(4) eGFR 30 -44 + UACR 100 mg /g\n(5) eGFR 15 -29 + UACR < 30 mg /g   \nA.(2)+(3)+(4)+(5)\nB.(1)+(3)+(5)\nC.(2)+(4)+(5)\nD.(3)+(4)+(5)\nE.(1)+(2)+(3)+(4)+(5)   \n": "[C]", "109-69.72\u6b72\u7537\u6027\u6709\u591a\u5e74\u9ad8\u8840\u58d3 \u3001\u9ad8\u81bd\u56fa\u9187\u8840\u75c7 \u3001\u6162\u6027\u814e\u75c5\u7b2c\u4e09\u671f (\u7a69\u5b9a\u7121\u60e1\u5316 )\uff0c\u8fd1\u534a\u5e74\u56e0\u8f15\u5fae\u8840\u5c3feGFR 46 \nmL/min/1.73m2\uff0c\u505a\u814e\u81df\u8d85\u97f3\u6ce2\u767c\u73fe\u5de6\u5074\u814e\u81df (\u9577\u5f918\u516c\u5206)\u6bd4\u53f3\u5074\u5c0f 2\u516c\u5206\uff0c\u9032\u4e00\u6b65\u7684MR angiography (\u5982\n\u5716) \u767c\u73fe \u5728\u5de6\u5074\u814e\u52d5\u8108\u5165\u53e3\u8655\u6709\u4e00\u72f9\u7a84 \uff0c\u8acb\u554f\u5e95\u4e0b\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u6b63\u78ba \uff1f\n(1) \u5176\u9ad8\u8840\u58d3\u8207\u6162\u6027\u814e\u75c5\u6975\u53ef\u80fd\u70ba\u52d5\u8108\u786c\u5316\u5f15\u8d77\u814e\u52d5\u8108\u72f9\u7a84\u6240\u9020\u6210\n(2) \u53ef\u5b89\u6392\u505acaptopril renogram \u770b\u5de6\u5074\u814e\u81df\u8840\u6d41\u662f\u5426\u6709\u6e1b\u5c11\n(3) \u56e0\u814e\u529f\u80fd\u5df2\u4e0d\u6b63\u5e38 \uff0c\u61c9\u5efa\u8b70\u653e\u652f\u67b6\u6216\u6c23\u7403\u64f4\u5f35\u8853\u4f86\u6539\u5584\n(4) \u82e5\u90fd\u535c\u52d2\u8d85\u97f3\u6ce2\u986f\u793a\u5de6\u5074\u814e\u81df\u4e4bresistive index\u5c0f\u65bc80 \uff0c\u61c9\u8a72\u8981\u9700\u8981\u9032\u4e00\u6b65\u6aa2\u67e5\n(5) ACEi/ARB \u8207 Statins\u7684\u85e5\u7269\u6cbb\u7642\u5373\u53ef   \nA.(1)+(2)+(5)\nB.(1)+(3)+(5)\nC.(2)+(4)+(5)\nD.(1)+(3)+(4)\nE.(1)+(4)+(5)\n": "[C]", "109-70.\u95dc\u65bc\u5e38\u7528\u7684\u6c2b\u96e2\u5b50\u5e6b\u6d66\u963b\u65b7\u5291\u5c0d\u814e\u81df\u7684\u4e0d\u826f\u4f5c\u7528\u4e2d\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.Chronic kidney disease\nB.Acute kidney injury\nC.Acute interstitial nephritis\nD.Metabolic alkalosis\nE.Hypomagnesemia\n": "[D]", "109-71.\u5e95\u4e0b\u4e0d\u540c\u6e2c\u91cf\u8840\u58d3\u4e4b\u65b9\u5f0f\uff0c\u5176\u9ad8\u8840\u58d3\u7684\u5b9a\u7fa9\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f    \nA.\u8a3a\u9593\u6c34\u9280\u8840\u58d3\u8a08 \u6536\u7e2e\u58d3 \u2265140 and/or \u8212\u5f35\u58d3 \u226590  mmHg\nB.\u81ea\u91cf\u8a3a\u9593\u81ea\u52d5\u8840\u58d3\u8a08 \u6536\u7e2e\u58d3\u2265140 and/or\u8212\u5f35\u58d3\u226590 mmHg\nC.\u5c45\u5bb6\u8840\u58d3\u91cf\u6e2c \u6536\u7e2e\u58d3\u2265135 and/or\u8212\u5f35\u58d3\u226585 mmHg\nD.24 \u5c0f\u6642\u52d5\u614b\u8840\u58d3\u76e3\u6e2c (\u5168\u5929) \u6536\u7e2e\u58d3\u2265130 and/or \u8212\u5f35\u58d3\u226580 mmHg\nE.24 \u5c0f\u6642\u52d5\u614b\u8840\u58d3\u76e3\u6e2c (\u591c\u9593) \u6536\u7e2e\u58d3\u2265120 and/or \u8212\u5f35\u58d3\u226570 mmHg\n": "[B]", "109-72.\u95dc\u65bc\u75db\u98a8\u6d41\u884c\u75c5\u5b78\u8207\u81e8\u5e8a\u8868\u5fb5\uff0c\u5e95\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u70ba\u4e0d\u6b63\u78ba\uff1f    \nA.\u53f0\u7063\u539f\u4f4f\u6c11\u6bcf\u5341\u4eba\u81f3\u5c11\u6709\u4e00\u4eba\u6709\u75db\u98a8\uff0c\u5373\u76db\u884c\u7387\u8d85\u904e10%\nB.\u75db\u98a8\u75c5\u4eba\u4e5d\u6210\u662f\u56e0\u70ba\u814e\u81df\u7121\u6cd5\u6392\u51fa\u5c3f\u9178\u6240\u9020\u6210\nC.\u5973\u6027\u8f03\u5c11\u7f79\u60a3\u75db\u98a8\uff0c\u4e14\u5e38\u5728\u505c\u7d93\u4e4b\u5f8c\u5c31\u9bae\u5c11\u767c\u4f5c\nD.\u82e525\u6b72\u524d\u5c31\u6709\u75db\u98a8\u767c\u4f5c\uff0c\u53ef\u80fd\u6709\u5c3f\u9178\u4ee3\u8b1d\u4e4b\u57fa\u56e0\u7570\u5e38\nE.Thiazide\u3001low dose aspirin\u3001\u4eba\u5de5\u751c\u5473\u5291\uff0c\u90fd\u6703\u589e\u52a0\u75db\u98a8\u4e4b\u767c\u4f5c\n": "[C]", "109-73.\u6709\u4f4d39\u6b72\u5973\u6027\u56e0\u591a\u65e5\u8179\u7009 \u3001\u5168\u8eab\u7121\u529b \u3001\u547c\u5438\u77ed\u4fc3\u800c\u5230\u6025\u8a3a \uff0c\u904e\u53bb\u53f2\u6709\u7d93\u5e38\u6027\u4fbf\u79d8\u4f7f\u7528\u7009\u5291\u53ca\u8207\u5c0f\u4fbf\u56f0\u96e3\u81ea\n\u884c\u670d\u7528\u5229\u5c3f\u5291 \u3002\u7406\u5b78\u6aa2\u67e5 \uff1a\u7a0d\u55dc\u7761\u4f46\u53ef\u6e05\u9192 \u3001\u8840\u58d385/55,\u5fc3\u8df375/min.\u76ae\u819a\u5f35\u529b\u7a0d\u5dee \uff0c\u5176\u4ed6\u7121\u751a\u7570\u5e38 \u3002\u5be6\u9a57\n\u5ba4\u6aa2\u67e5\uff1aNa+ 125 mmol /l. , K+ 2.8 mmol/l., Cl 101- mmol /l., Glucose 94mg /dL, BUN 34 mg /dL, Cre 1.6 \nmg/dL\u3002Arterial Blood Gases  (pH 7.29; pCO2 25 .6 mmHg; pO2 111 mmHg; HCO 3\u207b  14.0 mmol/l)\u3002\u5c31\n\u5176Blood gas\u65b9\u9762\u800c\u8a00 \uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u70ba\u6b63\u78ba \uff1f   \nA.\u61c9\u70ba High anion gap metabolic acidosis\nB.\u61c9\u70ba High anion gap acidosis + metabolic alkalosis\nC.\u660e\u986f\u70baLactic acidosis\u9020\u6210\uff0c\u61c9\u6aa2\u6e2cserum lactate level   \nD.\u61c9\u7e7c\u7e8c\u6aa2\u6e2c Urine Anion Gap (UAG)\nE.\u61c9\u7e7c\u7e8c\u6aa2\u6e2c Osmolar gap \u53ca Delta ratio\n": "[D]", "109-74.\u95dc\u65bc\u986f\u5f71\u5291\u76f8\u95dc\u6025\u6027\u814e\u50b7\u5bb3(Contrast-associated AKI)\uff0c\u8fd1\u5e74\u6587\u737b\u56de\u9867\u6307\u51fa\u5e95\u4e0b\u63cf\u8ff0\u4f55\u8005\u70ba\u4e0d\u6b63\u78ba\uff1f    \nA.\u56b4\u91cd\u6162\u6027\u814e\u75c5\u662f\u767c\u751f\u986f\u5f71\u5291\u76f8\u95dc\u6025\u6027\u814e\u50b7\u5bb3\u4e4b\u6700\u5f37\u70c8\u4e4b\u7368\u7acb\u98a8\u96aa\u56e0\u5b50\nB.\u82e5\u975e\u5408\u4f75\u6162\u6027\u814e\u75c5\uff0c\u7cd6\u5c3f\u75c5\u672c\u8eab\u4e26\u4e0d\u662f\u986f\u5f71\u5291\u76f8\u95dc\u6025\u6027\u814e\u50b7\u5bb3\u4e4b\u7368\u7acb\u98a8\u96aa\u56e0\u5b50\nC.\u986f\u5f71\u5291\u76f8\u95dc\u6025\u6027\u814e\u50b7\u5bb3\u96d6\u7136\u7a0b\u5ea6\u8f15\u5fae\uff0c\u4f46\u4e5f\u6703\u589e\u52a0\u75c5\u4eba\u4e4b\u6b7b\u4ea1\u7387\nD.\u986f\u5f71\u5291\u76f8\u95dc\u6025\u6027\u814e\u50b7\u5bb3\u4e4b\u56b4\u91cd\u7a0b\u5ea6\uff0c\u8207\u96a8\u5f8c\u814e\u529f\u80fd\u6301\u7e8c\u60e1\u5316\u6709\u95dc\nE.\u6162\u6027\u814e\u75c5\u75c5\u4eba\u56e0\u986f\u5f71\u5291\u5c0e\u81f4\u56b4\u91cd\u6025\u6027\u814e\u50b7\u5bb3\u6216\u5c0e\u81f4\u900f\u6790\u7684\u6a5f\u7387\u9084\u662f\u660e\u986f\u9ad8\u51fa\u5f88\u591a\n": "[E]", "109-75.70 y/o\u5973\u6027\u9ad8\u8840\u58d3\u75c5\u4eba \uff0c\u56e0\u4e2d\u98a8\u9577\u5e74\u81e5\u75c5\u5728\u5e8a\u4e14\u9808\u9760\u9f3b\u80c3\u7ba1\u9935\u98df \uff0c\u5e73\u5e38\u53ea\u6709\u670d\u7528\u964d\u58d3\n\u85e5(Thiazide \u3001Beta/calcium blocer) (\u4ea6\u7121\u5176\u4ed6\u7cbe\u795e\u79d1\u85e5\u7269 )\uff0c\u8fd1\u65e5\u9023\u7e8c\u5929\u6c23\u9ad8\u6eab\u800c\u5bb6\u4e2d\u6c92\u6709\u7a7a\u8abf\u4e14\u901a\u98a8\u6b20\u4f73\n\u4e14\u672a\u88ab\u770b\u8b77\u597d\u597d\u7167\u9867 \uff1b\u5bb6\u5c6c\u63a2\u671b\u624d\u767c\u73fe\u6709\u767c\u71d2 \u3001\u610f\u8b58\u5446\u6eef\u53cd\u61c9\u9072\u920d \u3001\u5fc3\u60b8\u547c\u5438\u6025\u4fc3\u7b49\u800c\u88ab\u9001\u81f3\u6025\u8a3a \uff0c\u521d\u6b65\n\u6aa2\u67e5\uff1a\u809b\u6eab\u651d\u6c0f41 \u5ea6\uff0c\u8840\u58d390/66, \u5fc3\u8df3110 /min, Resp: 22 /min, \u76ae\u819a\u7121\u767c\u6c57 \u3001\u6392\u5c3f\u6e1b\u5c11 \u3002\u521d\u6b65\u4ea6\u7121\u660e\u986f\u611f\n\u67d3\u8de1\u8c61\uff0c\u8acb\u554f\u5176\u53ef\u80fd\u4e4b\u521d\u6b65\u8a3a\u65b7\u70ba \uff1f   \nA.Heat cramps\nB.Heat edema\nC.Heat syncope\nD.Heat stroke\nE.Heat exhaustion\n": "[D]", "109-76.\u5e95\u4e0b\u54ea\u4e00\u500b\u6297\u751f\u7d20\u85e5\u7269\u7576\u4f7f\u7528\u5291\u91cf\u8f03\u5927\u6642\uff0c\u6709\u53ef\u80fd\u7522\u751f\u808c\u8089\u6bd2\u6027\u751a\u81f3\u767c\u751f\u808c\u8089\u6eb6\u89e3\u75c7\u4e4b\u4e0d\u826f\u5f8c\u679c\uff1f    \nA.Erythromycin\nB.Colistin\nC.Quinolone\nD.Daptomycin.\nE.Vancomycin\n": "[D]", "109-77.\u95dc\u65bc\u814e\u81df\u7d30\u80de\u764c\u7684\u81e8\u5e8a\u8868\u73fe\uff0c\u5e95\u4e0b\u4f55\u8005\u70ba\u6b63\u78ba\uff1f    \nA.\u75c5\u4eba\u5e38\u56e0\u660e\u986f\u75c7\u72c0\u5982\u8840\u5c3f\u3001\u8179\u90e8\u816b\u584a\u3001\u75bc\u75db\u800c\u88ab\u6aa2\u67e5\u767c\u73fe\uff0c\u6545\u88ab\u7a31\u70ba\u201cinternist's tumor\u201d\nB.\u82e5\u8f49\u79fb\u81f3\u809d\u81df\u9020\u6210\u809d\u529f\u80fd\u5931\u5e38\uff0c\u5373Stauffer syndrome\nC.\u82e5\u5df2\u6709\u8f49\u79fb\uff0c\u814e\u81df\u5167\u816b\u7624\u6216\u8f49\u79fb\u4ed6\u8655\u816b\u7624\u4e4b\u5207\u9664\u53ef\u4ee5\u5ef6\u9577\u5b58\u6d3b\nD.\u8fd1\u5e74\u65b0\u7684\u751f\u7269\u88fd\u5291\u7121\u6cd5\u6539\u5584\u665a\u671f\u814e\u81df\u7d30\u80de\u764c\u7684\u4e94\u5e74\u5b58\u6d3b\u7387>70%\nE.\u814e\u81df\u7d30\u80de\u764c\u865f\u767c\u5e74\u9f61\u5c64\u70ba\u56db\u5341\u5230\u4e94\u5341\u6b72\u4e4b\u524d\n": "[C]", "109-78.\u9577\u671f\u7cd6\u5c3f\u75c5\u6703\u5f15\u8d77\u591a\u7a2e\u814e\u81df\u75c5\u8b8a \uff0c\u5305\u62ec: \u86cb\u767d\u5c3f \u3001\u814e\u529f\u80fd\u4e0d\u5168\u6216\u814e\u5c0f\u7ba1\u9178\u8840\u75c7 (renal tubular acidosis, \u7c21\n\u7a31RTA)\u3002\u6709\u95dc\u9019\u7a2e\u7cd6\u5c3f\u75c5\u6703\u5f15\u8d77\u7684RTA \uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f   \nA.\u6b64\u7a2eRTA\u7d93\u5e38\u51fa\u73fehyperkalemia\nB.\u6700\u5e38\u5f15\u8d77\u7684\u662ftype 2 RTA\nC.\u6b64\u7a2eRTA\u5f15\u8d77\u7684\u9178\u8840\u75c7\uff0c\u901a\u5e38serum pH\u503c\u6703\u5f88\u4f4e\uff0c\u9700\u8981\u975c\u8108\u6ce8\u5c04\u88dc\u5145bicarbonate\nD.\u6b64\u7a2eRTA\u662f\u56e0\u70ba\u8840\u4e2drenin \u8207 aldosterone\u6fc3\u5ea6\u5f88\u9ad8\u6240\u5f15\u8d77\nE.\u6b64\u7a2eRTA\uff0c\u56e0\u70ba\u5c3f\u6db2\u7121\u6cd5\u9178\u5316\uff0c\u901a\u5e38urine pH\u503c\u6703 > 6.5   \n": "[A]", "109-79.\u4e00\u4f4d\u5e74\u8f15\u5973\u6027 \uff0c\u6709\u9811\u56fa\u6027\u9ad8\u8840\u58d3 \uff0c\u9700\u540c\u6642\u4f7f\u7528\u4ee5\u4e0b\u591a\u7a2e\u964d\u8840\u58d3\u85e5\u7269 \u3002\u91ab\u5e2b\u56e0\u61f7\u7591\u662f\u6b21\u767c\u6027\u9ad8\u8840\u58d3 \uff0c\u6b32\u6aa2\n\u67e5renin-angiotensin -aldosterone system \u3002\u6aa2\u67e5\u524d\u53ef\u4ee5\u4fdd\u7559\u4f7f\u7528\u4ee5\u4e0b\u4f55\u7a2e\u85e5\u7269 \uff0c\u800c\u66ab\u505c\u5176\u4ed6\u7684 \uff0c\u624d\u80fd\u5920\u5c40\n\u90e8\u63a7\u5236\u8840\u58d3 \uff0c\u53c8\u4e0d\u81f4\u5f71\u97ff\u6aa2\u67e5\u7d50\u679c\u8207\u5224\u8b80 \uff1f\n(1) Alpha-blocker, \u5982: prazosin\n(2) Beta-blocker, \u5982: propranolol\n(3) Calcium channel blocker, \u5982: nifedipine\n(4) Diuretics, \u5982: aldosterone antagonists\n(5) ACEI (angiotensin- converting enzyme inhibitors ), \u5982: ramipril   \nA.(1)+(3)\nB.(1)+(5)\nC.(1)+(3)+(4)\nD.(2)+(3)+(4)\nE.(2)+(3)+(5)\n": "[A]", "109-80.28\u6b72\u5b55\u5a66 \uff0c\u9ad4\u91cd82KG, \u9577\u671f\u62bd\u83f8 \u3002\u9019\u6b21\u56e0\u61f7\u5b5522\u9031\u51fa\u73fe\u9ad8\u8840\u58d3 \u3001\u4e0b\u80a2\u6c34\u816b(+), \u91ab\u5e2b\u5df2\u7d93\u7d66\n\u4e88methyldopa \uff0c\u4f46\u662f\u8840\u58d3\u9084\u662f\u504f\u9ad8 \uff0c\u4ee5\u4e0b\u85e5\u7269\u4e5f\u53ef\u4ee5\u77ed\u671f\u5408\u4f75\u4f7f\u7528\u5728\u61f7\u5b55\u671f\u9593\u63a7\u5236\u8840\u58d3 \uff0c\u4f55\u8005\u9664\u5916 \uff1f   \nA.Ramipril, an angiotensin-converting enzyme (ACE) inhibitors\nB.hydralazine\nC.Labetalol , a beta-blocker\nD.Clonidine\nE.Sustained-release nifedipine, a calcium channel blocker\n": "[A]", "109-81.\u4e00\u4f4d38\u6b72\u7537\u6027 \uff0cnon-DM, non-obese, \u4e5f\u6c92\u6709\u65e9\u767c\u6027\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u5bb6\u65cf\u53f2 \u3002\u537b\u56e0\u70ba\u6025\u6027\u51a0\u5fc3\u75c7\u63a5\u53d7\u5fc3\u5c0e\u7ba1\n\u624b\u8853\u8207\u653e\u7f6e\u5169\u6839\u652f\u67b6 \u3002\u4f4f\u9662\u5f8c\u6aa2\u67e5\u7d50\u679c\u5982\u4e0b: BP 142 /90 mmHg, HR 86 /min and regular, pedal edema \n(2+), t-Chol 400 mg /dL, LDL 285 mg /dL, albumin 2.8 g/dL, AST 40 IU /L, ALT 38 IU /L, creatinine 1.2 \nmg/dL, HbA1C 6.8%, WBC 7400 /mm3\u3002\u70ba\u4e86\u9032\u4e00\u6b65\u63a2\u67e5\u75c5\u56e0 \uff0c\u60a8\u6703\u512a\u5148\u5b89\u6392\u4ee5\u4e0b\u54ea\u7a2e\u6aa2\u67e5 \uff1f   \nA.Serum protein electrophoresis\nB.Urine protein electrophoresis\nC.Urine albumin/creatinine ratio\nD.Urine total protein/creatinine ratio\nE.Hs-CRP, ANA (antinuclear antibody)\n": "[D]", "109-82.\u4e00\u4f4d24\u6b72\u5973\u6027 \uff0c\u6709\u591a\u5e74SLE (Systemic Lupus Erythematosus )\u75c5\u53f2\uff0c\u4f46\u6c92\u6709\u898f\u5247\u8ffd\u8e64\u8207\u6cbb\u7642 \u3002\u6700\u8fd1\u5169\u9031\u51fa\n\u73fe\u75b2\u5026\u3001\u4e0b\u80a2\u6c34\u816b \uff0c\u9ad4\u91cd\u589e\u52a0\u8fd1 7\u516c\u65a4\u800c\u4e14\u611f\u89ba\u5c3f\u91cf\u6e1b\u5c11 \u3002\u4f4f\u9662\u5f8c\u62bd\u8840\u6aa2\u67e5: BUN 74 mg /dL\uff0ccreatinine \n2.8 mg/dL, urine protein (4+)\uff0c\u8a3a\u65b7\u70ba\u6025\u6027\u814e\u708e (acute glomerulonephritis, AGN )\uff0c\u5b89\u6392\u75c5\u4eba\u63a5\u53d7\u814e\u81df\u751f\n\u6aa2(renal biopsy )\uff0c\u4ee5\u4e0b\u75c5\u7406\u8b8a\u5316 \uff0c\u4f55\u8005\u6700\u4e0d\u53ef\u80fd \uff1f   \nA.Diffuse proliferative nephritis with diffuse subendothelial deposit\nB.Membranous glomerulonephritis with subepithelial immune complex deposit\nC.Global endocapillary proliferation, with crescent formation\nD.Focal segmental glomerulosclerosis\nE.Glomerular necrotizing lesion of renal arteriole\n": "[D]", "109-83.\u4e00\u4f4d65\u6b72\u5973\u6027 \uff0c\u56e0\u5c3f\u6bd2\u75c7 \uff0c9\u500b\u6708\u524d\u958b\u59cb\u9577\u671f\u63a5\u53d7\u8179\u819c\u900f\u6790 (CAPD)\u6cbb\u7642\u3002\u6700\u8fd1\u5169\u5929\u56e0\u70ba\u767c\u71d2 \u3001\u8179\u75db\uff0c\u900f\u6790\n\u5f15\u6d41\u6db2(effluent)\u6df7\u6fc1\u800c\u88ab\u9001\u81f3\u6025\u8a3a \u3002\u8eab\u9ad4\u6aa2\u67e5: \u9ad4\u6eab37 .6\u2103, \u8179\u90e8tenderness (+). \u60a8\u6703\u512a\u5148\u5b89\u6392\u505a\u4ee5\u4e0b\u4f55\u7a2e\n\u8a55\u4f30(initial evaluation )\uff1f      \nA.Abdominal CT\nB.PD effluent: for culture, cytology and Gram staining\nC.\u7167\u6703\u5916\u79d1\uff0c\u66f4\u63db PD catheter\nD.Empirical antibiotics and stopping PD, shift to HD\nE.\u6e2c\u91cf CAPD Kt/V, \u4e26\u5b89\u6392\u8179\u819c\u529f\u80fd\u6e2c\u8a66 (peritoneal equilibration test, PET)\n": "[B]", "109-84.\u4e00\u4f4d58\u6b72\u7537\u6027 \uff0c\u904e\u53bb\u75c5\u53f2\u6709\u591a\u5e74\u814e\u75c5\u5fb5\u5019\u7fa4 (nephrotic syndrome )\uff0c\u5f8c\u4f86\u9032\u5c55\u6210\u5c3f\u6bd2\u75c7 \uff0c\u4e09\u5e74\u524d\u958b\u59cb\u6bcf\u9031\n\u4e09\u6b21\u63a5\u53d7\u8840\u6db2\u900f\u6790\u6cbb\u7642 (hemodialysis )\u3002\u534a\u5e74\u524d\u56e0\u51a0\u5fc3\u75c7 \uff0c\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u624b\u8853\u4e26\u653e\u7f6e\u8840\u7ba1\u5167\u652f\u67b6 \u3002\u6700\u8fd1\u4e00\u6b21\n\u7684\u8eab\u9ad4\u6aa2\u67e5\u6578\u64da\u5982\u4e0b: BUN 138 mg /dL, creatinine 13 .5 mg/dL, K 6.4 mEq/L, P 8.7 mg/dL, albumin 4.6 \ng/dL, Hb 9.6 g/dL, ferritin 364 mg /dL. \u4e0b\u80a2\u6709\u8f15\u5ea6\u6c34\u816b(+). \u6bcf\u6b21\u900f\u6790 4\u5c0f\u6642\u671f\u9593\u5e73\u5747\u9700\u812b\u6c344 KG  \u4ee5\u4e0b\u5e7e\u9805\n\u8a3a\u65b7\uff0c\u4f55\u8005\u8f03\u4e0d\u5408\u9069 \uff1f   \nA.Dialysis inadequacy\nB.Protein energy wasting (PEW) and ongoing nephrotic syndrome\nC.Excessive protein intake\nD.Volume overload\nE.Renal anemia\n": "[B]", "109-85.\u4e00\u4f4d52\u6b72\u591a\u5e74\u9ad8\u8840\u58d3\u7684\u75c5\u4eba \uff0c\u9019\u6b21\u56e0malignant hypertension (systolic BP 210 mmHg )\u88ab\u9001\u81f3\u6025\u8a3a \uff0c\u8eab\u9ad4\n\u6aa2\u67e5: edema (3+), creatinine 1.4 mg/dL\u3002\u75c5\u4eba\u63a5\u53d7\u814e\u81df\u751f\u6aa2 (renal biopsy )\uff0c\u4ee5\u4e0b\u81e8\u5e8a\u8207\u75c5\u7406\u8b8a\u5316\u6558\n\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba \uff1f\n(1) \u814e\u81df\u75c5\u7406\u5207\u7247: Fibrinoid necrosis and medial hypertrophy of small vessels\n(2) \u814e\u81df\u75c5\u7406\u5207\u7247: mesangial proliferation and cellular crescent formation\n(3) \u814e\u81df\u75c5\u7406\u5207\u7247: global sclerosis of glomerulus with pericapillary fibrosis\n(4) \u814e\u81df\u75c5\u7406\u5207\u7247: IgA or IgM immune deposition at glomerular area\n(5) \u8840\u6db2\u6aa2\u67e5: hypocomplementemia (low serum C 3, low serum C 4)\n(6) Urinalysis \u6709heavy proteinuria, \u4f46\u5f88\u5c11\u6709hematuria   \nA.(1)+(3)+(6)\nB.(1)+(2)+(3)+(4)+(6)\nC.(1)+(2)+(5)+(6)\nD.(1)+(4)+(5)\nE.(1)+(2)+(3)+(4)+(5)\n": "[A]", "109-86.\u4e00\u4f4d72\u6b72\u5973\u6027 \uff0c\u8fd1\u4f86\u56e0\u53cd\u61c9\u8b8a\u9072\u920d \u3001\u55dc\u7761\uff0c\u88ab\u5bb6\u4eba\u9001\u81f3\u9580\u8a3a\u5c31\u91ab \u3002\u8eab\u9ad4\u6aa2\u67e5: BP 138 /84 mmHg, edema \n(-), \u5fc3\u640f88 /min (\u4e0d\u898f\u5247\uff0c\u6709atrial fibrillation )\u3002\u6aa2\u8996\u9577\u671f\u7528\u85e5\u6e05\u55ae\u6709 \uff1aamiodarone, carbamazepine \n(selective serotonin reuptake inhibitors ), haloperidol (a antipsychotics )\u3002\u8840\u6db2\u6aa2\u67e5 \uff1aNa 118 mEq /L, K \n3.9 mEq/L, creatinine 0.8 mg/dL, glucose 118 mg /dL, albumin 3.4 g/dL, globulin 3.7 g/dL, t-Chol 164 \nmg/dL, TG 180 mg /d, serum osmolality 250 mOsm /kg\u3002\u5c3f\u6db2\u6aa2\u67e5 \uff1aNa 34 mEq /L, K 4.0 mEq/L, urine \nosmolality 436 mOsm /kg\u3002\u4ee5\u4e0b\u8a3a\u65b7\u8207\u6cbb\u7642\u7684\u6558\u8ff0 \uff0c\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u8a3a\u65b7\u7b26\u5408pseudo -hyponatremia\n(2) \u8a3a\u65b7\u7b26\u5408 SIADH (syndrome of inappropriate antidiuretic hormone secretion )\n(3) \u8a3a\u65b7\u7b26\u5408 Reset Osmostat\n(4) \u53ef\u80fd\u8207\u76ee\u524d\u7528\u85e5amiodarone, carbamazepine\u6216 haloperidol\u6709\u95dc\n(5) \u7531\u8840\u6db2\u8207\u5c3f\u6db2\u7684Na, K, \u53ca osmolality \u6578\u503c \uff0c\u53ef\u80fd\u8207\u9577\u671f\u81ea\u884c\u4f7f\u7528\u5229\u5c3f\u5291\u6709\u95dc\n(6) \u6cbb\u7642\uff1a\u5efa\u8b70\u9069\u91cf\u9650\u6c34 800 -1000 mL /day\n(7) \u6cbb\u7642\uff1a\u5efa\u8b70diuretics + 0.9% saline (NaCl) solution infusion   \nA.(1)+(4)+(7)   \nB.(2)+(4)+(6)\nC.(3)+(4)+(5)+(6)\nD.(1)+(5)+(6)\nE.(2)+(5)+(7)\n": "[B]", "109-87.53\u6b72\u7537\u6027 \uff0c\u904e\u53bb\u6709\u9ad8\u8840\u58d3\u8207 C\u578b\u809d\u708e\u75c5\u53f2 \u3002\u6700\u8fd1\u4e09\u500b\u6708\u4f86 \uff0c\u51fa\u73fe\u86cb\u767d\u5c3f \uff0c\u811b\u524d\u8207\u8db3\u8e1d\u8f15\u5ea6\u6c34\u816b \uff0c\u9ad4\u91cd\u7565\u589e\n\u52a0\u7d043\u516c\u65a4\u3002\u62bd\u8840\u6aa2\u67e5: \u6709\u8840\u6e05\u88dc\u9ad4 (complement, C3\u8207C4) \u504f\u4f4e\u60c5\u5f62 \u3002\u56e0\u70ba\u4e0d\u660e\u539f\u56e0\u814e\u75c5 \uff0c\u5b89\u6392\u75c5\u4eba\u63a5\u53d7\n\u814e\u81df\u751f\u6aa2 (renal biopsy )\u3002\u4ee5\u4e0b\u75c5\u7406\u8b8a\u5316 \uff0c\u4f55\u8005\u6700\u53ef\u80fd \uff1f   \nA.Cryoglobulinemia, especially type II\nB.Polyarteritis nodosa\nC.IgA nephropathy or idiopathic chronic interstitial nephritis\nD.Membranous nephropathy\nE.Henoch-Sch\u00f6nlein purpura (HSP)\n": "[A]", "109-88.ACEI/ARB\u985e\u85e5\u7269 \uff0c\u5728\u81e8\u5e8a\u4e0a\u5177\u6709\u4fdd\u8b77\u814e\u81df\u8207\u6cbb\u7642\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u6548\u679c \u3002\u5728COVID-19\u75ab\u60c5\u671f\u9593 \uff0c\u7531\u6d41\u884c\u75c5\n\u5b78\u8cc7\u6599\u767c\u73fe \uff1a\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u53ca\u5fc3\u8840\u7ba1\u75be\u75c5\u75c5\u4eba \uff0c\u662f\u5bb9\u6613\u611f\u67d3COVID -19\u7684\u9ad8\u5371\u96aa\u7fa4 \uff0c\u800c\u9019\u4e09\u985e\u75c5\u4eba\u6070\u597d\n\u4e5f\u662f\u6700\u5e38\u4e14\u9577\u671f\u4f7f\u7528ACEI /ARB\u985e\u85e5\u7269\u7684\u65cf\u7fa4 \u3002\u91dd\u5c0d\uff1a\u300cCOVID -19\u75ab\u60c5\u671f\u9593 \uff0c\u662f\u5426\u61c9\u505c\u7528ACEI /ARB\u985e\u85e5\n\u7269\uff1f\u300d\uff0c \u8acb\u9078\u51fa\u76ee\u524d\u8f03\u88ab\u63a5\u53d7\u7684\u5171\u8b58\u89c0\u9ede \uff1f   \nA.COVID-19 virus\u6703\u85c9\u7531\u7d50\u5408\u4eba\u985e\u7d30\u80de\u8868\u9762\u7684angiotensin receptor\u800c\u611f\u67d3\u7d30\u80de \u3002ACEI/ARB\u985e\u85e5\u7269\u6703\u589e\n\u52a0angiotensin receptor \uff0c\u6240\u4ee5\u6703\u589e\u52a0\u611f\u67d3COVID -19\u7684\u98a8\u96aa \uff0c\u56e0\u6b64\u9084\u662f\u61c9\u8a72\u5168\u9762\u4f7f\u7528\u6bd4\u8f03\u597d\nB.\u7e7c\u7e8c\u4f7f\u7528ACEI /ARB\u985e\u85e5\u7269 \uff0c\u7684\u78ba\u6703\u589e\u52a0\u611f\u67d3COVID -19\u7684\u98a8\u96aa\u8207\u75be\u75c5\u56b4\u91cd\u5ea6 \uff0c\u4f46\u662f\u4e0d\u6703\u589e\u52a0\u6b7b\u4ea1\n\u7387\u3001\u56e0\u6b64\u5df2\u7d93\u611f\u67d3COVID -19\u7684\u75c5\u4eba\u518d\u505c\u7528\u5c31\u597d\nC.\u5982\u679c\u662f\u5973\u6027\u3001\u5e74\u9f61\u5927\u65bc65\u6b72\u3001\u6709\u5fc3\u81df\u8870\u7aed(CHF)\u7684\u75c5\u4eba\uff0c\u61c9\u8a72\u7acb\u5373\u505c\u6b62\u4f7f\u7528\nD.\u7d9c\u5408\u6240\u6709\u89c0\u5bdf\u578b\u7814\u7a76\u7684\u8cc7\u6599\u5206\u6790\uff0c\u8fc4\u4eca\u4ecd\u652f\u6301ACEI/ARB\u985e\u85e5\u7269\u53ef\u4ee5\u7e7c\u7e8c\u4f7f\u7528\uff0c\u7121\u9808\u505c\u7528\nE.\u904e\u53bb\u672a\u66fe\u4f7f\u7528ACEI /ARB\u985e\u85e5\u7269\u7684\u75c5\u4eba \uff0c\u5982\u679c\u611f\u67d3COVID -19\uff0c\u57fa\u65bc\u4fdd\u8b77\u814e\u81df\u8207\u5fc3\u8840\u7ba1 \uff0c\u5efa\u8b70\u91ab\u5e2b\u61c9\n\u8a72\u65b0\u958b\u7acb\u6b64\u985e\u85e5\u7269 \uff0c\u9810\u9632\u5668\u5b98\u8870\u7aed\n": "[D]", "110-55.Statement on management strategy for patients with autosomal dominant polycystic kidney disease \n(ADPKD), which is incorrect :   \nA.Dietary salt restriction may be beneficial in the management of ADPKD\u3002\nB.Angiotensin -converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are the \nfirst-line antihypertensive drugs in ADPKD \u3002\nC.Nonsteroidal anti -inflammatory drugs (NSAIDs) is more effective and safe than acetaminophen or \ntramadol for cystic pain relief in ADPKD patients \u3002   \nD.Oral tolvaptan can slow the increase in total kidney volume and the decline in kidney function of \nADPKD patients \u3002\nE.ADPKD patients can be a recipient for renal transplantation\u3002\n": "[C]", "110-56.A 54 y/o diabetic female patient with 4 days of fever, respiratory symptoms and dyspnea. At emergency \nservice, physical examination revealed postural hypotension, tachycardia, and Kussmaul respiration. \nLaboratory tests were: blood glucose level of 385 mg /dL. The arterial pH is 7.35, pCO\u2082 is 22 mm Hg, \npO\u2082 86 mmHg, HCO \u2083\u207b 14 mEq /L. Serum electrolyte values were: Na 130 meq /L; K 5.1 meq/L; Cl 96 \nmeq/L; Chest x -ray film indicated consolidation of bilateral lower lobe. \nWhich of the following statements is most likely to be true ?\n(1)The patient has respiratory acidosis, possibly related to pneumonia\n(2)The patient has metabolic acidosis, possibly related to diabetes\n(3)The patient has respiratory alkalosis, possibly related to pneumonia\n(4)The anion gap is still within normal range\n(5)Be cautious with hyperphospatemia during combined insulin and glucose therapy   \nA.(1)+(2)+(5)\u3002\nB.(1)+(2)+(4)+(5)\u3002\nC.(2)+(3)+(5)\u3002\nD.(2)+(3)\u3002\nE.(2)+(3)+(4)\u3002\n": "[D]", "110-57.A middle aged woman was referred to renal clinic for evaluation of her renal disorder. She had \nintermittent pre -tibial swelling for almost 3 months. She has mild hypertension, but no diabetes. Neither \nviral hepatitis B nor C history. Laboratory tests were: albumin 3.1 g/dL, creatinine 1.7 mg/dL, Both \nserum complement levels (C3 and C4) are low, with a particularly depressed C4 compared with C 3.  \nWhich of the following should be considered ?   \nA.Cryoglobulinemia\u3002\nB.Post-streptococcal glomerulonephritis\u3002\nC.Membranoproliferative glomerulonephritis\u3002\nD.Lupus nephritis, stage III or V\u3002\nE.Infectious endocarditis or shunt nephritis\u3002\n": "[A]", "110-58.Struvite stones occurs in patients of repeated urinary tract infections (UTI) from bacteria that produce \nthe enzyme urease, including both gram -positive and gram -negative species.  \nWhich is the least possible micropathogen causing struvite stone and repeated UTI ?   \nA.Klebsiella spp\u3002\nB.Escherichia coli\u3002\nC.Mycoplasma spp\u3002\nD.Staphylococcus epidermidis\u3002\nE.Proteus\u3002   \n": "[B]", "110-59.Which are correct statements regarding hyperuricemia and related nephropathy? \n(1)The renal tubular transporters responsible for determining how much of the filtered uric acid is \nactually excreted are located in the distal nephron\n(2)Renal clearance of uric acid can be inhibited by the angiotensin -converting -enzyme inhibitors or by \n\u03b2-Blockers .\n(3)Initiation of colchicine can induce acute flares of gout\n(4)Initiation of allopurinol or febuxostat can induce acute flares of gout\n(5)Routine use of allopurinol (100-300 mg/day) in patients with stage 3-4 CKD can slow kidney disease \nprogression   \nA.(1)+(2)+(4)+(5)\u3002\nB.(1)+(4)+(5)\u3002\nC.(2)+(3)\u3002\nD.(2)+(4)\u3002\nE.(2)+(4)+(5)\u3002\n": "[D]", "110-60.A 26-year-old girl of type I diabetes had poor appetite and body weight loss for 3 kg (6%) in recent one \nmonth. After admission, she received partial parenteral nutrition due to anorexia and poor oral intake. \nHypophosphatemia (0.8 mg/dL) was notcied on the third day of admission . \nThe most likely mechanism for her acute hypophosphatemia is :   \nA.Acute stage of diabetic ketoacidosis\u3002\nB.Hungry bone syndrome\u3002\nC.Primary hypoparathyroidism\u3002\nD.Renal phosphate wasting\u3002\nE.Shift of phosphorus into intracellular stores\u3002\n": "[E]", "110-61.A 50-year-old male visited outpatient clinic due to difficult -to-control hypertension. After initial work up, \nhypokalemic hypertensive disorder was impressed, Further laboratory evaluation of adrenal hormones \nincluding plasma renin, aldosterone, cortisol, and androgen levels were arranged to distinguish among \nspecific diagnoses. The results are: high renin level, high aldosterone level, an aldosterone -to-renin ratio \nof 10 : 1 ; and a normal serum cortisol level \nWhich is the most possible diagnosis ?   \nA.ACTH-secreting tumor\u3002\nB.Bartter syndrome\u3002\nC.Liddle syndrome\u3002\nD.Primary hyperaldosteronism\u3002\nE.Unilateral renal artery stenosis\u3002\n": "[E]", "110-62.Laboratory indices for differentiation of prerenal versus Intrinsic renal azotemia. \nWhich of the followings prefers pre -renal azotemia ?   \nA.High urine Na concentration >20 (mmol/L)\u3002\nB.High Urine specific gravity >1.020\u3002\nC.Low urine osmolality <300 (mosmol/kg H\u2082O)\u3002\nD.High renal failure index (UNa/UCr/PCr)  >1\u3002   \nE.Urinary sediment analysis reveals a lot of muddy -brown granular casts and casts containing tubular \nepithelial cells \u3002\n": "[B]", "110-63.\u4e0b\u5217\u4f55\u7a2e\u60c5\u6cc1\u6703\u9020\u6210\u9ad8\u8840\u78f7\u75c7 \uff08Hyperphosphatemia \uff09? (1)\u7dad\u751f\u7d20D\u4e2d\u6bd2 (2)\u4ee3\u8b1d\u6027\u9e7c\u4e2d\u6bd2 (3)\u539f\u767c\u6027\u526f\u7532\n\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032 (4)\u56b4\u91cd\u4f4e\u8840\u9382\u75c7 \uff08Severe hypomagnesemia )\uff09 (5)\u816b\u7624\u6eb6\u89e3\u75c7\u5019\u7fa4 (tumor lysis syndrome, \nTLS)   \nA.(1)+(2)+(4)\u3002\nB.(1)+(3)+(5)\u3002\nC.(2)+(3)+(4)\u3002\nD.(2)+(3)+(5)\u3002\nE.(1)+(4)+(5)\u3002\n": "[E]", "110-64.\u4e00\u4f4d74\u6b72\u7cd6\u5c3f\u75c5\u5973\u6027\u60a3\u8005\u5408\u4f75\u6162\u6027\u814e\u81df\u75c5\u7b2c\u56db\u671f \uff0c\u9577\u671f\u670d\u7528\u53e3\u670d\u964d\u8840\u7cd6\u7528\u85e5\u642d\u914d\u80f0\u5cf6\u7d20\u63a7\u5236 \uff0c\u7531\u65bc\u610f\u8b58\u4e0d\n\u6e05\u9192\u88ab\u9001\u5230\u6025\u8a3a\u5c31\u91ab \uff0c\u7d93\u6aa2\u67e5\u6709\u4ee3\u8b1d\u6027\u9178\u4e2d\u6bd2 (metabolic acidosis )\uff0c\u5176\u9670\u96e2\u5b50\u9699 (anion gap )\u70ba26 \nmmol/L\uff0c\u7d93\u7a4d\u6975\u4f7f\u7528\u78b3\u9178\u6c2b\u9209 \uff08sodium bicarbonate )\u77ef\u6b63\uff0c\u4ecd\u7121\u6cd5\u63a7\u6b63 \uff0c\u4e0b\u5217\u4f55\u7a2e\u7528\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u53ef\n\u80fd\u70ba\u8a98\u767c\u7684\u539f\u56e0 \uff1f   \nA.\u4e8c\u80bd\u57fa\u80bd\u9176-4\u6291\u5236\u5291\uff08Dipeptidyl peptidase-4 inhibitor\uff09\u3002\nB.\u904e\u6c27\u5316\u7269\u9176\u9ad4\u589e\u6b96\u7269\u6d3b\u5316\u53d7\u9ad4\u03b3\uff08PPAR-\u03b3\uff09\u3002\nC.\u03b1-\u8461\u8404\u7cd6\u82f7\u9176\u6291\u5236\u5291(\u03b1-glucosidase inhibitor)\u3002\nD.\u4e8c\u7532\u96d9\u80cd\u985e\u964d\u8840\u7cd6\u85e5\u7269 (Metformin)\u3002\nE.\u78fa\u91af\u57fa\u5c3f\u7d20(sulfonylurea)\u3002\n": "[D]", "110-65.\u4e00\u4f4d60\u6b72\u7537\u6027\u9ad8\u8840\u58d3\u80a5\u80d6\u60a3\u8005 \uff0c\u8fd1\u5e7e\u500b\u6708\u8840\u58d3\u5347\u9ad8\u4ee5 4\u7a2e\u964d\u58d3\u5291\u63a7\u5236 \uff0c\u8840\u58d3\u70ba166 /92 mm Hg \u3002\u75c5\u60a3\u7121\u5bb6\n\u65cf\u9ad8\u8840\u58d3\u75c5\u53f2 \uff0c\u4e00\u5e74\u524d\u6aa2\u67e5\u96d9\u5074\u814e\u5728\u5927\u5c0f\u4e00\u81f4\u7d0411cm \uff0c\u814e\u81df\u529f\u80fd\u6b63\u5e38 \u3002\u5b89\u6392\u814e\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5f8c\u767c\u73fe: \u53f3\n\u814e10.6 cm, \u5de6\u814e 8.6 cm\uff0c\u8840\u6db2\u751f\u5316\u6aa2\u9a57\u986f\u793a \uff1a\u808c\u9178\u9150(Creatinine) 2.0 mg/dL\u3002\u4ee5\u4e0b\u6558\u8ff0 \uff0c\u4f55\u8005\u6700\u6b63\u78ba ?   \nA.9\u6210\u4ee5\u4e0a\u60a3\u8005\u5728\u7406\u5b78\u6aa2\u67e5\u6709\u8179\u90e8\u96dc\u97f3(bruit)\u4e14\u6aa2\u67e5\u8840\u9240[K]\u901a\u5e38\u6703\u5347\u9ad8\u3002\nB.\u5982\u679c\u8179\u90e8\u96dc\u97f3\u504f\u5074\u5316\u6216\u5ef6\u4f38\u5230\u6574\u500b\u6536\u7e2e\u671f\u5230\u8212\u5f35\u671f\uff0c\u5247\u5b83\u66f4\u6709\u53ef\u80fd\u5728\u8840\u6d41\u52d5\u529b\u5b78\u4e0a\u5177\u6709\u986f\u8457\u610f\u7fa9\u3002\nC.\u7528\u6838\u78c1\u5171\u632f\u8840\u7ba1\u651d\u5f71 (MRA)\u5f71\u50cf\u6aa2\u67e5 \uff0c\u5982\u679c\u767c\u73ferenal artery stenosis \uff0c\u901a\u5e38\u4ee5fibromuscular \ndysplasia (FMD)\u578b\u6700\u5e38\u898b \u3002\nD.\u964d\u58d3\u5291\u4e2d\uff0c\u4ee5ACEI \u6216ARB\u985e\u70ba\u9996\u9078\u7528\u85e5\u3002\nE.\u9ad8\u8840\u58d3\u7684\u539f\u56e0\u5c6c\u5148\u5929\u6027\u7570\u5e38 \uff0c\u8207\u8840\u6e05\u81bd\u56fa\u9187\u8f03\u7121\u95dc\u4fc2 \uff0c\u7121\u9700\u4f7f\u7528HMG -CoA \u9084\u539f\u9176\u6291\u5236\u5291( statins )\u63a7\n\u5236\u81bd\u56fa\u9187 \u3002\n": "[B]", "110-66.\u6709\u95dc\u6162\u6027\u9593\u8cea\u6027\u814e\u81df\u75c5\u5e38\u898b\u4e4b\u81e8\u5e8a\u8868\u73fe \uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba (\u61c9\u9078\u51fa\u6240\u6709\u7b54\u6848) ( 1)\u8303\u5eb7\u5c3c\u6c0f\u75c7\u5019\u7fa4 (Fanconi \nsyndrome)  ( 2)\u5be1\u5c3f\uff08Oliguria\uff09\u8207\u7b49\u5f35\u5c3f \uff08isosthenuria \uff09(3)\u8ca7\u8840 (4)\u9ad8\u9670\u96e2\u5b50\u9593\u9699\u4ee3\u8b1d\u6027\u9178\u4e2d\u6bd2\u5408\u4f75\u4f4e\u8840\n\u9240 (5)\u814e\u75c5\u75c7\u5019\u7fa4   \nA.(1)+(4)+(5)\u3002\nB.(1)+(2)+(3)\u3002\nC.(2)+(3)+(4)\u3002\nD.(4)+(5)\u3002\nE.(1)+(3)\u3002\n": "[E]", "110-67.\u4e00\u540d45 \u6b72\u5973\u6027\u60a3\u6709\u7cd6\u5c3f\u75c5 \uff0c\u56e0\u660e\u986f\u75b2\u52de\u800c\u5c31\u8a3a \u3002\u62bd\u8840\u6aa2\u67e5\u986f\u793a \uff1a\u8840\u6e05\u5c3f\u7d20\u6c2e (BUN) \u70ba 100 mg /dL\uff0c\u8840\u6e05\n\u808c\u9150\u9178\u70ba 2.5 mg/dL\u3002 \u8a55\u4f30\u9700\u8981\u54ea\u4e9b\u521d\u6b65\u8655\u7f6e \uff1f   \nA.\u5b89\u6392\u814e\u81df\u8d85\u97f3\u6ce2\u53ca\u814e\u81df\u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u3002   \nB.\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57\u3002\nC.\u8f49\u4ecb\u5230\u904b\u52d5\u5fa9\u5065\u4e2d\u5fc3\u935b\u934a\u3002\nD.\u8840\u7d05\u7d20\uff08Hb\uff09\u53ca\u5927\u4fbf\u6f5b\u8840\u6aa2\u67e5\u3002\nE.\u9650\u5236\u75c5\u53cb\u86cb\u767d\u651d\u53d6\u3002\n": "[D]", "110-68.\u4e00\u540d 23 \u6b72\u7684\u7537\u6027\u7814\u7a76\u751f \uff0c\u56e0\u4e00\u6b21\u7121\u75db\u6027\u660e\u986f\u8840\u5c3f\u7531\u5b78\u6821\u4fdd\u5065\u4e2d\u5fc3\u8f49\u8a3a\u5230\u814e\u81df\u79d1\u9580\u8a3a \u3002\u4ed6\u8eab\u9ad4\u5065\u5eb7 \uff0c\u6c92\u6709\n\u660e\u986f\u7684\u5bb6\u65cf\u53f2 \u3002\u8eab\u9ad4\u8a3a\u5bdf\u6642\u8840\u58d3\u6b63\u5e38 \uff0c\u7121\u5176\u4ed6\u7570\u5e38 \u3002\u8ffd\u8e64\u5be6\u9a57\u5ba4\u6aa2\u67e5\u986f\u793a\u751f\u5316\u53ca\u8840\u6db2\u5b78\u6b63\u5e38 \u3001\u814e\u529f\u80fd\u6aa2\u67e5\n\u6b63\u5e38\uff0c\u4ee5\u53ca\u5c3f\u57f9\u990a\u9670\u6027 \u3002\u8840\u6e05\u514d\u75ab\u5b78\u6aa2\u6e2c\u5305\u62ec\u88dc\u9ad4 \u3001\u6297\u6838\u6297\u9ad4 (ANA)\u3001\u6297\u4e2d\u6027\u7c92\u7d30\u80de\u80de\u6f3f\u6297\u9ad4 (ANCA)\u548c\n\u809d\u708e\u6aa2\u6e2c\u5747\u5448\u9670\u6027 \u3002\u5c3f\u6db2\u8a66\u7d19\u6aa2\u67e5\u986f\u793a :\u6f5b\u8840(2+)\u548c\u86cb\u767d\u8cea(+) \uff0c\u986f\u5fae\u93e1\u6aa2\u67e5\u4e2d\u6709\u5c11\u8a31\u578b\u8b8aRBC\u4f46\u4e26\u7121RBC \ncast\u3002\u4ed6\u7684\u814e\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u662f\u6b63\u5e38\u7684 \u30021 \u9031\u5f8c\u91cd\u8907\u9ad4\u6aa2\u548c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u986f\u793a\u5c3f\u6db2\u6f5b\u8840 1+ \u548c\u7d05\u8840\u7403\u7d30\n\u80de5\u81f38\u500b\u7d05\u7d30\u80de\u548c\u5fae\u91cf\u5c3f\u86cb\u767d \uff0c\u5b9a\u91cf\u70ba 150 \u6beb\u514b /\u5929\u3002\u4e0b\u5217\u4f55\u8005\u662f\u6700\u9069\u7576\u5efa\u8b70   \nA.\u7e7c\u7e8c\u8ffd\u8e64\u89c0\u5bdf\u3002\nB.\u814e\u81df\u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u3002\nC.\u5c0d\u60a3\u8005\u53ca\u5176\u5bb6\u5c6c\u9032\u884c\u57fa\u56e0\u6aa2\u6e2c\u3002\nD.\u958b\u59cb\u985e\u56fa\u9187\u7d93\u9a57\u6027\u6cbb\u7642\u3002\nE.\u6ccc\u5c3f\u79d1\u8f49\u8a3a\u67e5\u660e\u539f\u56e0\u3002\n": "[A]", "110-69.\u4e00\u540d68\u6b72\u60a3\u6709\u814e\u75c5\u75c7\u5019\u7fa4\u5973\u6027 \uff08\u5c3f\u86cb\u767d 3.5 g/\u5929\uff0c\u814e\u529f\u80fd\u6b63\u5e38 \uff0c\u8840\u6e05\u767d\u86cb\u767d 2.2 g/dL\uff09\u6700\u8fd1\u7d93\u814e\u81df\u5207\u7247\u8a3a\n\u65b7\u70ba\u819c\u6027\u814e\u75c5\u8b8a \uff08membranous nephropathy\uff09\u3002 \u8840\u6e05PLA 2R\u6aa2\u6e2c\u548c\u814e\u7d44\u7e54\u67d3\u8272\u5448\u5747\u70ba\u9670\u6027 \u3002\u4ee5\u4e0b\u76f8\u95dc\u7684\n\u6558\u8ff0\u4f55\u8005 \u300c\u932f\u8aa4\u300d\uff1a   \nA.\u9032\u4e00\u6b65\u8abf\u67e5\u61c9\u5305\u62ec\u60e1\u6027\u816b\u7624\u6aa2\u67e5\u3002\nB.\u60a3\u8005\u61c9\u958b\u59cb\u4ea4\u66ff\u4f7f\u7528\u74b0\u78f7\u91af\u80fa\uff08cyclophosphamide\uff09\u548c\u985e\u56fa\u9187\u3002\nC.\u767c\u751f\u8840\u6813\u4e8b\u4ef6\u7684\u98a8\u96aa\u5f88\u5927\uff0c\u51fa\u8840\u98a8\u96aa\u4f4e\u7684\u60a3\u8005\u53ef\u4ee5\u8003\u616e\u9810\u9632\u6027\u6297\u51dd\u5291\u3002\nD.\u5979\u61c9\u8a72\u63a5\u53d7 B\u578b\u809d\u708e\u7be9\u67e5\uff0c\u5df2\u77e5 B\u578b\u809d\u708e\u8207\u819c\u6027\u814e\u75c5\u6709\u95dc\u3002\nE.\u5982\u679c\u7d93\u904e 6 \u500b\u6708\u5f8c\u5176\u86cb\u767d\u5c3f\u4ecd\u4fdd\u6301\u76ee\u524d\u72c0\u6cc1\uff0c\u5979\u7684\u814e\u81df\u529f\u80fd\u53ef\u80fd\u51fa\u73fe\u9032\u884c\u6027\u814e\u75c5\u7684\u98a8\u96aa\u3002\n": "[B]", "110-70.\u814e\u524d\u6027\u6c2e\u8840\u75c7 \uff08Prerenal azotemia \uff09\u7684\u8a3a\u65b7\u5fc5\u9808\u7d93\u7531\u9069\u7576\u7684\u75c5\u53f2\u8a62\u554f\u548c\u7406\u5b78\u6aa2\u67e5\u5f8c\u78ba\u7acb\uff0c \u4e0b\u5217\u5c3f\u6db2\u548c\u8840\n\u6e05\u6aa2\u9a57\u53ef\u7528\u65bc\u5e6b\u52a9\u78ba\u8a8d\u814e\u524d\u6027\u6c2e\u8840\u75c7\u7684\u8a3a\u65b7 \uff1f   \nA.\u5c3f\u7d20\u6c2e\uff08BUN\uff09\u8207\u808c\u9178\u9150\uff08creatinine\uff09\u7684\u6bd4\u503c\u5927\u65bc 20\u3002\nB.\u9209\u6392\u6cc4\u5206\u7387\uff08fractional excretion of sodium\uff0cFeNa\uff09\u5c0f\u65bc 1%\u3002\nC.\u5c3f\u6db2\u6ef2\u900f\u58d3\uff08urine osmolality\uff09\u5927\u65bc500 (mOsm/kg H2O)\u3002\nD.\u5c3f\u6db2\u9209\u6fc3\u5ea6\u5927\u65bc 20 (mEq/L)\u3002\nE.\u5c3f\u6db2\u6bd4\u91cd\u5927\u65bc1.020\u3002\n": "[B]", "110-71.\u6025\u6027\u814e\u640d\u50b7\u5f8c\u9700\u8981\u7dca\u6025\u900f\u6790\u662f\u56b4\u91cd\u814e\u81df\u640d\u50b7\u7684\u6307\u6a19 \uff0c\u60a3\u8005\u7684\u5408\u4f75\u75c7\u548c\u6b7b\u4ea1\u7387\u589e\u52a0 \u3002\u95dc\u65bc\u6025\u6027\u814e\u640d\u50b7\u7684\u900f\u6790\n\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u662f\u6b63\u78ba\u7684 \uff1f   \nA.\u61c9\u8a72\u9700\u8981\u9ad8\u5f37\u5ea6\u7684\u900f\u6790\u983b\u7387\u548c\u6642\u9593\uff0c\u4ee5\u4fbf\u70ba\u60a3\u8005\u63d0\u4f9b\u6700\u5408\u9069\u7684\u9ad4\u5167\u6046\u5b9a\u74b0\u5883\u3002\nB.\u6025\u6027\u814e\u640d\u50b7\u60a3\u8005\u958b\u59cb\u900f\u6790\u7684\u4e3b\u8981\u539f\u56e0\u5305\u62ec\u9178\u4e2d\u6bd2\u3001\u9ad8\u8840\u9240\u548c\u5168\u8eab\u9ad4\u6db2\u904e\u591a\u3002\nC.\u8207\u9593\u6b47\u6027\u8840\u6db2\u900f\u6790\u76f8\u6bd4\uff0c\u9023\u7e8c\u814e\u81df\u66ff\u4ee3\u6cbb\u7642\u5df2\u88ab\u8b49\u660e\u5c0d\u60a3\u8005\u6709\u66f4\u597d\u7684\u7d50\u679c\u3002\nD.\u900f\u6790\u958b\u59cb\u6642\u7684\u8840\u6e05\u808c\u9150\u9ad8\u4f4e\u8207\u6025\u6027\u814e\u640d\u50b7\u60a3\u8005\u7684\u9810\u5f8c\u8ca0\u76f8\u95dc\u3002\nE.\u6557\u8840\u75c7\uff08sepsis\uff09\u60a3\u8005\u65e9\u671f\u958b\u59cb\u900f\u6790\u53ef\u6539\u5584\u9810\u5f8c\u3002\n": "[B]", "110-72.\u6709\u95dc\u814e\u5c0f\u7ba1\u814e\u7d72\u7403\u56de\u994b\uff08Tubuloglomerular Feedback\uff0cTGF\uff09\u7684\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?       \nA.\u814e\u5c0f\u7ba1\u814e\u7d72\u7403\u56de\u994b\u662f\u6307\u9060\u5074\u814e\u5c0f\u7ba1\u5c0d\u5c3f\u6db2\u6ef2\u900f\u58d3\u7684\u611f\u89ba\u4fe1\u865f\u5c0d\u55ae\u500b\u814e\u5143\u55ae\u4f4d\u814e\u7d72\u7403\u904e\u6ffe\n\u7387\uff08glomerular filtration rate \uff0cGFR\uff09\u7684\u56de\u994b\u8abf\u7bc0 \u3002\nB.\u7cd6\u5c3f\u75c5\u521d\u671f\u6703\u9020\u6210\u51fa\u7403\u5c0f\u52d5\u8108\u58c1\u4e2d\u7684\u9846\u7c92\u7d30\u80de\u5c07\u814e\u7d20\u5927\u91cf\u91cb\u653e\u5230\u5faa\u74b0\u4e2d\u3002\nC.\u814e\u7d20\u5206\u6ccc\u5f8c \uff0c\u9032\u4e00\u6b65\u6d3b\u5316\u814e\u7d20 -\u8840\u7ba1\u6536\u7e2e\u7d20\u7cfb\u7d71 \uff08renin-angiotensin system \uff0cRAS\uff09\u6536\u7e2e\u5165\u7403\u5c0f\u52d5\n\u8108\u3002\nD.\u7dfb\u5bc6\u6591\uff08macula densa \uff09\u7d30\u80de\uff0c\u611f\u77e5\u5230\u5927\u91cf\u9209 /\u6c2f\u96e2\u5b50\u6642 \uff0c\u4ee3\u8b1d\u589e\u52a0\u817a\u82f7 \uff08Adenosine \uff09\u542b\u91cf\uff0c\u8b93\u5165\n\u7403\u5c0f\u52d5\u8108\u8212\u5f35 \u3002\nE.\u7cd6\u5c3f\u75c5\u60a3\u8005\u4f7f\u7528SGLT -2 \u6291\u5236\u5291\u963b\u65b7\u8461\u8404\u7cd6\u8207\u9209\u518d\u5438\u6536 \uff0c\u6703\u4f7f\u5165\u7403\u5c0f\u52d5\u8108\u6536\u7e2e \uff0c\u5f9e\u800c\u4f7f\u540c\u4e00\u814e\u5143\u55ae\u4f4d\n\u7684\u814e\u5c0f\u7403\u904e\u6ffe\u7387\u6e1b\u5c11 \u3002\n": "[E]", "111-55.\u8840\u6db2\u900f\u6790\u75c5\u4eba\u7684\u8840\u7ba1\u901a\u8def (AVF, arterio -venous fistula )\uff0c\u900f\u904e\u4f8b\u884c\u6aa2\u8996 (physical examination )\u53ef\u4ee5\u53ca\u65e9\u767c\n\u73fe\u963b\u585e\u6216\u8840\u6d41\u7570\u5e38 \uff0c\u53ca\u6642\u8655\u7406 \u3002\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u5fb5\u5146\u7b26\u5408AVF \u52d5\u8108\u7aef\u72f9\u7a84 (inflow stenosis )\u8207\u8840\u6d41\u704c\u6ce8\u4e0d\u8db3 ?\n(1) increased pulsatility or water hammer pulse during systole\n(2) reduced pulsatility during systole\n(3) reduced softening and\u201cempty\u201d access during diastole\n(4) a high pitch, discontinuous bruit \n(5) weak thrill\n(6) Increased pulse intensity (augmentation) test   \nA.(1) + (4) + (6)\u3002\nB.(1) + (3) + (5)\u3002\nC.(2) + (3) + (5) + (6)\u3002\nD.(2) + (3) + (4) + (5)\u3002\nE.(2) + (3) + (4) + (5) + (6)\u3002\n": "[D]", "111-56.\u4e00\u4f4d60\u6b72\u7537\u6027 \uff0c\u814e\u529f\u80fd\u6b63\u5e38 \u3002\u4f8b\u884c\u6027\u8d85\u97f3\u6ce2\u6aa2\u67e5\u7121\u610f\u9593\u767c\u73fe\u6709\u826f\u6027\u524d\u5217\u817a\u80a5\u5927 (BPH)\uff0c\u5169\u5074\u4e2d\n\u5ea6hydronephrosis \uff0c\u5169\u5074\u814e\u81df\u5927\u5c0f\u4ecd\u5728\u6b63\u5e38\u7bc4\u570d \u3002\u91ab\u5e2b\u64ec\u5b89\u6392\u9032\u4e00\u6b65\u6aa2\u67e5\u53ef\u80fd\u7684\u75c5\u56e0 \uff0c\u4e26\u5e0c\u671b\u80fd\u85c9\u6b64\u9805\u6aa2\n\u67e5\u4f86\u9078\u64c7\u54ea\u4e00\u5074\u5148\u505a\u7d93\u76ae\u814e\u81df\u9020\u763b (Percutaneous Nephrostomy, PCN) \u4f86\u66ab\u6642\u7de9\u89e3\u814e\u81df\u50b7\u5bb3\u3002   \u4ee5\u4e0b\u4f55\u9805\n\u6aa2\u67e5\u6700\u5408\u9069 ?   \nA.high-resolution multidetector row computed tomography (CT) scan\u3002\nB.retrograde urography\u3002\nC.radionuclide renal scan with furosemide\u3002\nD.Magnetic resonance urography\u3002\nE.endoscopic voiding cystourethrography\u3002\n": "[C]", "111-57.\u4ee5\u4e0b\u6709\u95dc\u591a\u56ca\u814e (ADPKD\uff0cAutosomal Dominant Polycystic Kidney Disease )\u7684\u6558\u8ff0\uff0c\u4f55\u7a2e\u7d44\u5408\u662f\u6b63\u78ba\u7684 ?\n(1) \u8840\u58d3\u5efa\u8b70\u4ee5140 /90 mmHg \u70ba\u76ee\u6a19 \uff0c\u53ef\u964d\u4f4e\u5fc3\u8840\u7ba1\u4f75\u767c\u75c7 \uff0c\u800c\u82e5\u662f\u80fd\u9032\u4e00\u6b65\u63a7\u5236\u6536\u7e2e\u58d3\u76ee\u6a19\u9054110 \nmmHg\uff0c\u53ef\u4ee5\u5ef6\u7de9\u814e\u529f\u80fd\u60e1\u5316 \u3002\n(2) \u9078\u64c7\u8102\u6eb6\u6027\u6297\u751f\u7d20 [\u5982trimethoprim -sulfamethoxazole, quinolones, \u53ca chloramphenicol] \u5c0d\u56ca\u6ce1 (cyst)\u611f\n\u67d3\uff0c\u7a7f\u900f\u6027\u8207\u6cbb\u7642\u6548\u679c\u8f03\u4f73 \u3002\n(3 )\u559d\u6c34\u91cf\u4e0d\u5efa\u8b70\u904e\u591a (> 2500 mL /day)\uff0c\u4ee5\u514d\u4fc3\u9032\u56ca\u6ce1\u751f\u9577 (cyst growth )\n(4)\u6291\u5236\u814e\u7d20 -\u8840\u7ba1\u5f35\u529b\u7d20\u7cfb\u7d71 (RAA\uff0c renin -angiotensin -aldosterone system )\uff0c\u53ef\u63a7\u5236\u8840\u58d3\u8207\u6e1b\u7de9\u814e\u529f\u80fd\n\u60e1\u5316\u3002\n(5) tolvaptan, \u4e00\u7a2evasopressin V2 receptor (V2R) antagonists \uff0c\u53ef\u4ee5\u6291\u5236\u56ca\u6ce1 (cyst)\u7d30\u80de\u589e\u751f \u3002\u5efa\u8b70\u65e9\u671f\n\u4f7f\u7528tolvaptan \uff0c\u9810\u9632\u56ca\u6ce1\u751f\u9577\u8207\u9032\u5c55\u81f3\u5c3f\u6bd2\u75c7 \u3002   \nA.(1) + (2) + (3) + (4) + (5)\u3002\nB.(2) + (3) + (4) + (5)\u3002\nC.(2) + (3) + (4)\u3002\nD.(2) + (4) + (5)\u3002\nE.(2) + (4)\u3002   \n": "[E]", "111-58.\u5065\u6aa2\u767c\u73fe\u7121\u81e8\u5e8a\u75c7\u72c0\u8840\u5c3f (asymptomatic hematuria )\u75c5\u4eba\uff0c 2020 \u5e74AUA guideline\u5efa\u8b70 \uff0c\u4f9d\u64da\u5371\u96aa\u7b49\u7d1a\u7a0b\n\u5ea6\u9032\u884c\u8ffd\u8e64\u8655\u7f6e\u5efa\u8b70\u3002    \u4ee5\u4e0b\u4f55\u7a2e\u75c5\u4eba \uff0c\u5efa\u8b70\u61c9\u5b89\u6392CT scan \u6216cystoscopy \u4ee5\u6392\u9664\u6ccc\u5c3f\u9053\u816b\u7624 (urological \nmalignancy )\u7684\u98a8\u96aa ?   \nA.< 50 \u6b72\u5973\u6027\uff0c\u7121\u62bd\u83f8\u75c5\u53f2\u3002\nB.< 60\u6b72\u7537\u6027\uff0c\u6709\u62bd\u83f8\u75c5\u53f2\u3002\nC.> 60 \u6b72\uff0c\u4e0d\u8ad6\u7537\u5973\uff0c\u66fe\u5408\u4f75\u6709gross hematuria\u75c5\u53f2\u3002\nD.\u6709dysmorphic RBC, cellular cast \u53caproteinuria\u7684\u75c5\u4eba\u3002\nE.\u5df2\u7d93\u9023\u7e8c\u591a\u5e74\uff0c\u6bcf\u5e74\u5065\u6aa2\u90fd\u662fasymptomatic hematuria\uff0c\u814e\u81df\u8d85\u97f3\u6ce2\u4e5f\u672a\u767c\u73fe\u7570\u5e38\u3002\n": "[C]", "111-59.\u8840\u58d3\u63a7\u5236\u5c0d\u65bc\u56b4\u91cd\u5b50\u7647\u524d\u75c7(severe preeclampsia)\u7684\u5a66\u5973\u5f88\u95dc\u9375\u3002\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u85e5\u7269\u8f03\u4e0d\u5408\u9069?    \nA.oral renin \u2013angiotensin \u2013aldosterone inhibitors\u3002\nB.oral nifedipine\u3002\nC.oral methyldopa\u3002\nD.parenteral hydralazine\u3002\nE.oral or parenteral labetalol\u3002\n": "[A]", "111-60.\u4ee5\u4e0b\u6709\u95dclupus nephritis\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?    \nA.Class IV lupus nephritis\u82e5\u662f\u5728renal biopsy\u6642\u767c\u73fe\u6709crescent \uff0c\u61c9\u7a4d\u6975\u6cbb\u7642 \uff0c\u907f\u514d\u9032\u5c55\u81f3rapidly \nprogressive glomerulonephritis (RPGN) \u8207renal fibrosis \u3002\nB.\u6709anti-phospholipid antibody\u967d\u6027\u7684\u75c5\u4eba \uff0c\u6709\u8f03\u9ad8\u6a5f\u6703\u767c\u751fthrombotic microangiopathy \uff0c\u61c9\u7d66\n\u4e88anticoagulant\u53ef\u4ee5\u6709\u6548\u9810\u9632lupus nephritis\u60e1\u5316 \u3002\nC.\u8a3a\u65b7\u70baClass I, II\u7684\u75c5\u4eba \uff0c\u61c9\u76e1\u65e9\u7d66\u4e88moderate or high dose steroid\u4ee5\u9810\u9632\u75c5\u60c5\u9032\u5c55\u81f3Class IV or V \n\u7684lupus nephritis \u8207renal fibrosis \u3002\nD.\u81e8\u5e8a\u9810\u5f8c\u8207ANA level \u53cacomplement levels\u5bc6\u5207\u76f8\u95dc \uff0c\u5b9c\u5b9a\u671f\u8ffd\u8e64ANA \u8207C3, C4 levels\uff0c\u8a55\u4f30\u6cbb\u7642\u6548\n\u679c\u3002\nE.Class IV lupus nephritis\u75c5\u4eba \uff0c\u5efa\u8b70\u5118\u65e9\u4f7f\u7528rituximab or tacrolimus \uff0c\u53ef\u8f03\u50b3\u7d71high dose steroid \u66f4\n\u6709\u6548\u9054\u5230\u53ca\u7dad\u6301renal remission \u3002\n": "[A]", "111-61.\u6709\u95dcasymptomatic bacteriuria (\u5b9a\u7fa9: voided urine specimen > 10\u2075 cfu /ml of an uropathogen isolated, \nabsence of signs and symptoms of UTI )\uff0c\u4f9d\u64da2019 IDSA (Infectious Diseases of America )\uff0c\u4e00\u822c\u662f\u4e0d\n\u9700\u8981\u4f8b\u884c\u6027\u7be9\u6aa2\u8207\u6cbb\u7642 (screen and treatment )\u7684\uff0c\u4ee5\u514d\u7522\u751f\u4e0d\u5fc5\u8981\u7684\u6297\u85e5\u6027 \u3002\u4ee5\u4e0b\u4f55\u7a2e\u60c5\u6cc1IDSA\u624d\u5efa\u8b70\n\u4f8b\u884c\u6027\u7be9\u6aa2\u8207\u5fc5\u8981\u6642\u7684\u6cbb\u7642 ?   \nA.pregnant woman\u3002\nB.older patients with cognitive impairment, delirium\u3002\nC.diabetes\u3002\nD.kidney transplant patients\u3002\nE.patients with spinal cord injury\u3002\n": "[A]", "111-62.\u4e00\u4f4d40\u6b72\u7537\u6027 \uff0c\u8f15\u5ea6\u9ad8\u8840\u58d3 (sBP 148 mmHg )\uff0cserum creatinine 1.0 mg/dL, urine protein 0.6 g/24-Hr \nurine, renal biopsy\u70ba IgA nephropathy, without advanced tubulointerstitial fibrosis, nor crescent \nformation. \u91ab\u5e2b\u5148\u7d66\u4e88 RAAS blocker, \u6301\u7e8c\u8ffd\u8e64 6\u500b\u6708\uff0c\u518d\u6aa2\u6e2c\u5be6\u9a57\u5ba4\u6578\u503c\u70ba: serum creatinine 1.4 \nmg/dL, urine protein 1.3 g/24-Hr urine, sBP 120 mmHg.  \u8acb\u554f: \u4ee5\u4e0b\u8655\u7f6e \uff0c\u4f55\u8005\u6700\u9069\u5b9c ?   \nA.intravenous methylprednisolone (500-1000 mg /day, for 3 days) followed by oral azathioprine for \ndeclining renal function \u3002   \nB.add on oral steroid 0.4 mg/kg/day\u3002\nC.add on fish oil\u3002\nD.arrange tonsillectomy + add on fish oil\u3002\nE.hold RAAS blocker, shift to SGLT2i (sodium glucose cotransporter 2 inhibitor)\u3002\n": "[B]", "111-63.\u4e00\u4f4d56\u6b72\u7537\u6027 \uff0c15\u500b\u6708\u524d\u6709lung cancer, liver metastasis, \u7d93cisplatin \u6cbb\u7642 \uff0c\u66fe\u767c\u751fAKI (acute kidney \ninjury\uff0c\u6700\u9ad8serum creatinine 4.6 mg/dL)\u3002\u672c\u6b21\u56e0\u75b2\u618a\u7121\u529b\u88ab\u9001\u81f3\u6025\u8a3a \u3002\u8840\u58d3 150 /88 mmHg \uff0c\u5be6\u9a57\u5ba4\u6578\n\u64da\u5982\u4e0b: albumin 3.2 g/dL, creatinine 2.5 mg/dL, Na 145 mEq /L, K 2.0 mEq/L, Cl 84 mEq /L, ABG (pH \n7.48, paCO\u2082 60, PaO\u2082 97, HCO \u2083\u207b  40, BE 10 .5)\uff0cplasma osmolality 298 mOsm /kg, urine data \n(osmolality 388 mOsm /kg, Na 35 mEq /L, K 26 mEq /L)\u3002\u9032\u4e00\u6b65\u6aa2\u67e5plasma renin activity (PRA) \n\u8207plasma aldosterone concentration (PAC)\u90fd\u5728\u6b63\u5e38\u7bc4\u570d\u3002 \u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \u3002   \nA.\u75c5\u4eba\u767c\u751fmetabolic alkalosis with adequate respiratory compensation\u3002\nB.\u75c5\u4eba\u767c\u751fmixed type acid-base disorder, metabolic alkalosis with respiratory alkalosis\u3002\nC.\u7b26\u5408 Bartter-Gitelman syndrome \u7684\u8a3a\u65b7\u3002\nD.Ectopic ACTH: Cushing syndrome\u53ef\u4ee5\u6709\u5982\u4e0a\u7684\u8868\u73fe\u3002\nE.\u75c5\u4eba\u7684TTKG (\u5c0d\u7167\u7576\u6642serum [K] 2.0 mEq/L)\u4ecd\u5c6c\u9069\u7576\uff0c\u5224\u5b9a\u975erenal loss\u3002\n": "[D]", "111-64.\u6709\u95dc\u65e9\u671f\u5075\u6e2c\u6025\u6027\u814e\u640d\u50b7\u767c\u751f\u7684\u751f\u7269\u6a19\u8a8c\u7269\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u8840\u5c3f\u7d20\u6c2e\uff08BUN\uff09\u3002\nB.\u767d\u7d30\u80de\u4ecb\u7d20-18 \uff08IL-18\uff09\u3002\nC.\u814e\u640d\u50b7\u5206\u5b50-1 (KIM-1)\u3002\nD.\u4e2d\u6027\u7c92\u7d30\u80de\u660e\u81a0\u9176\u76f8\u95dc\u8f09\u8102\u86cb\u767d (NGAL)\u3002\nE.\u809d\u81df\u578b\u8102\u80aa\u9178\u7d50\u5408\u86cb\u767d(L-FABP)\u3002\n": "[A]", "111-65.\u6162\u6027\u814e\u75c5\u60a3\u8005\u6b7b\u4ea1\u7684\u4e3b\u8981\u539f\u56e0\u662f\u4ec0\u9ebc\uff1f    \nA.\u5fc3\u8840\u7ba1\u75be\u75c5\u3002\nB.\u9ad8\u9240\u8840\u75c7\u3002\nC.\u611f\u67d3\u3002\nD.\u60e1\u6027\u816b\u7624\u3002\nE.\u5c3f\u6bd2\u75c7\u3002\n": "[A]", "111-66.\u4e00\u540d\u60a3\u6709\u672b\u671f\u814e\u75c5\u7684 27 \u6b72\u5973\u6027\u6b63\u5728\u63a5\u53d7\u8840\u6db2\u900f\u6790 \uff0c\u5728\u6cbb\u7642\u671f\u9593\u88ab\u767c\u73fe\u51fa\u73fe\u4f4e\u8840\u58d3\u3002 \u6709\u95dc\u8840\u6db2\u900f\u6790\u671f\u9593\u4f4e\n\u8840\u58d3\uff0c\u4e0b\u5217\u6f5b\u5728\u6a5f\u5236\u4f55\u8005\u70ba\u975e \uff1f   \nA.\u964d\u58d3\u85e5\u3002\nB.\u904e\u5ea6\u8d85\u6ffe\u812b\u6c34\u3002\nC.\u81ea\u5f8b\u795e\u7d93\u53cd\u61c9\u53d7\u640d\u3002\nD.\u6ef2\u900f\u58d3\u8b8a\u5316\u3002\nE.\u52d5\u975c\u8108\u5ed4\u7ba1\u8840\u6d41\u8f03\u5927\u3002\n": "[E]", "111-67.\u4e00\u540d 28 \u6b72\u7684\u5973\u6027 \uff0c\u5728\u5979\u7b2c\u4e8c\u6b21\u61f7\u5b55\u7684\u7b2c 30 \u9031\u5167 \uff0c\u7531\u65bc\u8f15\u5ea6\u9ad8\u8840\u58d3\u800c\u5bc6\u5207\u8ffd\u8e64\u3002 \u7b2c\u4e00\u6b21\u61f7\u5b55\u66fe\u56e0\u5b50\u7647\u524d\n\u75c7\u800c\u51fa\u73fe\u5408\u4f75\u75c7\uff0c \u73fe\u5728\u75b2\u52de\u52a0\u5287\u3002 \u8840\u58d3\u70ba 140 /90 mmHg \uff0c\u5fc3\u7387\u70ba 84 bpm \uff0c\u8840\u6c27\u98fd\u548c\u5ea6\u70ba 95 %\u3002 \u80ce\u5152\n\u76e3\u6e2c\u986f\u793a\u6c92\u6709\u7570\u5e38\u3002 \u5be6\u9a57\u5ba4\u6aa2\u9a57\u986f\u793a\u8840\u7d05\u7d20\u70ba 6 g/dL\uff081 \u9031\u524d\u70ba 10 g/dL\uff09\u548c\u8840\u5c0f\u677f\u70ba 80 K/\u03bcL\uff081 \u9031\u524d\u70ba \n180K/\u03bcL\uff09\u3002  \u5468\u908a\u8840\u6db2\u62b9\u7247\u986f\u793a\u7834\u88c2\u7d05\u8840\u7403\u7d30\u80de \u3002\u6709\u95dc\u65bc\u5979\u7684\u60c5\u6cc1\u7684\u9673\u8ff0 \uff0c\u4e0b\u5217\u4f55\u8005\u662f\u932f\u8aa4\u7684 \uff1a   \nA.\u7cd6\u76ae\u8cea\u6fc0\u7d20\uff08Glucocorticoids\uff09\u53ef\u6709\u6548\u964d\u4f4e\u767c\u75c5\u7387\u548c\u6b7b\u4ea1\u7387\u3002   \nB.\u809d\u529f\u80fd\u9176\u53ef\u80fd\u5347\u9ad8\u3002\nC.\u5b50\u7647\u524d\u75c7\u662f\u6b64\u75c5\u7684\u524d\u9a45\u75c5\u5fb5\u3002\nD.\u5f88\u5e38\u898b\u814e\u8870\u7aed\u3002\nE.\u5206\u5a29\u5f8c\u75c5\u60c5\u53ef\u80fd\u6703\u597d\u8f49\u3002\n": "[A]", "111-68.\u4e00\u540d35 \u6b72\u5973\u6027\u60a3\u6709\u9ad8\u8840\u58d3\u6162\u6027\u814e\u81df\u75c5\u60a3\u8005 \uff0c\u9032\u5c55\u70ba\u672b\u671f\u814e\u75c5\u8b8a\u3002 \u4e26\u65bc 1 \u5e74\u524d\u958b\u59cb\u9032\u884c\u8179\u819c\u900f\u6790 \uff0c\u5c3f\u6bd2\u75c7\n\u75c7\u72c0\u7372\u5f97\u660e\u986f\u6539\u5584\u3002 \u8fd1\u65e5 \uff0c\u56e0\u767c\u71d2\u3001\u7cbe\u795e\u72c0\u614b\u6539\u8b8a \u3001\u7030\u6f2b\u6027\u8179\u75db\u548c\u900f\u6790\u6db2\u6df7\u6fc1\u88ab\u9001\u5f80\u6025\u8a3a\u5ba4\u3002 \u5979\u7684\u8179\u819c\n\u900f\u6790\u6db2\u5be6\u9a57\u5ba4\u5206\u6790\u986f\u793a\uff1a \u767d\u8840\u7403\u7d30\u80de\u8a08\u6578\u70ba 125 /\u03bcL\uff0c\u542b\u6709 85% \u7684\u591a\u5f62\u6838\u4e2d\u6027\u9846\u7c92\u767d\u8840\u7403\u7d30\u80de\u3002 \u8179\u819c\u6db2\n\u57f9\u990a\u4e2d\u6700\u6709\u53ef\u80fd\u767c\u73fe\u54ea\u7a2e\u5fae\u751f\u7269 \uff1f   \nA.\u767d\u8272\u5ff5\u73e0\u83cc\uff08Candida albicans\uff09\u3002\nB.\u5947\u7570\u8b8a\u5f62\u687f\u83cc\uff08Proteus mirabilis\uff09\u3002\nC.\u7d50\u6838\u5206\u679d\u687f\u83cc \uff08Mycobacterium tuberculosis\uff09\u3002\nD.\u7da0\u81bf\u55ae\u80de\u687f\u83cc\uff08Pseudomonas aeruginosa\uff09\u3002\nE.\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc \uff08Staphylococcus aureus\uff09\u3002\n": "[E]", "111-69.\u4ee5\u4e0b\u54ea\u4e9b\u6025\u6027\u814e\u640d\u50b7\u60a3\u8005\u5728\u814e\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u4e2d\u6700\u6709\u53ef\u80fd\u6709\u300e\u96d9\u5074\u300f\u814e\u7a4d\u6c34\u7684\u8b49\u64da\uff1f    \nA.\u4e00\u540d 22 \u6b72\u7537\u6027\u60a3\u6709\u731b\u66b4\u6027\u7d2b\u6591\u75c7\u5408\u4f75\u6dcb\u7403\u83cc\u6557\u8840\u75c7\u3002\nB.\u4e00\u540d 42 \u6b72\u7684\u5973\u6027\uff0c\u56e0\u665a\u671f\u5b50\u5bae\u9838\u764c\u6b63\u5728\u63a5\u53d7\u5316\u7642\u548c\u653e\u7642\u3002\nC.\u4e00\u540d48 \u6b72\u7537\u6027\uff0c\u56e0\u9ad8\u8840\u58d3\u800c\u60a3\u6709\u6162\u6027\u814e\u81df\u75c5\uff0c\u63a5\u53d7\u63a5\u53d7\u542b\u7898\u986f\u5f71\u5291\u6ce8\u5c04\u7684\u8179\u90e8\u8840\u7ba1\u9020\u5f71\u3002\nD.\u4e00\u540d 56 \u6b72\u7537\u6027\u60a3\u6709\u5927\u8178\u687f\u83cc 0157:H7 \u76f8\u95dc\u6eb6\u8840\u6027\u5c3f\u6bd2\u75c7\u3002\nE.\u4e00\u540d85 \u6b72\u4f4f\u5728\u5b89\u990a\u4e2d\u5fc3\u5973\u6027\uff0c\u56e0\u814e\u76c2\u814e\u708e\u548c\u6557\u8840\u75c7\u7684\u60a3\u8005\u3002\n": "[B]", "111-70.\u4e00\u540d 28 \u6b72\u7684\u5973\u6027\u5728\u4e00\u6b21\u8840\u5c3f\u5f8c \uff0c\u88ab\u8a3a\u65b7\u70ba\u5e38\u67d3\u8272\u9ad4\u986f\u6027\u591a\u56ca\u814e\u75c5 \uff08autosomal dominant polycystic \nkidney disease \uff0cADPCKD\uff09\uff0c \u5979\u64d4\u5fc3\u9871\u5167\u52d5\u8108\u7624\u7684\u98a8\u96aa\u3002 \u95dc\u65bc\u9019\u7a2e\u98a8\u96aa \uff0c\u4e0b\u5217\u54ea\u9805\u9673\u8ff0\u662f\u6b63\u78ba\u7684 \uff1f   \nA.\u9871\u5167\u52d5\u8108\u7624\u7834\u88c2\u5bb6\u65cf\u53f2\u4e0d\u6703\u589e\u52a0\u7834\u88c2\u98a8\u96aa\u3002\nB.\u65e2\u5f80\u9871\u5167\u51fa\u8840\u4e0d\u6703\u589e\u52a0\u96a8\u5f8c\u51fa\u8840\u7684\u98a8\u96aa\u3002\nC.\u52d5\u8108\u7624\u7684\u5927\u5c0f\u8207\u5176\u81ea\u767c\u7834\u88c2\u7684\u98a8\u96aa\u7121\u95dc\u3002\nD.\u6709\u591a\u56ca\u814e\u75c5\u4eba\uff0c\u9871\u5167\u52d5\u8108\u7624\u7684\u98a8\u96aa\u4e0d\u6703\u589e\u52a0\u3002\nE.\u4e0d\u53d7\u63a7\u5236\u7684\u9ad8\u8840\u58d3\u6703\u589e\u52a0\u81ea\u767c\u7834\u88c2\u7684\u98a8\u96aa\u3002\n": "[E]", "111-71.\u4e00\u540d 48\u6b72\u7684\u80a5\u80d6\u5973\u6027 \uff0c\u6709 5 \u5e74\u7684\u8f15\u5ea6\u9ad8\u8840\u58d3\u75c5\u53f2 \uff0c\u4f7f\u7528\u9223\u96e2\u5b50\u901a\u9053\u963b\u65b7\u5291 (Calcium-channel Blockers )\u63a7\n\u5236\uff0c\u5728\u5979\u6bcf\u5e74\u7684\u5065\u5eb7\u6aa2\u67e5\u6642 \uff0c\u5c3f\u8a66\u7d19\u4e0a\u986f\u793a\u6709\u86cb\u767d\u5c3f \u3002\u9ad4\u683c\u6aa2\u67e5\u986f\u793a\u8eab\u9ad8 167 .6 \u516c\u5206\uff0c\u9ad4\u91cd 91 \u516c\u65a4 \uff0c\u8840\n\u58d3 130/80 \u6beb\u7c73\u6c5e\u67f1 \uff0c\u9838\u975c\u8108\u58d3\u5347\u9ad8 \uff0c\u7b2c\u56db\u5fc3\u97f3\u548c\u5fae\u91cf\u8db3\u90e8\u6c34\u816b \u3002\u5be6\u9a57\u5ba4\u6578\u503c\u5982\u4e0b \uff1a\n\u2022 \u8840\u6e05\u808c\u9150 \uff1a0.9mg/dL\uff1b eGFR \uff1a79 \u6beb\u5347/\u5206\u9418\n\u2022 BUN\uff1a18 \u6beb\u514b/\u5206\u5347\n\u2022 \u5c3f\u6db2\u5206\u6790 \uff1apH 5.0\uff1b\u6bd4\u91cd1.018\uff1b\u86cb\u767d\u8cea 3+; \u6c92\u6709\u8461\u8404\u7cd6 \uff1b\u900f\u660e\u5713\u67f1\u9ad4 (Hyaline cast )\n\u2022 \u5c3f\u6db2 PCR (protein-creatinine ratio )\uff1a5.9 g/g\n\u814e\u81df\u5207\u7247\u7d50\u679c\u986f\u793a 60% \u7684\u814e\u7d72\u7403 \uff0c\u5728\u5149\u5b78\u986f\u5fae\u93e1\u4e0b\u6709\u7bc0\u6bb5\u6027\u7622\u75d5 \uff0c\u5176\u9918\u7684\u814e\u5c0f\u7403\u770b\u8d77\u4f86\u6c92\u6709\u660e\u986f\u8b8a\n\u5316\uff08\u57161\uff09\u3002 \u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\u4ec0\u9ebc \uff1f   \nA.\u9ad8\u8840\u58d3\u6027\u814e\u786c\u5316\u3002\nB.\u5c40\u90e8\u7bc0\u7d50\u6027\u814e\u7d72\u7403\u786c\u5316\u75c7\u3002\nC.\u5fae\u5c0f\u6027\u814e\u75c5\u8b8a\u3002\nD.\u819c\u6027\u814e\u75c5\u8b8a\u3002\nE.\u65b0\u6708\u578b\u814e\u7d72\u7403\u814e\u708e\u3002   \n": "[B]", "111-72.\u4ee5\u4e0b\u6240\u6709\u95dc\u65bc\u5728\u6162\u6027\u814e\u75c5\u60a3\u8005\u4e2d\u4f7f\u7528\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20\u662f\u6b63\u78ba\u9673\u8ff0 \uff1a(1).\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20\u61c9\u4ee5 \n10-11.5 g/dL \u7684\u76ee\u6a19\u8840\u7d05\u86cb\u767d\u6fc3\u5ea6\u7d66\u85e5 \u3002(2).\u4f7f\u7528\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20\u8207\u6539\u5584\u5fc3\u8840\u7ba1\u9810\u5f8c\u76f8\u95dc \u3002(3).\u4f7f\u7528\n\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20\u8207\u5408\u4f75 2 \u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u589e\u52a0\u8166\u4e2d\u98a8\u96aa\u6709\u95dc \u3002(4).HIF\u52a0\u5f37\u5291 \uff0chypoxia-inducible \nfactors enhancer \uff0c\u53ef\u80fd\u6210\u70ba\u4e00\u500b\u53e3\u670d\u7684\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20 \u3002(5).\u4f7f\u7528\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20\u8207\u8840\u6813\u6813\n\u585e\u4e8b\u4ef6\u7684\u767c\u751f\u7387\u589e\u52a0\u6709\u95dc \u3002   \nA.(1)+ (2)+ (3)+ (4)\u3002\nB.(2)+ (3)+ (4)+ (5)\u3002\nC.(1)+ (2)+ (4)+ (5)\u3002\nD.(1)+ (2)+ (3)+ (5)\u3002\nE.(1)+ (3)+ (4)+ (5)\u3002\n": "[E]"}